0001615774-16-005331.txt : 20160511 0001615774-16-005331.hdr.sgml : 20160511 20160511163849 ACCESSION NUMBER: 0001615774-16-005331 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 57 CONFORMED PERIOD OF REPORT: 20160331 FILED AS OF DATE: 20160511 DATE AS OF CHANGE: 20160511 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ANAVEX LIFE SCIENCES CORP. CENTRAL INDEX KEY: 0001314052 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 208365999 STATE OF INCORPORATION: NV FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-37606 FILM NUMBER: 161640402 BUSINESS ADDRESS: STREET 1: 51 W 52ND STREET, STREET 2: 7TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10019-6163 BUSINESS PHONE: 800-689-3939 MAIL ADDRESS: STREET 1: 51 W 52ND STREET, STREET 2: 7TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10019-6163 FORMER COMPANY: FORMER CONFORMED NAME: Thrifty Printing Inc. DATE OF NAME CHANGE: 20050111 10-Q 1 s103199_10q.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: March 31, 2016

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____to _____

Commission File Number: 000-51652

ANAVEX LIFE SCIENCES CORP.

(Exact name of registrant as specified in its charter)

Nevada	98-0608404
(State or other jurisdiction of	(IRS Employer
incorporation or organization)	Identification No.)

51 West 52^nd Street, 7^th Floor, New York, NY USA 10019

(Address of principal executive offices) (Zip Code)

1-844-689-3939

(Registrant’s telephone number, including area code)

N/A
(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

x Yes ¨ No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

x Yes ¨ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	¨		Accelerated filer	¨
Non-accelerated filer	¨	(Do not check if a smaller reporting company)	Smaller reporting company	x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

¨ Yes x No

APPLICABLE ONLY TO CORPORATE ISSUERS:

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 35,710,862 shares of common stock outstanding as of May 11, 2016.

TABLE OF CONTENTS

PART I - FINANCIAL INFORMATION	1

Item 1. Financial Statements	1

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	21

Item 3. Quantitative and Qualitative Disclosures about Market Risks	31

Item 4. Controls and Procedures	31

PART II – OTHER INFORMATION	31

Item 1. Legal Proceedings	31

Item 1A. Risk Factors	32

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	32

Item 3. Defaults Upon Senior Securities	32

Item 4. Mine Safety Disclosures	32

Item 5. Other Information	32

Item 6. Exhibits	33

SIGNATURES	34

iii

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements.

ANAVEX LIFE SCIENCES CORP.

INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2016

(Unaudited)

Page 2

ANAVEX LIFE SCIENCES CORP.

INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS

March 31, 2016 and September 30, 2015

(Unaudited)

	March 31			September 30,
	2016			2015
Current
Cash	$	11,950,847		$	15,290,976
Sales Tax Recoverable		78,670			76,840
Prepaid expenses and deposits		84,977			100,845
		12,114,494			15,468,661
Equipment		755			1,252
	$	12,115,249		$	15,469,913

Current
Accounts payable and accrued liabilities	$	2,338,137		$	2,503,726
Deferred grant income		5,445			71,614
Promissory notes payable		88,145			85,238
		2,431,727			2,660,578

Senior Convertible Debentures		337			332
		2,432,064			2,660,910

Capital stock
Authorized:
100,000,000 common shares, par value $0.001 per share
Issued and outstanding:
35,695,572 common shares (September 30, 2015 - 32,044,213)		35,697			32,044
Additional paid-in capital		78,914,253			74,060,999
Common stock to be issued		-			1,997,415
Accumulated deficit		(69,266,765	)		(63,281,455	)
		9,683,185			12,809,003
	$	12,115,249		$	15,469,913

SEE ACCOMPANYING NOTES

Page 3

ANAVEX LIFE SCIENCES CORP.

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

for the three and six months ended March 31, 2016 and 2015

(Unaudited)

	Three months ended March 31,						Six months ended March 31,
	2016			2015			2016			2015
Operating expenses
General and administrative	$	852,775		$	451,193		$	4,714,473		$	903,246
Research and development		1,327,393			407,146			1,998,129			725,771

Total operating expenses		(2,180,168	)		(858,339	)		(6,712,602	)		(1,629,017	)

Other income (expenses)
Grant income		26,879			-			637,027			-
Interest income (expense), net		2,064			2,228			4,206			(74,781	)
Gain on settlement of accounts payable		151,402			-			151,402			-
Financing related charges and adjustments		(72	)		(912,357	)		(1,167	)		(874,706	)
Foreign exchange (loss) gain		(30,906	)		43,609			(46,561	)		66,927
Total other income (expenses), net		149,367			(866,520	)		744,907			(882,560	)
Net loss before provision for income taxes		(2,030,801	)		(1,724,859	)		(5,967,695	)		(2,511,577	)

Income tax expense		-			-			17,615			-

Net loss and comprehensive loss for the period	$	(2,030,801	)	$	(1,724,859	)	$	(5,985,310	)	$	(2,511,577	)

Loss per share
Basic	$	(0.06	)	$	(0.12	)	$	(0.17	)	$	(0.18	)
Diluted	$	(0.06	)	$	(0.12	)	$	(0.17	)	$	(0.18	)

Weighted average number of shares outstanding
Basic		35,214,793			14,326,945			34,589,957			13,609,473
Diluted		35,214,793			14,326,945			34,589,957			13,609,473

SEE ACCOMPANYING NOTES

Page 4

ANAVEX LIFE SCIENCES CORP.

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

for the six months ended March 31, 2016 and 2015

(Unaudited)

	2016			2015

Cash Flows used in Operating Activities
Net loss for the period	$	(5,985,310	)	$	(2,511,577	)
Adjustments to reconcile net loss to net cash used in operations:
Amortization and depreciation		497			498
Accretion of debt discount		1,167			493,451
Stock-based compensation		1,048,710			31,544
Non-cash financing related charges		-			29,000
Change in fair value of derivative financial instruments		-			487,000
Gain on extinguishment of debt		-			(105,745	)
Gain on settlement of accounts payable		(151,402	)		-
Unrealized foreign exchange		2,907			(13,509	)
Changes in non-cash working capital balances related to operations:
Sales tax recoverable		(1,830	)		-
Prepaid expenses and deposits		15,868			-
Accounts payable and accrued liabilities		(14,187	)		225,987
Deferred grant income		(66,169	)		-
Net cash used in operating activities		(5,149,749	)		(1,363,351	)

Cash Flows provided by Financing Activities
Issuance of common shares, net of share issue costs		1,809,620			500,000
Repayment of promissory note		-			(88,144	)
Net cash provided by financing activities		1,809,620			411,856

Decrease in cash during the period		(3,340,129	)		(951,495	)
Cash, beginning of period		15,290,976			7,262,138
Cash, end of period	$	11,950,847		$	6,310,643

Supplemental Cash Flow Information - Note 11

SEE ACCOMPANYING NOTES

Page 5

ANAVEX LIFE SCIENCES CORP.

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY

for the six months ended March 31, 2016

(Unaudited)

	Common Stock
					Additional			Common
					Paid-in			Shares to be			Accumulated
	Shares		Par Value		Capital			Issued			Deficit			Total
Balance, October 1, 2015		32,044,213	$	32,044	$	74,060,999		$	1,997,415		$	(63,281,455	)	$	12,809,003
Equity units issued under Purchase Agreement		290,523		291		1,684,270			-			-			1,684,561
Commitment shares issued under terms of Purchase Agreement		185,179		185		(185	)		-			-			-
Capital stock issued pursuant to debt conversions - at $1.00		168,577		169		168,407			(167,415	)		-			1,161
Shares issued pursuant to the exercise of warrants - at $3.00		41,687		42		125,018			-			-			125,060
Shares issued pursuant to the exercise of warrants - cashless		1,963,956		1,964		(1,964	)		-			-			-
Shares issued pursuant to employment agreement		1,000,000		1,000		2,439,000			(1,830,000	)					610,000
Shares issued for rounding in connection with 4:1 reverse stock split		1,437		2		(2	)		-			-			-
Stock option compensation		-		-		438,710			-			-			438,710
Net loss for the period		-		-		-			-			(5,985,310	)		(5,985,310	)

Balance, March 31, 2016		35,695,572	$	35,697	$	78,914,253		$	-		$	(69,266,765	)	$	9,683,185

SEE ACCOMPANYING NOTES

Page 6

Anavex Life Sciences Corp.

Notes to the Interim Condensed Consolidated Financial Statements

March 31, 2016

(Unaudited)

Note 1

Business Description and Basis of Presentation

Business

Anavex Life Sciences Corp. (the “Company”) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer. The Company’s lead compound ANAVEX 2-73 is being developed to treat Alzheimer’s disease and potentially other central nervous system (CNS) diseases, including rare diseases, such as Rett syndrome.

In December 2014 a Phase 2a clinical trial was initiated for ANAVEX 2-73, which is being evaluated for the treatment of Alzheimer’s disease. The randomized trial is designed to assess the safety and exploratory efficacy of ANAVEX 2-73 alone as well as in combination with donepezil (ANAVEX PLUS) in patients with mild to moderate Alzheimer’s disease. ANAVEX 2-73 targets sigma-1 and muscarinic receptors, which have been shown in preclinical studies to reduce stress levels in the brain and to reverse the pathological hallmarks observed in Alzheimer’s disease. ANAVEX 2-73 showed no serious adverse events in a previously performed Phase 1 study. In pre-clinical studies, ANAVEX 2-73 demonstrated anti-amnesic and neuroprotective properties in various animal models including the transgenic mouse model Tg2576. In February 2016 the Company presented positive preclinical data for ANAVEX 2-73 in Rett syndrome, a rare neurodevelopmental disease indication. In March 2016, the Company received approval from the Ethics Committee in Australia to extend the ongoing Phase 2a clinical trial, which had been requested by the patients and their caregivers. The trial extension will allow participants who complete 52 weeks in Part B to roll-over into a new trial and continue taking ANAVEX 2-73 for an additional 104 weeks, providing an opportunity to gather extended safety data. The trial is independent of the Company’s planned larger Phase 2/3 double-blinded placebo-controlled study of ANAVEX 2-73 in Alzheimer’s disease.

Effective October 7, 2015, the Company effected a reverse stock split on the basis of 1:4. As such, the Company’s authorized capital was decreased from 400,000,000 shares of common stock, par value $0.001 to 100,000,000 shares of common stock, par value $0.001 and all shares of common stock issued and outstanding were decreased on the basis of one new share for each four old shares. These condensed consolidated financial statements give retroactive effect to such reverse split and all share and per share amounts have been adjusted accordingly.

Basis of Presentation

These interim condensed consolidated financial statements have been prepared, without audit pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, certain information and footnote disclosures normally included in the annual financial statements in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, the disclosures are adequate to make the information presented not misleading.

These statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained herein. These interim condensed financial statements should be read in conjunction with the audited financial statements included in its annual report on Form 10-K for the year ended September 30, 2015. The Company follows the same accounting policies in the preparation of interim reports.

Operating results for the six months ended March 31, 2016 are not necessarily indicative of the results that may be expected for the year ending September 30, 2016.

Page 7

Anavex Life Sciences Corp.

Notes to the Interim Condensed Consolidated Financial Statements

March 31, 2016

(Unaudited)

Note 1

Business Description and Basis of Presentation – (cont’d)

Basic and Diluted Loss per Share

The basic loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding. Diluted loss per common share is computed similar to basic loss per common share except that the denominator is increased to include the weighted average of all potentially dilutive shares of common stock that were outstanding during the period. Additionally, the numerator is also adjusted for changes in fair value of the derivative financial instruments where it is presumed they will be share settled.

As of March 31, 2016, loss per share excludes 3,691,291 (September 30, 2015 – 6,101,534) potentially dilutive common shares related to outstanding options, warrants, and convertible debentures as their effect was anti-dilutive.

Note 2

Recent Accounting Pronouncements

Recent Accounting Pronouncements Not Yet Adopted

In June 2014, the FASB issued ASU No. 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period ("ASU 2014-12"). ASU 2014-12 requires that a performance target that affects vesting, and that could be achieved after the requisite service period, be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant date fair value of the award. This update further clarifies that compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. The amendments in this ASU are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. The Company is currently evaluating the impact this guidance will have on its financial condition, results of operations and cash flows.

In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”). ASU 2014-15 will explicitly require management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosure in certain circumstances. The new standard will be effective for all entities in the first annual period ending after December 15, 2016. The Company is currently evaluating the impact this guidance will have on its financial condition, results of operations and cash flows.

In May, 2014, the FASB and the International Accounting Standards Board (IASB) issued a converged standard on revenue recognition from contracts with customers, ASU 2014-09 (Topic 606 and IFRS 15). This standard will supersede nearly all existing revenue recognition guidance. ASU 2014-09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. The adoption of this standard is not expected to have a material impact for any period presented.

Page 8

Anavex Life Sciences Corp.

Notes to the Interim Condensed Consolidated Financial Statements

March 31, 2016

Stated in US Dollars

(Unaudited)

Note 2

Recent Accounting Pronouncements – (cont’d)

In April 2015, the Financial Accounting Standards Board (FASB), issued the Accounting Standards Update 2015-03, Interest - Imputation of Interest (Subtopic 835-30) - Simplifying the Presentation of Debt Issuance Costs, that requires debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction from the debt liability rather than as an asset. For public business entities, the final guidance will be effective for fiscal years beginning after December 15, 2015, however, early adoption (including in interim periods) is permitted. Upon adoption, an entity must apply the new guidance retrospectively to all prior periods presented in the financial statements. An entity is also required in the year of adoption to provide certain disclosures about the change in accounting principle, including the nature of and reason for the change, the transition method, a description of the prior-period information that has been retrospectively adjusted and the effect of the change on the financial statement line items (that is, debt issuance cost asset and the debt liability). The adoption of this standard is not expected to have a material impact for any period presented.

In November 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2015-17 “Income Taxes: Balance Sheet Classification of Deferred Taxes (“ASU 2015-17”). ASU 2015-17 eliminates the requirement to bifurcate deferred taxes between current and non-current on the balance sheet and requires that deferred tax liabilities and assets be classified as noncurrent on the balance sheet. ASU 2015-17 is effective for public entities in fiscal years beginning after December 15, 2016, and for interim periods within those fiscal years. The amendments for ASU-2015-17 can be applied retrospectively or prospectively and early adoption is permitted. The adoption of this standard is not expected to have a material impact for any period presented.

In February 2016, FASB issued ASU 2016-02, Leases. The guidance would require lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right –of-use assets. The guidance is effective for annual and interim reporting periods beginning on or after December 15, 2018. The Company is currently evaluating the impact this guidance will have on its financial condition, results of operations and cash flows.

In March 2016, the FASB issued ASC 2016-09, “Compensation – Stock Compensation (Topic 718) – Improvements to Employee Share-Based Payment Accounting”. These amendments are intended to simplify several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. These amendments are effective for annual and interim reporting periods beginning on or after December 15, 2016. Early adoption is permitted. Entities have the option to apply the amendments on either a prospective basis or a modified retrospective basis. The Company is currently evaluating the impact this guidance will have on its financial condition, results of operations and cash flows.

Other than noted above, the Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on its results of operations, financial position or cash flow.

Page 9

Anavex Life Sciences Corp.

Notes to the Interim Condensed Consolidated Financial Statements

March 31, 2016

Stated in US Dollars

(Unaudited)

Note 3

Equipment

	March 31, 2016
			Accumulated
	Cost		Depreciation		Net

Computer equipment	$	3,015	$	2,260	$	755

	September 30, 2015
			Accumulated
	Cost		Depreciation		Net

Computer equipment	$	3,015	$	1,763	$	1,252

Note 4

Promissory Notes Payable

	March 31,		September 30,
	2016		2015

Promissory note dated January 9, 2013 with a principal balance of CDN$86,677, bearing interest at 12% per annum, secured by all the present and future assets of the Company; due on demand	$	66,834	$	64,630

Promissory note dated January 9, 2013 with a principal balance of CDN$27,639, bearing interest at 12% per annum, secured by all the present and future assets of the Company; due on demand		21,311		20,608
	$	88,145	$	85,238

On January 9, 2013, the Company issued two (2) promissory notes (the “Secured Notes”);

The Company issued a promissory note in the amount of CDN$86,677 to the former President, Secretary, Treasurer, CFO and director of the Company (the “President”) in exchange for unpaid consulting fees owing to the President. The note is bearing interest at 12% per annum and was due June 30, 2013.

The Company issued a promissory note in the amount of CDN$27,639 to a former director of the Company (the “Director”) in exchange for unpaid consulting fees owing to the Director. The note is bearing interest at 12% per annum and was due June 30, 2013.

Page 10

Anavex Life Sciences Corp.

Notes to the Interim Condensed Consolidated Financial Statements

March 31, 2016

Stated in US Dollars

(Unaudited)

Note 4

Promissory Notes Payable – (continued)

The Secured Notes are secured by a right to delay the transfer of any or all of the Company’s assets until the obligations of the Secured Notes are satisfied, including a restriction on the transfer of cash by the Company and a security interest over the intellectual property of the Company. The security interests of the Secured Notes is ranked senior to any and all security interests granted prior to the issuance of the notes and to all subsequent security interests granted, unless the holders agree in writing to other terms.

In addition, the Secured Notes contain a provision whereby if they are not repaid within 10 days of their maturity dates, they shall bear late fees in addition to interest accruing, at a rate of $100 per day per note. In an event of default by the Company, under the terms of the Secured Notes, the notes shall bear additional late fees of $500 per day per note.

Subsequent to the issuance of these Secured Notes, the former President resigned as President, Secretary, Treasurer, CFO and director of the Company and the former Director resigned as director of the Company.

The Company did not repay the notes on their maturity. The Company has disputed the issuance and enforceability of the Secured Notes and should there be an attempt to enforce the Secured Notes or collection on them, the Company will consider a legal remedy. The Company has not accrued any late fees in connection with these Secured Notes as of March 31, 2016 or September 30, 2015, as the Company does not consider these amounts to be legally enforceable.

Note 5

Deferred Grant Income

During the year ended September 30, 2015, the Company was awarded grant funding in the amount of $286,455, of which the Company received $71,614 during the year ended September 30, 2015 and the remainder will be received in equal semi-annual instalments over the 24-month commitment. The grant was received in exchange for a commitment to provide research and development for preclinical validation of Sigma-1 receptor agonism as potential treatment for Parkinsons’ disease.

The grant income was deferred and is being amortized as an increase to other income over a two-year period as the related research and development expenditures are incurred. During the three and six months ended March 31, 2016, the Company recognized $26,879 and $65,934, respectively (2015: $0 and $0, respectively) of this grant on its statement of operations.

During the six months ended March 31, 2016, the Company recognized other grant income of $571,093 in respect of a research and development incentive program offered by the Australian government.

Page 11

Anavex Life Sciences Corp.

Notes to the Interim Condensed Consolidated Financial Statements

March 31, 2016

Stated in US Dollars

(Unaudited)

Note 6

Senior Convertible Debentures

	March 31,			September 30,
Senior Convertible Debentures	2016			2015

Senior Convertible Debentures, non-interest bearing, unsecured, due March 18, 2044	$	4,982		$	6,144
Less: Debt Discount		(4,645	)		(5,812	)
Total carrying value		337			332
Less: current portion		-			-
Long term liability	$	337		$	332

On March 13, 2014, the Company entered into a Securities Purchase Agreement with certain purchasers, pursuant to which the Company issued senior convertible debentures in the aggregate principal amount of $10,000,000 (the “Debentures”). At March 31, 2016, aggregate principal amounts of $4,982 (September 30, 2015: $6,144) of these Debentures remained outstanding.

The Debentures are unsecured, non-interest bearing and are due on March 18, 2044. The Debentures were originally convertible, in whole or in part, at the option of the holder into common shares of the Company at $1.20 per share (“the Conversion Price”). The Conversion Price of the debenture will be adjusted in the event of common stock dividend, split or consolidation. The Conversion Price was later amended to $1.00 per share.

The Company has recorded a debt discount in connection with the issuance and amendment of the Debentures during the year ended September 30, 2014, which is being amortized using the effective interest method over the term of the Debentures. During the three and six months ended March 31, 2016, the Company recorded $72 and $1,167, respectively (2015: $486,334 and $493,451, respectively) in respect of the amortization of this discount.

During the six months ended March 31, 2016, the Company issued an aggregate of 1,161 shares of common stock based on a conversion price of $1.00 per share pursuant to the conversion of $1,161 in outstanding principal amounts due under the Debentures.

Page 12

Anavex Life Sciences Corp.

Notes to the Interim Condensed Consolidated Financial Statements

March 31, 2016

Stated in US Dollars

(Unaudited)

Note 7

Capital Stock

Authorized

100,000,000 shares of common stock.

Equity Transactions

During the six months ended March 31, 2016, the Company issued 167,415 shares of common stock pursuant to the application of an incorrect conversion price for conversion notices received in respect of the Debentures, during the year ended September 30, 2015.

During the six months ended March 31, 2016, the Company issued 1,000,000 shares of common stock to a director and officer of the Company pursuant to the terms of an employment agreement with that director and officer (Note 9).

Note 8

Lincoln Park Purchase Agreement

2013 Purchase Agreement

On July 5, 2013, the Company entered into a $10,000,000 purchase agreement (the “2013 Purchase Agreement”) with Lincoln Park Capital Fund, LLC, (“Lincoln Park”) an Illinois limited liability company (the “Financing”) pursuant to which the Company sold and issued to Lincoln Park, and Lincoln Park purchased $10,000,000 in value of its shares of common stock from time to time over a 25-month period. At any time, the Company would determine, at its own discretion, the timing and amount of its sales of common stock, subject to certain conditions and limitations.

During the six months ended March 31, 2016, the Company issued to Lincoln Park an aggregate of 296,104 shares of common stock under the 2013 Purchase Agreement, including 290,523 shares of common stock for an aggregate purchase price of $1,684,561 and 5,581 commitment shares, representing all remaining purchase amounts available under the 2013 Purchase Agreement. As such, no further shares will be sold under the 2013 Purchase Agreement.

2015 Purchase Agreement

On October 21, 2015, the Company entered into a $50,000,000 purchase agreement (the “2015 Purchase Agreement”) with Lincoln Park pursuant to which the Company may sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase, up to $50,000,000 in value of its shares of common stock from time to time over a 36-month period. In connection with the 2015 Purchase Agreement, the Company also entered into a registration rights agreement with Lincoln Park whereby the Company agreed to file a registration statement with the SEC covering the shares of the Company’s common stock that may be issued to Lincoln Park under the 2015 Purchase Agreement.

The Company may direct Lincoln Park, at its sole discretion, and subject to certain conditions, to purchase up to 50,000 shares of common stock on any business day, provided that at least one business day has passed since the most recent purchase. The amount of a purchase may be increased under certain circumstances provided, however that Lincoln Park’s committed obligation under any single purchase shall not exceed $2,000,000. The purchase price of shares of common stock related to the future funding will be based on the then prevailing market prices of such shares at the time of sales as described in the 2015 Purchase Agreement.

Page 13

Anavex Life Sciences Corp.

Notes to the Interim Condensed Consolidated Financial Statements

March 31, 2016

Stated in US Dollars

(Unaudited)

Note 8

Lincoln Park Purchase Agreement – (continued)

During the six months ended March 31, 2016 and in consideration for entering into the 2015 Purchase Agreement, the Company issued to Lincoln Park 179,598 shares of common stock as an initial commitment fee and shall issue up to 89,799 shares pro rata, when and if, Lincoln Park purchases at the Company’s discretion the $50,000,000 aggregate commitment.

Note 9

Related Party Transactions

During the three and six months ended March 31, 2016, the Company accrued general and administrative expenses totaling $125,078 and $3,169,933, respectively (March 31, 2015: $16,082 and $32,465, respectively) in respect of directors fees, restricted stock compensation and stock option compensation charges paid or accrued to directors and officers of the Company. Of the total, $121,578 and $258,092, respectively (March 31, 2015: $13,582 and $27,465, respectively) related to non-cash stock option compensation charges, $0 and $610,000, respectively (March 31, 2015: $0 and $0, respectively) related to non-cash restricted stock compensation charges, and $0 and $2,290,341, respectively (March 31, 2015: $0 and $0, respectively) related to a tax payment made on behalf of a director and officer of the Company, in accordance with the terms of a 2013 employment agreement.

The fair value of $2.44 per share for non-cash restricted stock compensation charges was determined with reference to the quoted market price of the Company’s shares on the commitment date.

As at March 31, 2016, included in accounts payable and accrued liabilities was $30,500 (September 30, 2015: $33,000) owing to directors and officers of the Company for director fees and reimbursable expenses, and a former director and officer of the Company for unpaid fees.

Page 14

Anavex Life Sciences Corp.

Notes to the Interim Condensed Consolidated Financial Statements

March 31, 2016

Stated in US Dollars

(Unaudited)

Note 10

Commitments

Share Purchase Warrants

A summary of the Company’s share purchase warrants outstanding is presented below:

				Weighted
				Average
	Number of Shares			Exercise Price
Balance, October 1, 2014		18,728,910		$	1.59
Expired		(62,500	)	$	1.40
Exercised		(15,468,520	)	$	1.43
Issued		1,075,000		$	0.76
Balance, September 30, 2015		4,272,890		$	2.11
Exercised		(2,444,831	)	$	1.68
Balance, March 31, 2016		1,828,059		$	2.68

During the six months ended March 31, 2016, the Company issued 1,963,956 shares of common stock pursuant to the exercise of 2,403,144 share purchase warrants on a cashless basis.

At March 31, 2016, the Company has 1,828,059 currently exercisable share purchase warrants outstanding as follows:

Number		Exercise Price		Expiry Date
	1,462,180	$	3.00	July 5, 2018
	30,000	$	4.00	February 24, 2019
	277,127	$	1.20	March 13, 2019
	1,252	$	1.68	March 13, 2019
	12,500	$	1.24	May 31, 2019
	45,000	$	1.00	July 31, 2019
	1,828,059

All of the warrants expiring on July 5, 2018 contain a contingent call provision whereby the Company may have the option to call for cancellation of all or any portion of the warrants for consideration equal to $0.001 per share, provided the quoted market price of the Company’s common stock exceeds $6.00 for a period of twenty consecutive trading days, subject to certain minimum volume restrictions and other restrictions as provided in the warrant agreements.

During the years ended September 30, 2015 and 2014, the Company issued an aggregate of 57,500 warrants exercisable at a weighted average exercise price of $1.24 per share for a period of 4.58 years from the date of issuance in exchange for consulting services to be rendered. The weighted average grant date fair value of these warrants at issuance was $0.899 per warrant, based on the Black-Scholes option pricing model using the following weighted average assumptions: expected term 4.44 years, expected volatility 108.43%, expected dividend yield 0.00%, risk free interest rate 1.21%. Stock based compensation is being recorded in the financial statements over the vesting term of three years from the date of grant. During the three and six months ended March 31, 2016, the Company recorded $23,570 and $47,230, respectively (March 31, 2015: $2,378 and $3,634, respectively), in connection with the warrants granted.

Page 15

Anavex Life Sciences Corp.

Notes to the Interim Condensed Consolidated Financial Statements

March 31, 2016

Stated in US Dollars

(Unaudited)

Note 10

Commitments – (cont’d)

Stock–based Compensation Plan

2015 Stock Option Plan

On September 18, 2015, the Company’s board of directors approved a 2015 Omnibus Incentive Plan (the “2015 Plan”), which provides for the grant of stock options and restricted stock awards to directors, officers, employees and consultants of the Company.

The maximum number of our common shares reserved for issue under the plan is 6,050,553 shares subject to adjustment in the event of a change of the Company’s capitalization. As a result of the adoption of the 2015 Plan, no further option awards will be granted under any previously existing stock option plan. Stock option awards previously granted under previously existing stock option plans remain outstanding in accordance with their terms.

The 2015 Plan is administered by the board of directors, except that it may, in its discretion, delegate such responsibility to a committee of such board. The exercise price will be determined by the board of directors at the time of grant but in no event will be less than 110% of fair market value of the Company’s shares of common stock on the grant date. Stock options may be granted under the 2015 Plan for an exercise period of up to ten years from the date of grant of the option or such lesser periods as may be determined by the board, subject to earlier termination in accordance with the terms of the 2015 Plan.

A summary of the status of Company’s outstanding stock purchase options for the six months ended March 31, 2016 and for the year ended September 30, 2015 is presented below:

				Weighted		Weighted Average
	Number of			Average		Grant Date fair
	Shares			Exercise Price		value
Outstanding at October 1, 2014		792,500		$	2.82
Forfeited		(67,500	)	$	12.00
Granted		1,097,500		$	2.02	$	1.66
Outstanding at September 30, 2015		1,822,500		$	2.00
Forfeited		-		$	-
Granted		60,750		$	7.02	$	5.75
Expired		(25,000	)	$	14.68
Outstanding at March 31, 2016		1,858,250		$	1.99
Exercisable at March 31, 2016		890,399		$	1.73
Exercisable at September 30, 2015		825,002		$	1.78

Page 16

Anavex Life Sciences Corp.

Notes to the Interim Condensed Consolidated Financial Statements

March 31, 2016

Stated in US Dollars

(Unaudited)

Note 10

Commitments – (cont’d)

Stock–based Compensation Plan – (cont’d)

At March 31, 2016, the following stock options were outstanding:

Number of Shares								Aggregate		Remaining
			Number		Exercise			Intrinsic		Contractual
Total			Vested		Price		Expiry Date	Value		Life (yrs)
	500,000	⁽¹⁾		500,000	$	1.60	July 5, 2023		1,650,000		7.26
	75,000	⁽²⁾		25,000	$	1.20	May 7, 2024		277,500		8.10
	125,000	⁽³⁾		31,250	$	1.32	May 8, 2024		447,500		8.10
	718,750	⁽⁴⁾		239,585	$	0.92	April 2, 2025		2,860,625		9.00
	50,000	⁽⁵⁾		12,500	$	1.44	June 8, 2025		173,000		9.19
	50,000	⁽⁶⁾		-	$	1.68	June 15, 2025		161,000		9.21
	278,750	⁽⁷⁾		69,688	$	5.04	September 18, 2025		-		9.47
	1,500	⁽⁸⁾		1,500	$	5.64	September 30, 2025		-		9.50
	31,250	⁽⁹⁾		5,209	$	5.68	October 2, 2025		-		9.51
	25,000	⁽¹⁰⁾		4,167	$	8.98	October 16, 2025		-		9.54
	1,500	⁽¹¹⁾		1,500	$	5.57	December 31, 2025		-		9.75
	1,500	⁽¹²⁾		-	$	4.90	March 31, 2026		-		10.00
	1,858,250			890,399				$	5,569,625

The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted market price of the Company’s stock for the options that were in-the-money at March 31, 2016.

⁽¹⁾

⁽²⁾

As of March 31, 2016 and September 30, 2015, 25,000 of these options had vested. These options were issued during the year ended September 30, 2014 and vest annually over a three-year period commencing on the first anniversary of the date of the grant. The Company recognized stock based compensation expense of $5,764 and $11,590 during the three and six months ended March 31, 2016, respectively (March 31, 2015: $5,830 and $11,660, respectively) in connection with these options. These amounts have been included in general and administrative expenses on the Company’s statement of operations.

Page 17

Anavex Life Sciences Corp.

Notes to the Interim Condensed Consolidated Financial Statements

March 31, 2016

Stated in US Dollars

(Unaudited)

Note 10

Commitments – (cont’d)

Stock–based Compensation Plan – (cont’d)

⁽³⁾

As of March 31, 2016 and September 30, 2015, 31,250 of these options had vested. These options were issued during the year ended September 30, 2014 and vest annually over a four-year period commencing on the first anniversary of the date of the grant. The Company recognized stock based compensation expense of $7,960 and $16,008 during the three and six months ended March 31, 2016, respectively (March 31, 2015: $8,053 and $16,106, respectively) in connection with these options. These amounts have been included in general and administrative expenses on the Company’s statement of operations.

⁽⁴⁾

As of March 31, 2016, 239,585 of these options had vested (September 30, 2015: 239,585 of these options had vested). These options were issued during the year ended September 30, 2015 and vest in three equal installments on April 2, 2015, April 2, 2016 and April 2, 2017. The Company recognized stock based compensation expense of $42,811 and $86,093 during the three and six months ended March 31, 2016, respectively (March 31, 2015: $0 and $0, respectively) in connection with these options. These amounts have been included in general and administrative expenses on the Company’s statement of operations.

⁽⁵⁾

As of March 31, 2016, 12,500 of these options had vested. These options were issued during the year ended September 30, 2015 and vest quarterly over a three-year period commencing on September 8, 2015. The Company recognized stock based compensation expense of $4,775 and $9,603 during the three and six months ended March 31, 2016, respectively (March 31, 2015: $0 and $0, respectively) in connection with these options. These amounts have been included in general and administrative expenses on the Company’s statement of operations.

⁽⁶⁾

As of March 31, 2016 and September 30, 2015, none of these options had vested. These options were issued during the year ended September 30, 2015 and vest over a three-year period from the date of grant. The Company recognized stock based compensation expense of $5,573 and $11,207 during the three and six months ended March 31, 2016, respectively (March 31, 2015: $0 and $0, respectively) in connection with these options. These amounts have been included in general and administrative expenses on the Company’s statement of operations.

⁽⁷⁾

As of March 31, 2016 and September 30, 2015, 69,688 of these options had vested. These options were issued during the year ended September 30, 2015 and vest over a three-year period from the date of grant. The Company recognized stock based compensation expense of $92,875 and $192,024 during the three and six months ended March 31, 2016, respectively (March 31, 2015: $0 and $0, respectively) in connection with these options. These amounts have been included in general and administrative expenses on the Company’s statement of operations.

⁽⁸⁾

As of March 31, 2016, all of these options had vested. These options vested on December 31, 2015. The Company recognized stock based compensation expense of $0 and $6,800 during the three and six months ended March 31, 2016, respectively (March 31, 2015: $0 and $0) in connection with these options. These amounts have been included in general and administrative expenses on the Company’s statement of operations.

⁽⁹⁾

As of March 31, 2016, 5,209 of these options had vested. These options were issued during the six months ended March 31, 2016 and vest in equal quarterly instalments over a three-year period from the date of grant. The Company recognized stock based compensation expense of $11,456 and $23,449 during the three and six months ended March 31, 2016, respectively (March 31, 2015: $0 and $0, respectively) in connection with these options. These amounts have been included in general and administrative expenses on the Company’s statement of operations.

Page 18

Anavex Life Sciences Corp.

Notes to the Interim Condensed Consolidated Financial Statements

March 31, 2016

Stated in US Dollars

(Unaudited)

Note 10

Commitments – (cont’d)

Stock–based Compensation Plan – (cont’d)

⁽¹⁰⁾

As of March 31, 2016, 4,167 of these options had vested. These options were issued during the six months ended March 31, 2016 and vest in equal quarterly instalments over a three-year period from the date of grant. The Company recognized stock based compensation expense of $27,906 and $27,906 during the three and six months ended March 31, 2016, respectively (March 31, 2015: $0 and $0, respectively) in connection with these options. These amounts have been included in general and administrative expenses on the Company’s statement of operations.

⁽¹¹⁾

As of March 31, 2016, all of these options had vested. These options were issued during the six months ended March 31, 2016 and vested on December 31, 2015. The Company recognized stock based compensation expense of $0 and $6,800 during the three and six months ended March 31, 2016, respectively (March 31, 2015: $0 and $0) in connection with these options. These amounts have been included in general and administrative expenses on the Company’s statement of operations.

⁽¹²⁾

As of March 31, 2016, none of these options had vested. These options were issued during the six months ended March 31, 2016 and vest on December 31, 2016. The Company recognized stock based compensation expense of $0 and $0 during the three and six months ended March 31, 2016, respectively (March 31, 2015: $0 and $0) in connection with these options. These amounts have been included in general and administrative expenses on the Company’s statement of operations.

The fair value of each option award is estimated on the date of grant using the Black Scholes option pricing model based on the following weighted average assumptions:

	March 31,
	2016			2015
Risk-free interest rate		1.68	%		-
Expected life of options (years)		6.76			-
Annualized volatility		101.92	%		-
Dividend rate		0.00	%		-

Page 19

Anavex Life Sciences Corp.

Notes to the Interim Condensed Consolidated Financial Statements

March 31, 2016

Stated in US Dollars

(Unaudited)

Note 11

Supplemental Cash Flow Information

Investing and financing activities that do not have a direct impact on current cash flows are excluded from the statement of cash flows.

During the six months ended March 31, 2016;

the Company issued 1,161 shares of common stock upon conversion of $1,161 in principal amount of convertible debentures at a conversion price of $1.00 per share and 167,415 shares of common stock pursuant to the application of an incorrect conversion price for conversion notices received during the year ended September 30, 2015;

During the six months ended March 31, 2015;

the Company issued 3,918,478 shares of common stock of the Company pursuant to the conversion of convertible debentures at a conversion price of $1.00 per share

ii)

the Company reclassified an amount of $3,931,000 into equity upon modification of the terms of certain derivative instruments.

These transactions have been excluded from the statement of cash flows.

Page 20

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Forward-Looking Statements

This Quarterly Report on Form 10-Q includes forward-looking statements. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our anticipated future clinical and regulatory milestone events, future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. Such forward-looking statements include, without limitation, statements regarding the anticipated start dates, durations and completion dates of our ongoing and future clinical studies, statements regarding the anticipated designs of our future clinical studies, statements regarding our anticipated future regulatory submissions and statements regarding our anticipated future cash position. We have based these forward-looking statements largely on our current expectations and projections about future events, including the responses we expect from the U.S. Food and Drug Administration, or FDA, and other regulatory authorities and financial trends that we believe may affect our financial condition, results of operations, business strategy, preclinical and clinical trials and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions including without limitation the risks described in “Risk Factors” in Part I, Item 1A of our most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission on December 29, 2015. These risks are not exhaustive. Other sections of this Quarterly Report on Form 10-Q include additional factors which could adversely impact our business and financial performance. Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. We cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable laws including the securities laws of the United States, we assume no obligation to update or supplement forward-looking statements.

As used in this Quarterly Report on Form 10-Q, the terms “we,” “us,” “our,” and “Anavex” mean Anavex Life Sciences Corp., unless the context clearly requires otherwise.

Our Current Business

In December 2014 a Phase 2a clinical trial was initiated for ANAVEX 2-73, which is being evaluated for the treatment of Alzheimer’s disease. This randomized trial is designed to assess the safety and exploratory efficacy of ANAVEX 2-73 alone as well as in combination with donepezil (ANAVEX PLUS) in patients with mild to moderate Alzheimer’s disease. ANAVEX 2-73 targets sigma-1 and muscarinic receptors, which have been shown in preclinical studies to reduce stress levels in the brain and to reverse the pathological hallmarks observed in Alzheimer’s disease. ANAVEX 2-73 showed no serious adverse events in a previously performed Phase 1 study. In pre-clinical studies, ANAVEX 2-73 demonstrated anti-amnesic and neuroprotective properties in various animal models including the transgenic mouse model Tg2576. In March, 2016, we received approval from the Ethics Committee in Australia to extend the ongoing Phase 2a clinical trial, which had been requested by patients and their caregivers. The trial extension allows participants who complete 52 weeks in PART B to roll-over into a new trial and continue taking ANAVEX 2-73 for an additional 104 weeks, providing an opportunity to gather extended safety data. The trial is independent of the Company’s planned larger Phase 2/3 double-blinded, placebo-controlled study of ANAVEX 2-73 in Alzheimer’s disease.

Page 21

In February 2016 the Company presented positive preclinical data for ANAVEX 2-73 in Rett syndrome, a rare neurodevelopmental disease indication.

We intend to identify and initiate discussions with potential partners in the next 12 months. Further, we may acquire or develop new intellectual property and assign, license, or otherwise transfer our intellectual property to further our goals.

Effective October 7, 2015, our Company effected a reverse stock split on the basis of 1:4. As such, our Company’s authorized capital was decreased from 400,000,000 shares of common stock, par value $0.001 to 100,000,000 shares of common stock, par value $0.001 and all shares of common stock issued and outstanding were decreased on the basis of one new share for each four old shares.

Our Pipeline

Our research and development pipeline includes one clinical drug candidate and several compounds in different stages of pre-clinical study.

Our proprietary SIGMACEPTOR™ Discovery Platform produced small molecule drug candidates with unique modes of action, based on our understanding of sigma receptors. Sigma receptors may be targets for therapeutics to combat many human diseases, both of neurodegenerative nature, including Alzheimer’s disease, as well as of neurodevelopmental nature, like Rett syndrome, a rare disease. When bound by the appropriate ligands, sigma receptors influence the functioning of multiple biochemical signals that are involved in the pathogenesis (origin or development) of disease.

Compounds that have been subjects of our research include the following:

ANAVEX 2-73

ANAVEX 2-73 may offer a disease-modifying approach in Alzheimer’s disease (AD) by using ligands that activate sigma-1 receptors.

In AD animal models, ANAVEX 2-73 has shown pharmacological, histological and behavioral evidence as a potential neuroprotective, anti-amnesic, anti-convulsive and anti-depressive therapeutic agent, due to its potent affinity to sigma-1 receptors and moderate affinities to M1-4 type muscarinic receptors. In addition, ANAVEX 2-73 has shown a potential dual mechanism which may impact both amyloid and tau pathology. In a transgenic AD animal model Tg2576 ANAVEX 2-73 induced a statistically significant neuroprotective effect against the development of oxidative stress in the mouse brain, as well as significantly increased the expression of functional and synaptic plasticity markers that is apparently amyloid-beta independent. It also statistically alleviated the learning and memory deficits developed over time in the animals, regardless of sex, both in terms of spatial working memory and long-term spatial reference memory.

Based on the results of pre-clinical testing, we initiated and completed a Phase 1 single ascending dose (SAD) clinical trial of ANAVEX 2-73 in 2011. In this Phase 1 SAD trial, the maximum tolerated single dose was defined per protocol as 55-60 mg. This dose is above the equivalent dose shown to have positive effects in mouse models of AD. There were no significant changes in laboratory or electrocardiogram (ECG) parameters. ANAVEX 2-73 was well tolerated below the 55-60 mg dose with only mild adverse events in some subjects. Observed adverse events at doses above the maximum tolerated single dose included headache and dizziness, which were moderate in severity and reversible. These side effects are often seen with drugs that target central nervous system (CNS) conditions, including AD.

Page 22

The ANAVEX 2-73 Phase 1 SAD trial was conducted as a randomized, placebo-controlled study. Healthy male volunteers between the ages of 18 and 55 received single, ascending oral doses over the course of the trial. Study endpoints included safety and tolerability together with pharmacokinetic parameters. Pharmacokinetics includes the absorption and distribution of a drug, the rate at which a drug enters the blood and the duration of its effect, as well as chemical changes of the substance in the body. This study was conducted in Germany in collaboration with ABX-CRO, a clinical research organization that has conducted several Alzheimer’s disease studies, and the Technical University of Dresden.

Initial analysis of Phase 2a data demonstrated that the study met the primary objective of safety as ANAVEX 2-73 was well tolerated and results were consistent with prior Phase 1 clinical trial data. The secondary objectives were also met, with ANAVEX 2-73 showing cognitive improvement across all doses in all exploratory cognitive measurements, including the Cogstate battery, Mini Mental State Examination (MMSE), event-related potentials (ERP) and P300 tests, which consistently demonstrated improvements from baseline in the completed PART A portion of the study in 32 mild-to-moderate Alzheimer’s patients.

Recent preclinical data validates ANAVEX 2-73 as a prospective platform drug for other neurodegenerative diseases beyond Alzheimer’s as well as neurodevelopmental diseases, most specifically epilepsy and Rett syndrome. For epilepsy, data demonstrates both significant and dose related improvement in the reduction of seizures, as well as significant synergy with each of three generations of epilepsy drugs currently on the market. In Rett syndrome, a rare neurodevelopmental disease indication, administration of ANAVEX 2-73 resulted in both significant and dose related improvements in an array of behavioural paradigms in the MECP2 HET Rett syndrome disease model.

ANAVEX PLUS

ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept®) is a potential novel combination drug for Alzheimer’s disease. Aricept® (donepezil) is now generic. ANAVEX 2-73 showed in combination with donepezil an unexpected and clear synergic effect of memory improvement by up to 80% in animal models. A patent application was filed in the US for the combination of donepezil and ANAVEX 2-73 and if granted would give patent protection at least until 2033.

In a humanized calibrated cortical network computer model the unexpected pre-clinical synergy between ANAVEX 2-73 and donepezil was confirmed and ANAVEX PLUS showed an anticipated ADAS-Cog response of 7 points at 12 weeks and 5.5 points at 26 weeks, which represents more than 2x the ADAS-Cog of donepezil alone.

ANAVEX 3-71

ANAVEX 3-71, previously named AF710B is a preclinical drug candidate with a novel mechanism of action via sigma-1 receptor activation and M1 muscarinic allosteric modulation, which has shown to enhance neuroprotection and cognition in Alzheimer's disease. ANAVEX 3-71 is a CNS-penetrable mono-therapy that bridges treatment of both cognitive impairments with disease modifications. It is highly effective in very small doses against the major Alzheimer's hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also has beneficial effects on inflammation and mitochondrial dysfunctions. ANAVEX 3-71 indicates extensive therapeutic advantages in Alzheimer's and other protein-aggregation-related diseases given its ability to enhance neuroprotection and cognition via sigma-1 receptor activation and M1 muscarinic allosteric modulation.

Page 23

A recent preclinical study examined the response of ANAVEX 3-71 in aged transgenic animal models, and showed a significant reduction in rate of cognitive deficit, amyloid beta pathology and inflammation with the administration of ANAVEX 3-71. In April 2016 the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ANAVEX 3-71 for the treatment of Frontotemporal dementia (FTD).

ANAVEX 1-41

ANAVEX 1-41 is a sigma-1 agonist. Pre-clinical tests revealed significant neuroprotective benefits (i.e., protects nerve cells from degeneration or death) through the modulation of endoplasmic reticulum, mitochondrial and oxidative stress, which damages and destroys cells and is believed by some scientists to be a primary cause of AD. In addition, in animal models, ANAVEX 1-41 prevented the expression of caspase-3, an enzyme that plays a key role in apoptosis (programmed cell death) and loss of cells in the hippocampus, the part of the brain that regulates learning, emotion and memory. These activities involve both muscarinic and sigma-1 receptor systems through a novel mechanism of action.

ANAVEX 1037

ANAVEX 1037 is designed for the treatment of prostate cancer. It is a low molecular weight, synthetic compound exhibiting high affinity for sigma-1 receptors at nanomolar levels and moderate affinity for sigma-2 receptors and sodium channels at micromolar levels. In advanced pre-clinical studies, this compound revealed antitumor potential with no toxic side effects. It has also been shown to selectively kill human cancer cells without affecting normal/healthy cells and also to significantly suppress tumor growth in immune-deficient mice models. Scientific publications describe sigma receptor ligands positively, highlighting the possibility that these ligands may stop tumor growth and induce selective cell death in various tumor cell lines. Sigma receptors are highly expressed in different tumor cell types. Binding by appropriate sigma-1 and/or sigma-2 ligands can induce selective apoptosis. In addition, through tumor cell membrane reorganization and interactions with ion channels, our drug candidates may play an important role in inhibiting the processes of metastasis (spreading of cancer cells from the original site to other parts of the body), angiogenesis (the formation of new blood vessels) and tumor cell proliferation.

Our compounds are in the pre-clinical and clinical testing stages of development, and there is no guarantee that the activity demonstrated in pre-clinical models will be shown in human testing.

Our Target Indications

We have developed compounds with potential application to two broad categories and several specific indications. The two categories are diseases of the central nervous system, and cancer. Specific indications include:

Alzheimer’s disease - In 2014, an estimated 5.2 million Americans were suffering from Alzheimer’s disease. The Alzheimer’s Association® reports that by 2025, 7.1 million Americans will be afflicted by the disease, a 40 percent increase from currently affected patients. Medications on the market today treat only the symptoms of Alzheimer’s disease and do not have the ability to stop its onset or its progression. There is an urgent and unmet need for both a disease modifying cure for Alzheimer’s disease as well as for better symptomatic treatments.

Depression - Depression is a major cause of morbidity worldwide according to the World Health Organization (WHO). Pharmaceutical treatment for depression is dominated by blockbuster brands, with the leading nine brands accounting for approximately 75% of total sales. However, the dominance of the leading brands is waning, largely due to the effects of patent expiration and generic competition. Our market research leads us to believe that the worldwide market for pharmaceutical treatment of depression exceeds $11 billion annually.

Page 24

Epilepsy - Epilepsy is a common chronic neurological disorder characterized by recurrent unprovoked seizures. These seizures are transient signs and/or symptoms of abnormal, excessive or synchronous neuronal activity in the brain. According to the Centers for Disease Control and Prevention, epilepsy affects 2.2 million Americans. Today, epilepsy is often controlled, but not cured, with medication that is categorized as older traditional anti-epileptic drugs and second generation anti epileptic drugs. Because epilepsy afflicts sufferers in different ways, there is a need for drugs used in combination with both traditional anti-epileptic drugs and second generation anti-epileptic drugs. GBI Research estimates that the epilepsy market will increase to $4.5 billion by 2019.

Neuropathic Pain – We define neuralgia, or neuropathic pain, as pain that is not related to activation of pain receptor cells in any part of the body. Neuralgia is more difficult to treat than some other types of pain because it does not respond well to normal pain medications. Special medications have become more specific to neuralgia and typically fall under the category of membrane stabilizing drugs or antidepressants. Our market research leads us to believe the worldwide market for pharmaceutical treatment of neuropathic pain exceeds $5 billion annually.

Malignant Melanoma - Predominantly a skin cancer, malignant melanoma can also occur in melanocytes found in the bowel and the eye. Malignant melanoma accounts for 75% of all deaths associated with skin cancer. The treatment includes surgical removal of the tumor, adjuvant treatment, chemo and immunotherapy, or radiation therapy. According to IMS Health the worldwide Malignant Melanoma market is expected to grow to $4.4 billion by 2022.

Prostate Cancer – Specific to men, prostate cancer is a form of cancer that develops in the prostate, a gland in the male reproductive system. The cancer cells may metastasize from the prostate to other parts of the body, particularly the bones and lymph nodes. Drug therapeutics for Prostate Cancer are expected to increase to nearly $18.6 billion in 2017 according to BCC Research.

Pancreatic Cancer - Pancreatic cancer is a malignant neoplasm of the pancreas. In the United States approximately 45,000 new cases of pancreatic cancer will be diagnosed this year and approximately 38,000 patients will die as a result of their cancer. Sales predictions by GlobalData forecast that the market for the pharmaceutical treatment of pancreatic cancer in the five largest European countries and the United States, will increase to $1.63 billion by 2017.

Recent Corporate Developments

Since January 1, 2016, we have experienced the following significant corporate developments:

On January 11, 2016, our Company reported that a positive dose-response relationship had been observed in Alzheimer's patients. Cognition scores improved with ANAVEX 2-73 dose in a pre-planned interim analysis of data from the ongoing Phase 2a trial of ANAVEX 2-73 for treatment of mild to moderate Alzheimer’s disease.

In addition, in March, 2016, our Company received approval from the Ethics Committee in Australia to extend the ongoing Phase 2a trial, which had been requested by patients and their caregivers. The trial extension is designed to allow participants who complete 52 weeks in PART B to roll-over into a new trial and continue taking ANAVEX 2-73 for an additional 104 weeks, providing an opportunity to gather extended safety data. The trial is independent of our Company’s planned larger Phase 2/3 double-blinded, placebo-controlled study of ANAVEX 2-73 in Alzheimer’s disease.

On February 25, 2016, our Company announced positive data of ANAVEX 2-73 in an exploratory study in a Rett syndrome model at the 2016 Epilepsy Pipeline Conference held February 25-26, 2016 in San Francisco, CA. The data demonstrated dose related and significant improvements in an array of behavioral and gait paradigms in a mouse model with a MECP2-null mutation that causes neurological symptoms that mimic Rett syndrome.

On March 14, 2016, our Company announced positive preclinical data on sigma-1 agonist ANAVEX 3-71 (formerly AF710B). The data shows a statistically significant reduction in the rate of cognitive deficit, amyloid beta pathology and inflammation with the administration of ANAVEX 3-71 in animal models.

Page 25

On April 8, 2016, our Company announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ANAVEX 3-71 for the treatment of Frontotemporal dementia (FTD), a clinical syndrome associated with progressive shrinking of the frontal and temporal anterior lobes of the brain. FTD causes a decline in language and/or behavioral changes, which include inappropriate social conduct, lack of empathy, blunted emotions or agitation, neglect of personal hygiene and a decrease in energy and motivation. To date, no treatment has been shown to slow its progression and the prognosis for people with FTD is poor. FTD afflicts an estimated 50,000 to 60,000 patients in the United States and represents an estimated 10 to 20 percent of all dementia cases.

Results of Operations

Revenue

We have not earned any revenues since our inception on January 23, 2004. We do not anticipate earning any revenues until we can establish an alliance with other companies to develop, co-develop, license, acquire or market our products.

Operating Expenses

Three months ended March 31, 2016 compared to three months ended March 31, 2015

Our operating expenses for the three months ended March 31, 2016 were $2,180,168, which represents an increase of $1,321,829 compared to $858,339 for the three-month period ended March 31, 2015. The increase was mainly attributable to (i) an increase in research and development expenditures associated with the Company’s ongoing Phase 2a clinical trial, as well as ongoing preclinical work; and (ii) an increase in salaries and wages associated with our expanded team.

Other income (expenses)

The aggregate amount in the other income (expense) for the three-month period ended March 31, 2016, amounted to $149,367 as compared to $(866,520) for the comparable three-month period ended March 31, 2015. The largest reason for the increase in other income was as a result of a gain on the settlement of outstanding accounts payable and a decrease in the amount of financing-related charges as a result of the conversion of the majority of the outstanding convertible debentures during the third and fourth quarter of fiscal 2015. During the three months ended March 31, 2016, we also recognized $26,879 of the research grant from the Michael J. Fox Foundation (“MJFF”) on our statement of operations.

These increases in other income were partially offset by an increase in foreign exchange loss in the current period as a result of the rise of the Australian dollar against the US dollar, as the Company incurred many expenditures in Australia dollars in connection with our clinical trials being conducted in Australia.

Six months ended March 31, 2016 compared to six months ended March 31, 2015

Our operating expenses for the six months ended March 31, 2016 were $6,712,602, which represents an increase of $5,083,585 compared to $1,629,017 for the six-month period ended March 31, 2015. The increase was mainly the result of (i) an increase in research and development expenditures associated with the Company’s ongoing Phase 2a clinical trial, as well as ongoing preclinical work; (ii) an increase in salaries and wages expenses associated with an expanded management team and (iii) other one-time charges incurred in accordance with a 2013 employment agreement. We also incurred a one-time increase in registration and filing fees in connection with the listing of our common stock on the NASDAQ Capital Market.

Page 26

Other income

The aggregate amount in the other income (expense) for the six-month period ended March 31, 2016, amounted to $744,907 as compared to $(882,560) for the comparable six-month period ended March 31, 2015. The largest reason for the increase in other income was a result of an amount of $637,027 in grant income received during the period. We received a grant in the amount of $571,093 as part of a research and development incentive program offered by the Australian government, in connection with eligible expenditures on our Phase 2a clinical trial, which was conducted in Australia. In addition, we received a research grant from the MJFF to develop ANAVEX 2-73 for the treatment of Parkinson’s disease. The MJFF research grant is being received over a period of two years and is being recognized into income as the related expenditures are incurred. During the six months ended March 31, 2016, we recognized $65,934 of this grant on our statement of operations. In addition, there was a decrease in financing-related charges as a result of the conversion of a majority of the remaining principal balance on outstanding convertible debentures during the third and fourth quarter of fiscal 2015.

Liquidity and Capital Resources

Working Capital

	March 31, 2016		September 30, 2015
Current Assets	$	12,114,494	$	15,468,661
Current Liabilities		2,431,727		2,660,578
Working Capital	$	9,682,767	$	12,808,083

As of March 31, 2016, we had $11,950,847 in cash, a decrease of $3,340,129 from September 30, 2015.

Cash Flows

	Six months ended March 31,
	2016			2015
Cash flows used in operating activities	$	(5,149,749	)	$	(1,363,351	)
Cash flows used in investing activities		-			-
Cash flows from financing activities		1,809,620			411,856
Decrease in cash during the period	$	(3,340,129	)	$	(951,495	)

Cash flow used in operating activities

Our cash used in operating activities for the period ended March 31, 2016 was $(5,149,749) compared to $(1,363,351) used in operating activities for the comparative period ended March 31, 2015. The increase in cash used in operating activities was primarily as a result of one-time tax payments made on behalf of a director and officer of the Company, in accordance with a 2013 employment agreement.

Cash flow provided by financing activities

Our cash provided by financing activities for the period ended March 31, 2016 was $1,809,620, mostly attributable to cash received pursuant to the exercise of outstanding share purchase warrants, and cash received from the issuance of common shares under the 2013 Purchase Agreement with Lincoln Park Capital Fund, LLC (“Lincoln Park”).

In the comparative period ended March 31, 2015, we had cash inflows of $411,856 mostly attributable to cash received from the issuance of common shares under the 2013 Purchase Agreement with Lincoln Park.

Other Financing

On October 21, 2015, we entered into a Purchase Agreement (the “Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”), pursuant to which Lincoln Park committed to purchase up to $50,000,000 of our common stock. Concurrently with the execution of the Purchase Agreement, we issued 179,598 shares of our common stock to Lincoln Park as a fee for its commitment to purchase shares of our common stock under the Purchase Agreement. The purchase shares that may be sold pursuant to the Purchase Agreement may be sold by us to Lincoln Park at our discretion from time to time over a 36-month period commencing after the SEC declares effective the related registration statement.

Page 27

Other than our rights related to the Lincoln Park financing, there can be no assurance that additional financing will be available to us when needed or, if available, that it can be obtained on commercially reasonable terms. If we are not able to obtain the additional financing on a timely basis, if and when it is needed, we will be forced to delay or scale down some or all of our research and development activities or perhaps even cease the operation of our business.

We expect that we will be able to continue to fund our operations through existing cash on hand and through equity and debt financing in the future. If we raise additional financing by issuing equity securities, our existing stockholders’ ownership will be diluted. Obtaining commercial loans, assuming those loans would be available, will increase our liabilities and future cash commitments.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to our stockholders.

Application of Critical Accounting Policies

Our financial statements and accompanying notes are prepared in accordance with generally accepted accounting principles in the United States. Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses. These estimates and assumptions are affected by management’s application of accounting policies. We believe that understanding the basis and nature of the estimates and assumptions involved with the following aspects of our financial statements is critical to an understanding of our financial statements.

We base our assumptions and estimates on historical experience and other sources that we believe to be reasonable at the time. Actual results may vary from our estimates due to changes in circumstances, weather, politics, global economics, mechanical problems, general business conditions and other factors. Our significant estimates are related to the valuation of warrants and options.

There are accounting policies that we believe are significant to the presentation of our financial statements. The most significant of these accounting policies relates to the accounting for our research and development expenses and stock-based compensation expense and derivative liabilities.

Research and Development Expenses

Research and developments costs are expensed as incurred. These expenses are comprised of the costs of our proprietary research and development efforts, including salaries, facilities costs, overhead costs and other related expenses as well as costs incurred in connection with third-party collaboration efforts. Milestone payments made by us to third parties are expensed when the specific milestone has been achieved.

Page 28

In addition, we incur expenses in respect of the acquisition of intellectual property relating to patents and trademarks. The probability of success and length of time to developing commercial applications of the drugs subject to the acquired patents and trademarks is difficult to determine and numerous risks and uncertainties exist with respect to the timely completion of the development projects. There is no assurance the acquired patents and trademarks will ever be successfully commercialized. Due to these risks and uncertainties, we expense the acquisition of patents and trademarks.

Stock-based Compensation

We account for all stock-based payments and awards under the fair value based method.

Stock-based payments to non-employees are measured at the fair value of the consideration received, or the fair value of the equity instruments issued, or liabilities incurred, whichever is more reliably measurable. The fair value of stock-based payments to non-employees is periodically re-measured until the counterparty performance is complete, and any change therein is recognized over the vesting period of the award and in the same manner as if we had paid cash instead of paying with or using equity based instruments. The cost of the stock-based payments to non-employees that are fully vested and non-forfeitable as at the grant date is measured and recognized at that date, unless there is a contractual term for services in which case such compensation would be amortized over the contractual term.

We account for the granting of share purchase options to employees using the fair value method whereby all awards to employees will be recorded at fair value on the date of the grant. The fair value of all share purchase options are expensed over their vesting period with a corresponding increase to additional capital surplus. Upon exercise of share purchase options, the consideration paid by the option holder, together with the amount previously recognized in additional capital surplus, is recorded as an increase to share capital.

We use the Black-Scholes option valuation model to calculate the fair value of share purchase options at the date of the grant. Option pricing models require the input of highly subjective assumptions, including the expected price volatility. Changes in assumptions can materially affect the fair value estimate and therefore the Black-Scholes model does not necessarily provide a reliable single measure of the fair value of our share purchase options.

Derivative Liabilities

From time to time, we may issue warrants and convertible promissory notes with embedded conversion options which, dependent on their specific contractual terms or other conditions, may be required to be accounted for as separate derivative liabilities. These liabilities are required to be measured at fair value. These instruments are then adjusted to reflect fair value at each period end. Any increase or decrease in the fair value is recorded in results of operations as change in fair value of derivative liabilities. In determining the appropriate fair value, we use the binomial pricing model because these instruments are not quoted on an active market.

Option pricing models require the input of highly subjective assumptions, including the expected price volatility. Changes in assumptions can materially affect the fair value estimate and therefore the binomial model does not necessarily provide a reliable single measure of the fair value of these instruments.

Recent Accounting Pronouncements

In June 2014, the FASB issued ASU No. 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period ("ASU 2014-12"). ASU 2014-12 requires that a performance target that affects vesting, and that could be achieved after the requisite service period, be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant date fair value of the award. This update further clarifies that compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. The amendments in this ASU are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. We are currently evaluating the impact this guidance on our financial condition, results of operations and cash flows.

Page 29

In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”). ASU 2014-15 will explicitly require management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosure in certain circumstances. The new standard will be effective for all entities in the first annual period ending after December 15, 2016. We are currently evaluating the impact this guidance on our financial condition, results of operations and cash flows.

On May 28, 2014, the FASB and the International Accounting Standards Board (IASB) issued a converged standard on revenue recognition from contracts with customers, ASU 2014-09 (Topic 606 and IFRS 15). This standard will supersede nearly all existing revenue recognition guidance. ASU 2014-09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. We are currently evaluating the impact this guidance will have on our financial condition, results of operations and cash flows.

In April 2015, the Financial Accounting Standards Board (FASB), issued the Accounting Standards Update 2015-03, Interest - Imputation of Interest (Subtopic 835-30) - Simplifying the Presentation of Debt Issuance Costs, that requires debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction from the debt liability rather than as an asset. For public business entities, the final guidance will be effective for fiscal years beginning after 15 December 2015, however, early adoption (including in interim periods) is permitted. Upon adoption, an entity must apply the new guidance retrospectively to all prior periods presented in the financial statements. An entity is also required in the year of adoption to provide certain disclosures about the change in accounting principle, including the nature of and reason for the change, the transition method, a description of the prior-period information that has been retrospectively adjusted and the effect of the change on the financial statement line items (that is, debt issuance cost asset and the debt liability). The Company plans to adopt this standard beginning February 1, 2016. We are currently evaluating the impact this guidance will have on our financial condition, results of operations and cash flows.

In November 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2015-17 “Income Taxes: Balance Sheet Classification of Deferred Taxes (“ASU 2015-17”). ASU 2015-17 eliminates the requirement to bifurcate deferred taxes between current and non-current on the balance sheet and requires that deferred tax liabilities and assets be classified as noncurrent on the balance sheet. ASU 2015-17 is effective for public entities in fiscal years beginning after December 15, 2016, and for interim periods within those fiscal years. The amendments for ASU-2015-17 can be applied retrospectively or prospectively and early adoption is permitted. We are currently evaluating the impact this guidance will have on our financial condition, results of operations and cash flows.

In March 2016, the FASB issued ASC 2016-09, “Compensation – Stock Compensation (Topic 718) – Improvements to Employee Share-Based Payment Accounting”. These amendments are intended to simplify several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. These amendments are effective for annual and interim reporting periods beginning on or after December 15, 2016. Early adoption is permitted. Entities have the option to apply the amendments on either a prospective basis or a modified retrospective basis. We are currently evaluating the impact this guidance will have on our financial condition, results of operations and cash flows.

Other than noted above, we do not expect the adoption of recently issued accounting pronouncements to have a significant impact on our results of operations, financial position or cash flow.

Page 30

Item 3. Quantitative and Qualitative Disclosures about Market Risks.

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and are not required to provide information under this item.

Item 4. Controls and Procedures.

Disclosure Controls and Procedures

As required by Rule 13a-15 under the Exchange Act, our management, with the participation of our principal executive officer and principal financial officer, evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e) of the Exchange Act) as of the end of the period covered by this Quarterly Report on Form 10-Q. Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to our principal executive officer and principal financial officer to allow timely decisions regarding required disclosure.

Based on that evaluation, our management, with the participation of our principal executive officer and principal financial officer, concluded that as of the end of the period covered by this Quarterly Report on Form 10-Q, our disclosure controls and procedures were not effective. The ineffectiveness of our disclosure controls and procedures was due to the material weaknesses described disclosed in our Annual Report on Form 10-K filed on December 29, 2015.

Subsequent to March 31, 2016, we took steps to make the necessary improvements to remediate these deficiencies, and we intend to continue to take additional appropriate and reasonable steps to make the necessary improvements to remediate these deficiencies by the end of the current fiscal year.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the fiscal quarter ended March 31, 2016 that have materially affected, or are reasonably likely to materially affect our internal control over financial reporting.

Subsequent to March 31, 2016, we experienced the following changes in our internal control procedures, which we believe will materially affect our internal controls over financial reporting:

(i)

We updated written policies and procedures for our accounting and financial reporting process with respect to the requirements and application of both US GAAP and SEC guidelines; and

(ii)

We implemented additional security protocol and limited access rights over financial assets, which will enable us to establish adequate segregation of duties and effective risk management.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings.

On December 22, 2015, the Company received a subpoena from the SEC which indicated that the agency is conducting a formal investigation. The Company believes the subpoena and investigation relate to the recent unusual activity in the market for the Company’s common stock. The Company is fully cooperating with the SEC in this investigation and is unable to predict when this matter will be resolved or what further action, if any, the SEC may take in connection with it.

Page 31

On December 30, 2015, Kevin Cortina filed a purported class action lawsuit in the United States District Court for the Southern District of New York, Cortina v. Anaves Life Sciences Corp., et al., Case No. 1:15-cv-10162, against the Company, Christopher Missling, Sandra Boenisch, and Athanasios Skarpelos. The complaint alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of purchasers of the Company’s stock between May 17, 2013 and December 28, 2015. The complaint alleges that defendants made materially false and misleading statements regarding the Company’s business, operational, and compliance policies. Among other things, the complaint alleges that the Company failed to disclose that it used a paid stock promoter to artificially inflate the Company’s share price. The complaint does not specify an amount of damages sought. On April 5, 2016 the court appointed Lam Truong as lead plaintiff and Levi & Korsinsky to serve as lead counsel. On April 13, 2016, the court granted lead plaintiff thirty days to amend the complaint and set a briefing schedule. Defendants believe this action is meritless and deny all allegations against them. The Company intends to vigorously defend this matter.

On March 12, 2016, Jeffery Dhungana filed a purported shareholder derivative action in the Supreme Court of the State of New York, in the County of New York, Dhungana v. Missling, et. al., Case No. 651317-2016, against Christopher Missling and other officers and directors at the Company. The complaint alleges that the defendants breached their fiduciary duties to the Company in connection with events alleged in the Cortina matter described above. The complaint seeks damages of an unspecified amount, a declaration that the defendants violated their fiduciary duties, and an order directing the Company and defendants to improve its corporate governance and internal procedures. On March 18, 2016, Mary McCambell filed an action in the United States District Court for the Southern District of New York, McCambell v. Missling, et. al., Case No. 1:16-cv-02035. The allegations in the McCambell complaint are substantively similar to those asserted in the Dhungana complaint. Like the Dhungana complaint, the McCambell complaint seeks damages of an unspecified amount and an order directing the Company to take all necessary actions to reform and improve its corporate governance and internal procedures.

Item 1A. Risk Factors.

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide information under this item. However, current and prospective investors are encouraged to review the risks set forth in Part I, Item 1A, “Risk Factors” in our most recent Annual Report on Form 10-K as filed with the Securities and Exchange Commission on December 29, 2015.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

During the period covered by this Quarterly Report on Form 10-Q, we have not sold any equity securities that were not registered under the Securities Act of 1933 that were not previously reported in a Current Report on Form 8-K.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information.

None.

Page 32

Item 6. Exhibits.

Exhibit Number		Description
(3)		Articles of Incorporation and Bylaws
3.1		Articles of Incorporation (incorporated by reference to an exhibit to our Registration Statement on Form SB-2 filed on January 13, 2005)
3.2		Bylaws (incorporated by reference to an exhibit to our Current Report on Form 8-K filed on September 28, 2007)
3.3		Articles of Merger filed with the Secretary of State of Nevada on January 10, 2007 and which is effective January 25, 2007 (incorporated by reference to an exhibit to our Current Report on Form 8-K filed on January 25, 2007)
3.4		Certificate of Amendment to the Articles of Incorporation (incorporated by reference to an exhibit to our Current Report on Form 8-K filed on March 30, 2015)
3.5		Certificate of Change to the Articles of Incorporation (incorporated by reference to an exhibit to our Current Report on Form 8-K filed on October 6, 2015)
(4)		Instruments defining rights of security holders, including indentures
4.1		Specimen Stock Certificate (incorporated by reference to an exhibit to our Registration Statement on Form SB-2 filed on January 13, 2005)
4.2		Form of Convertible Loan Agreement (incorporated by reference to an exhibit to our Form 8-K filed on April 3, 2009)
4.3		8% Convertible Loan Agreement dated June 3, 2009 (incorporated by reference to an exhibit to our Current Report on Form 8-K filed on June 23, 2009)
4.4		8% Convertible Loan Agreement dated June 19, 2009 (incorporated by reference to an exhibit to our Current Report on Form 8-K filed on June 26, 2009)
(10)		Material Contracts
10.1		Purchase Agreement, dated as of October 21, 2015, by and between the Company and Lincoln Park Capital Fund, LLC (incorporated by reference to our Current Report on Form 8-K filed on October 26, 2015)
10.2		Registration Rights Agreement, dated as of October 21, 2015, by and between the Company and Lincoln Park Capital Fund, LLC (incorporated by reference to our Current Report on Form 8-K filed on October 26, 2015)
(31)		Section 302 Certifications
31.1*		Section 302 Certification of Christopher Missling, PhD.
31.2*		Section 302 Certification of Sandra Boenisch
(32)		Section 906 Certifications
32.1*		Section 906 Certification of Christopher Missling, PhD.
32.2*		Section 906 Certification of Sandra Boenisch
(101)		XBRL
101.INS*		XBRL INSTANCE DOCUMENT
101.SCH*		XBRL TAXONOMY EXTENSION SCHEMA
101.CAL*		XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
101.DEF*		XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
101.LAB*		XBRL TAXONOMY EXTENSION LABEL LINKBASE
101.PRE*		XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE

* Filed herewith.

Page 33

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ANAVEX LIFE SCIENCES CORP.

/s/Christopher Missling, PhD

Christopher Missling, PhD
Chief Executive Officer
(Principal Executive Officer)
Date: May 11, 2016

/s/Sandra Boenisch

Sandra Boenisch, CPA, CGA
Principal Financial Officer
(Principal Financial and Accounting Officer)
Date: May 11, 2016

Page 34

EX-31.1 2 s103199_ex31-1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATION

I, Christopher Missling, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the three month period ended March 31, 2016 of Anavex Life Sciences Corp. (the “registrant”);

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a–15(e) and 15d–15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a–15(f) and 15d–15(f)) for the registrant and have:

(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 11, 2016

/s/Christopher Missling, PhD
Christopher Missling, PhD
Chief Executive Officer
(Principal Executive Officer)

EX-31.2 3 s103199_ex31-2.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATION

I, Sandra Boenisch, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the three month period ended March 31, 2016 of Anavex Life Sciences Corp. (the “registrant”);

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 11, 2016

/s/Sandra Boenisch
Sandra Boenisch, CPA, CGA
Principal Financial Officer
(Principal Financial and Accounting Officer)

EX-32.1 4 s103199_ex32-1.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Anavex Life Sciences Corp. (the “Company”) on Form 10-Q for the period ended March 31, 2016 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, in the capacities and on the date indicated below, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: May 11, 2016	/s/Christopher Missling, PhD
	Christopher Missling, PhD
	Chief Executive Officer
	(Principal Executive Officer)

The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 5 s103199_ex32-2.htm EXHIBIT 32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: May 11, 2016	/s/Sandra Boenisch
	Sandra Boenisch, CPA, CGA
	Principal Financial Officer
	(Principal Financial and Accounting Officer)

EX-101.INS 6 avxl-20160331.xml XBRL INSTANCE FILE 0001314052 2015-10-01 2016-03-31 0001314052 2016-03-31 0001314052 2014-09-30 0001314052 2014-10-01 2015-03-31 0001314052 2015-09-30 0001314052 us-gaap:CommonStockMember 2015-10-01 2016-03-31 0001314052 us-gaap:CommonStockMember 2015-09-30 0001314052 us-gaap:CommonStockMember 2016-03-31 0001314052 us-gaap:AdditionalPaidInCapitalMember 2015-10-01 2016-03-31 0001314052 us-gaap:AdditionalPaidInCapitalMember 2015-09-30 0001314052 us-gaap:AdditionalPaidInCapitalMember 2016-03-31 0001314052 avxl:CommonSharesToBeIssuedMember 2015-10-01 2016-03-31 0001314052 avxl:CommonSharesToBeIssuedMember 2015-09-30 0001314052 avxl:CommonSharesToBeIssuedMember 2016-03-31 0001314052 us-gaap:RetainedEarningsMember 2015-10-01 2016-03-31 0001314052 us-gaap:RetainedEarningsMember 2015-09-30 0001314052 us-gaap:RetainedEarningsMember 2016-03-31 0001314052 2015-10-06 2015-10-07 0001314052 2015-10-07 0001314052 2014-10-01 2015-09-30 0001314052 us-gaap:ComputerEquipmentMember 2015-09-30 0001314052 us-gaap:ComputerEquipmentMember 2016-03-31 0001314052 avxl:NotesPayableOtherPayables1Member 2015-09-30 0001314052 avxl:NotesPayableOtherPayables2Member 2015-09-30 0001314052 avxl:NotesPayableOtherPayables1Member 2016-03-31 0001314052 avxl:NotesPayableOtherPayables2Member 2016-03-31 0001314052 avxl:NotesPayableOtherPayables1Member 2015-10-01 2016-03-31 0001314052 avxl:NotesPayableOtherPayables2Member 2015-10-01 2016-03-31 0001314052 avxl:NotesPayableOtherPayables1Member currency:CAD 2016-03-31 0001314052 avxl:NotesPayableOtherPayables2Member currency:CAD 2016-03-31 0001314052 avxl:NotesPayableOtherPayables1Member 2013-01-09 0001314052 avxl:NotesPayableOtherPayables1Member currency:CAD 2013-01-09 0001314052 avxl:NotesPayableOtherPayables1Member 2013-01-08 2013-01-09 0001314052 avxl:NotesPayableOtherPayables2Member 2013-01-09 0001314052 avxl:NotesPayableOtherPayables2Member currency:CAD 2013-01-09 0001314052 avxl:NotesPayableOtherPayables2Member 2013-01-08 2013-01-09 0001314052 avxl:SecuritiesPurchaseAgreementMember us-gaap:ConvertibleDebtMember avxl:PurchasersMember 2014-03-13 0001314052 avxl:PurchaseAgreementMember avxl:LincolnParkCapitalFundLLCMember 2013-07-04 2013-07-05 0001314052 avxl:PurchaseAgreementMember avxl:LincolnParkCapitalFundLLCMember 2015-10-01 2016-03-31 0001314052 avxl:PurchaseAgreement1Member avxl:LincolnParkCapitalFundLLCMember 2015-10-20 2015-10-21 0001314052 avxl:PurchaseAgreement1Member avxl:LincolnParkCapitalFundLLCMember 2015-10-01 2016-03-31 0001314052 us-gaap:ManagementMember 2016-03-31 0001314052 us-gaap:ManagementMember 2015-09-30 0001314052 avxl:EmployeeStockOption1Member 2016-03-31 0001314052 avxl:EmployeeStockOption1Member 2015-10-01 2016-03-31 0001314052 us-gaap:RestrictedStockMember 2015-10-01 2016-03-31 0001314052 avxl:PurchaseWarrantsMember 2014-10-01 2015-09-30 0001314052 avxl:PurchaseWarrantsMember 2015-10-01 2016-03-31 0001314052 avxl:PurchaseWarrantsMember 2014-09-30 0001314052 avxl:PurchaseWarrantsMember 2015-09-30 0001314052 avxl:PurchaseWarrantsMember 2016-03-31 0001314052 avxl:PurchaseWarrants1Member 2015-10-01 2016-03-31 0001314052 avxl:PurchaseWarrants2Member 2015-10-01 2016-03-31 0001314052 avxl:PurchaseWarrants3Member 2015-10-01 2016-03-31 0001314052 avxl:PurchaseWarrants4Member 2015-10-01 2016-03-31 0001314052 avxl:PurchaseWarrants5Member 2015-10-01 2016-03-31 0001314052 avxl:PurchaseWarrants6Member 2015-10-01 2016-03-31 0001314052 avxl:PurchaseWarrants1Member 2016-03-31 0001314052 avxl:PurchaseWarrants2Member 2016-03-31 0001314052 avxl:PurchaseWarrants3Member 2016-03-31 0001314052 avxl:PurchaseWarrants4Member 2016-03-31 0001314052 avxl:PurchaseWarrants5Member 2016-03-31 0001314052 avxl:PurchaseWarrants6Member 2016-03-31 0001314052 avxl:StockOptionPlan2015Member 2014-10-01 2015-09-30 0001314052 avxl:StockOptionPlan2015Member 2015-10-01 2016-03-31 0001314052 avxl:StockOptionPlan2015Member 2016-03-31 0001314052 us-gaap:EmployeeStockOptionMember 2016-03-31 0001314052 avxl:EmployeeStockOption2Member 2016-03-31 0001314052 avxl:EmployeeStockOption3Member 2016-03-31 0001314052 avxl:EmployeeStockOption4Member 2016-03-31 0001314052 avxl:EmployeeStockOption5Member 2016-03-31 0001314052 avxl:EmployeeStockOption6Member 2016-03-31 0001314052 avxl:EmployeeStockOption7Member 2016-03-31 0001314052 avxl:EmployeeStockOption8Member 2016-03-31 0001314052 avxl:EmployeeStockOption9Member 2016-03-31 0001314052 avxl:EmployeeStockOption10Member 2016-03-31 0001314052 us-gaap:EmployeeStockOptionMember 2015-10-01 2016-03-31 0001314052 avxl:EmployeeStockOption2Member 2015-10-01 2016-03-31 0001314052 avxl:EmployeeStockOption3Member 2015-10-01 2016-03-31 0001314052 avxl:EmployeeStockOption4Member 2015-10-01 2016-03-31 0001314052 avxl:EmployeeStockOption5Member 2015-10-01 2016-03-31 0001314052 avxl:EmployeeStockOption6Member 2015-10-01 2016-03-31 0001314052 avxl:EmployeeStockOption7Member 2015-10-01 2016-03-31 0001314052 avxl:EmployeeStockOption8Member 2015-10-01 2016-03-31 0001314052 avxl:EmployeeStockOption9Member 2015-10-01 2016-03-31 0001314052 avxl:EmployeeStockOption10Member 2015-10-01 2016-03-31 0001314052 avxl:StockOptionPlan2015Member us-gaap:EmployeeStockOptionMember 2014-10-01 2015-03-31 0001314052 avxl:StockOptionPlan2015Member avxl:EmployeeStockOption2Member 2014-10-01 2015-09-30 0001314052 avxl:StockOptionPlan2015Member avxl:EmployeeStockOption3Member 2015-10-01 2016-03-31 0001314052 avxl:StockOptionPlan2015Member avxl:EmployeeStockOption4Member 2015-10-01 2016-03-31 0001314052 avxl:StockOptionPlan2015Member avxl:EmployeeStockOption4Member us-gaap:GeneralAndAdministrativeExpenseMember 2015-10-01 2016-03-31 0001314052 avxl:StockOptionPlan2015Member avxl:EmployeeStockOption5Member 2015-10-01 2016-03-31 0001314052 avxl:StockOptionPlan2015Member avxl:EmployeeStockOption5Member us-gaap:GeneralAndAdministrativeExpenseMember 2015-10-01 2016-03-31 0001314052 avxl:StockOptionPlan2015Member avxl:EmployeeStockOption6Member 2015-10-01 2016-03-31 0001314052 avxl:StockOptionPlan2015Member avxl:EmployeeStockOption6Member us-gaap:GeneralAndAdministrativeExpenseMember 2015-10-01 2016-03-31 0001314052 avxl:StockOptionPlan2015Member avxl:EmployeeStockOption7Member us-gaap:GeneralAndAdministrativeExpenseMember 2015-10-01 2016-03-31 0001314052 avxl:StockOptionPlan2015Member avxl:EmployeeStockOption4Member us-gaap:GeneralAndAdministrativeExpenseMember 2014-10-01 2015-03-31 0001314052 avxl:StockOptionPlan2015Member avxl:EmployeeStockOption5Member us-gaap:GeneralAndAdministrativeExpenseMember 2014-10-01 2015-03-31 0001314052 avxl:StockOptionPlan2015Member avxl:EmployeeStockOption6Member us-gaap:GeneralAndAdministrativeExpenseMember 2014-10-01 2015-03-31 0001314052 avxl:StockOptionPlan2015Member avxl:EmployeeStockOption7Member us-gaap:GeneralAndAdministrativeExpenseMember 2014-10-01 2015-03-31 0001314052 avxl:StockOptionPlan2015Member avxl:EmployeeStockOption8Member us-gaap:GeneralAndAdministrativeExpenseMember 2015-10-01 2016-03-31 0001314052 avxl:StockOptionPlan2015Member avxl:EmployeeStockOption8Member us-gaap:GeneralAndAdministrativeExpenseMember 2014-10-01 2015-03-31 0001314052 avxl:StockOptionPlan2015Member avxl:EmployeeStockOption9Member 2015-10-01 2016-03-31 0001314052 avxl:StockOptionPlan2015Member avxl:EmployeeStockOption9Member us-gaap:GeneralAndAdministrativeExpenseMember 2015-10-01 2016-03-31 0001314052 avxl:StockOptionPlan2015Member avxl:EmployeeStockOption9Member us-gaap:GeneralAndAdministrativeExpenseMember 2014-10-01 2015-03-31 0001314052 avxl:StockOptionPlan2015Member 2014-09-30 0001314052 avxl:StockOptionPlan2015Member 2015-09-30 0001314052 avxl:EmploymentAgreementMember us-gaap:ManagementMember avxl:CommonSharesToBeIssuedMember 2015-10-01 2016-03-31 0001314052 avxl:StockOptionPlan2015Member avxl:EmployeeStockOption2Member 2015-10-01 2016-03-31 0001314052 2016-05-11 0001314052 2016-01-01 2016-03-31 0001314052 2015-01-01 2015-03-31 0001314052 2015-03-31 0001314052 avxl:PurchaseWarrantsMember avxl:ConsultantMember 2014-09-30 0001314052 avxl:PurchaseWarrantsMember avxl:ConsultantMember 2014-10-01 2015-09-30 0001314052 avxl:PurchaseWarrantsMember avxl:ConsultantMember 2013-10-01 2014-09-30 0001314052 avxl:PurchaseWarrantsMember avxl:ConsultantMember 2016-01-01 2016-03-31 0001314052 avxl:PurchaseWarrantsMember avxl:ConsultantMember 2015-10-01 2016-03-31 0001314052 avxl:PurchaseWarrantsMember avxl:ConsultantMember 2015-01-01 2015-03-31 0001314052 avxl:PurchaseWarrantsMember avxl:ConsultantMember 2014-10-01 2015-03-31 0001314052 avxl:SecuritiesPurchaseAgreementMember us-gaap:ConvertibleDebtMember avxl:PurchasersMember 2016-03-31 0001314052 avxl:SecuritiesPurchaseAgreementMember us-gaap:ConvertibleDebtMember avxl:PurchasersMember 2015-09-30 0001314052 avxl:SecuritiesPurchaseAgreementMember us-gaap:ConvertibleDebtMember avxl:PurchasersMember 2015-10-01 2016-03-31 0001314052 avxl:SecuritiesPurchaseAgreementMember us-gaap:ConvertibleDebtMember avxl:PurchasersMember 2016-01-01 2016-03-31 0001314052 avxl:SecuritiesPurchaseAgreementMember us-gaap:ConvertibleDebtMember avxl:PurchasersMember 2014-10-01 2015-03-31 0001314052 avxl:SecuritiesPurchaseAgreementMember us-gaap:ConvertibleDebtMember avxl:PurchasersMember 2015-01-01 2015-03-31 0001314052 avxl:PurchaseWarrantsMember avxl:ConsultantMember 2015-09-30 0001314052 avxl:StockOptionPlan2015Member avxl:EmployeeStockOption1Member 2015-10-01 2016-03-31 0001314052 avxl:StockOptionPlan2015Member avxl:EmployeeStockOption1Member us-gaap:GeneralAndAdministrativeExpenseMember 2015-10-01 2016-03-31 0001314052 avxl:StockOptionPlan2015Member avxl:EmployeeStockOption1Member us-gaap:GeneralAndAdministrativeExpenseMember 2016-01-01 2016-03-31 0001314052 avxl:StockOptionPlan2015Member avxl:EmployeeStockOption1Member us-gaap:GeneralAndAdministrativeExpenseMember 2014-10-01 2015-03-31 0001314052 avxl:StockOptionPlan2015Member avxl:EmployeeStockOption1Member us-gaap:GeneralAndAdministrativeExpenseMember 2015-01-01 2015-03-31 0001314052 avxl:StockOptionPlan2015Member avxl:EmployeeStockOption2Member 2016-01-01 2016-03-31 0001314052 avxl:StockOptionPlan2015Member avxl:EmployeeStockOption2Member 2014-10-01 2015-03-31 0001314052 avxl:StockOptionPlan2015Member avxl:EmployeeStockOption2Member 2015-01-01 2015-03-31 0001314052 avxl:StockOptionPlan2015Member avxl:EmployeeStockOption3Member us-gaap:GeneralAndAdministrativeExpenseMember 2015-10-01 2016-03-31 0001314052 avxl:StockOptionPlan2015Member avxl:EmployeeStockOption3Member us-gaap:GeneralAndAdministrativeExpenseMember 2016-01-01 2016-03-31 0001314052 avxl:StockOptionPlan2015Member avxl:EmployeeStockOption3Member us-gaap:GeneralAndAdministrativeExpenseMember 2014-10-01 2015-03-31 0001314052 avxl:StockOptionPlan2015Member avxl:EmployeeStockOption3Member us-gaap:GeneralAndAdministrativeExpenseMember 2015-01-01 2015-03-31 0001314052 avxl:StockOptionPlan2015Member avxl:EmployeeStockOption4Member us-gaap:GeneralAndAdministrativeExpenseMember 2016-01-01 2016-03-31 0001314052 avxl:StockOptionPlan2015Member avxl:EmployeeStockOption4Member us-gaap:GeneralAndAdministrativeExpenseMember 2015-01-01 2015-03-31 0001314052 avxl:StockOptionPlan2015Member avxl:EmployeeStockOption5Member us-gaap:GeneralAndAdministrativeExpenseMember 2016-01-01 2016-03-31 0001314052 avxl:StockOptionPlan2015Member avxl:EmployeeStockOption5Member us-gaap:GeneralAndAdministrativeExpenseMember 2015-01-01 2015-03-31 0001314052 avxl:StockOptionPlan2015Member avxl:EmployeeStockOption6Member us-gaap:GeneralAndAdministrativeExpenseMember 2016-01-01 2016-03-31 0001314052 avxl:StockOptionPlan2015Member avxl:EmployeeStockOption6Member us-gaap:GeneralAndAdministrativeExpenseMember 2015-01-01 2015-03-31 0001314052 avxl:StockOptionPlan2015Member avxl:EmployeeStockOption7Member us-gaap:GeneralAndAdministrativeExpenseMember 2016-01-01 2016-03-31 0001314052 avxl:StockOptionPlan2015Member avxl:EmployeeStockOption7Member us-gaap:GeneralAndAdministrativeExpenseMember 2015-01-01 2015-03-31 0001314052 avxl:StockOptionPlan2015Member avxl:EmployeeStockOption8Member 2015-10-01 2016-03-31 0001314052 avxl:StockOptionPlan2015Member avxl:EmployeeStockOption8Member us-gaap:GeneralAndAdministrativeExpenseMember 2016-01-01 2016-03-31 0001314052 avxl:StockOptionPlan2015Member avxl:EmployeeStockOption8Member us-gaap:GeneralAndAdministrativeExpenseMember 2015-01-01 2015-03-31 0001314052 avxl:StockOptionPlan2015Member avxl:EmployeeStockOption9Member us-gaap:GeneralAndAdministrativeExpenseMember 2016-01-01 2016-03-31 0001314052 avxl:StockOptionPlan2015Member avxl:EmployeeStockOption9Member us-gaap:GeneralAndAdministrativeExpenseMember 2015-01-01 2015-03-31 0001314052 avxl:StockOptionPlan2015Member avxl:EmployeeStockOption10Member us-gaap:GeneralAndAdministrativeExpenseMember 2015-10-01 2016-03-31 0001314052 avxl:StockOptionPlan2015Member avxl:EmployeeStockOption10Member us-gaap:GeneralAndAdministrativeExpenseMember 2014-10-01 2015-03-31 0001314052 avxl:StockOptionPlan2015Member avxl:EmployeeStockOption10Member us-gaap:GeneralAndAdministrativeExpenseMember 2016-01-01 2016-03-31 0001314052 avxl:StockOptionPlan2015Member avxl:EmployeeStockOption10Member us-gaap:GeneralAndAdministrativeExpenseMember 2015-01-01 2015-03-31 0001314052 avxl:StockOptionPlan2015Member avxl:EmployeeStockOption11Member us-gaap:GeneralAndAdministrativeExpenseMember 2015-10-01 2016-03-31 0001314052 avxl:StockOptionPlan2015Member avxl:EmployeeStockOption11Member us-gaap:GeneralAndAdministrativeExpenseMember 2016-01-01 2016-03-31 0001314052 avxl:StockOptionPlan2015Member avxl:EmployeeStockOption11Member us-gaap:GeneralAndAdministrativeExpenseMember 2014-10-01 2015-03-31 0001314052 avxl:StockOptionPlan2015Member avxl:EmployeeStockOption11Member us-gaap:GeneralAndAdministrativeExpenseMember 2015-01-01 2015-03-31 0001314052 avxl:EmployeeStockOption11Member 2016-03-31 0001314052 avxl:EmployeeStockOption11Member 2015-10-01 2016-03-31 0001314052 us-gaap:ManagementMember avxl:EmploymentAgreementMember 2016-01-01 2016-03-31 0001314052 us-gaap:ManagementMember avxl:EmploymentAgreementMember 2015-10-01 2016-03-31 0001314052 us-gaap:ManagementMember avxl:EmploymentAgreementMember 2015-01-01 2015-03-31 0001314052 us-gaap:ManagementMember avxl:EmploymentAgreementMember 2014-10-01 2015-03-31 0001314052 avxl:StockOptionPlan2015Member avxl:EmployeeStockOption1Member 2014-10-01 2015-09-30 0001314052 avxl:StockOptionPlan2015Member avxl:EmployeeStockOption3Member 2014-10-01 2015-09-30 0001314052 avxl:StockOptionPlan2015Member avxl:EmployeeStockOption6Member 2014-10-01 2015-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure avxl:N iso4217:CAD ANAVEX LIFE SCIENCES CORP. 0001314052 10-Q 2016-03-31 false --09-30 No No Yes Smaller Reporting Company Q2 2016 AVXL 35710862

12115249

15469913

9683185

12809003

32044

35697

74060999

78914253

1997415

-63281455

-69266765

-63281455

-1997415

78914253

74060999

35697

32044

2432064

2660910

337

332

2431727

2660578

88145

85238

64630

20608

66834

21311

5445 71614

2338137

2503726

12115249

15469913

755

1252

755

12114494

15468661

84977

100845

78670 76840

11950847

7262138

15290976

6310643

35695572

32044213

35695572

32044213

100000000

400000000

0.001

34589957

13609473

35214793

14326945

34589957

13609473

35214793

14326945

-0.17

-0.18

-0.06

-0.12

-0.17

-0.18

-0.06

-0.12

-5985310

-2511577

-5985310

-2030801

-1724859

17615

-5967695

-2511577

-2030801

-1724859

744907

-882560

149367

-866520

-46561

66927

-30906

43609

1167

874706

912357

151402 151402

-4206

74781

-2064

-2228

6712602

1629017

2180168

858339

1998129

725771

1327393

407146

4714473

903246

852775

451193

-3340129

-951495

1809620

411856

88144

-1809620

-500000

-5149749

-1363351

-66169

-14187

225987

-15868

1830

-2907

13509

105745

-487000

-29000

1048710

31544

1167

493451

497

498

290523

1684561

291

1684270

185179 185 -185

168577

1161

169

168407

-167415

41687 125060 42 125018 1963956 1964 -1964

1000000

610000

1000

2439000

-1830000

1437 2 -2

438710

1.00

1.20

1.00

3.00

<table cellspacing="0" cellpadding="0" style="margin-top: 0px; font-size: 10pt; margin-bottom: 0px"> <tr style="text-align: justify; vertical-align: top"> <td style="width: 0in"> </td> <td style="text-align: left; width: 45pt">Note 10</td> <td style="text-align: justify; text-decoration: underline">Commitments</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="margin-top: 0pt; font-size: 10pt; margin-bottom: 0pt; color: gray; width: 100%"> <tr style="vertical-align: top"> <td style="width: 45pt"> </td> <td style="width: 18pt">a)</td> <td style="text-align: justify">Share Purchase Warrants</td></tr> </table>   A summary of the Companys share purchase warrants outstanding is presented below:   <table cellspacing="0" cellpadding="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; margin-left: 1.25in"> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center">Weighted</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center">Average</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Number of Shares</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Exercise Price</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="width: 73%">Balance, October 1, 2014</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 11%">18,728,910</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 10%">1.59</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td>Expired</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(62,500</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">1.40</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td>Exercised</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(15,468,520</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">1.43</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="padding-bottom: 1pt">Issued</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,075,000</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">0.76</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td>Balance, September 30, 2015</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">4,272,890</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">2.11</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="padding-bottom: 1pt">Exercised</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(2,444,831</td> <td style="text-align: left; padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">1.68</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="padding-bottom: 2.5pt">Balance, March 31, 2016</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">1,828,059</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">2.68</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>   During the six months ended March 31, 2016, the Company issued 1,963,956 shares of common stock pursuant to the exercise of 2,403,144 share purchase warrants on a cashless basis.   At March 31, 2016, the Company has 1,828,059 currently exercisable share purchase warrants outstanding as follows:    <table cellspacing="0" cellpadding="0" align="center" style="width: 45%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Number</td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Exercise Price</td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Expiry Date</td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td nowrap="nowrap" style="text-align: left; width: 1%"> </td> <td nowrap="nowrap" style="text-align: right; width: 30%">1,462,180</td> <td nowrap="nowrap" style="text-align: left; width: 1%"> </td> <td nowrap="nowrap" style="width: 1%"> </td> <td nowrap="nowrap" style="text-align: left; width: 1%">$</td> <td nowrap="nowrap" style="text-align: right; width: 30%">3.00</td> <td nowrap="nowrap" style="text-align: left; width: 1%"> </td> <td nowrap="nowrap" style="width: 1%"> </td> <td nowrap="nowrap" style="text-align: right; width: 34%">July 5, 2018</td></tr> <tr style="background-color: white; vertical-align: bottom"> <td nowrap="nowrap" style="text-align: left"> </td> <td nowrap="nowrap" style="text-align: right">30,000</td> <td nowrap="nowrap" style="text-align: left"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: left">$</td> <td nowrap="nowrap" style="text-align: right">4.00</td> <td nowrap="nowrap" style="text-align: left"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: right">February 24, 2019</td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td nowrap="nowrap" style="text-align: left"> </td> <td nowrap="nowrap" style="text-align: right">277,127</td> <td nowrap="nowrap" style="text-align: left"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: left">$</td> <td nowrap="nowrap" style="text-align: right">1.20</td> <td nowrap="nowrap" style="text-align: left"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: right">March 13, 2019</td></tr> <tr style="background-color: white; vertical-align: bottom"> <td nowrap="nowrap" style="text-align: left"> </td> <td nowrap="nowrap" style="text-align: right">1,252</td> <td nowrap="nowrap" style="text-align: left"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: left">$</td> <td nowrap="nowrap" style="text-align: right">1.68</td> <td nowrap="nowrap" style="text-align: left"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: right">March 13, 2019</td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td nowrap="nowrap" style="text-align: left"> </td> <td nowrap="nowrap" style="text-align: right">12,500</td> <td nowrap="nowrap" style="text-align: left"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: left">$</td> <td nowrap="nowrap" style="text-align: right">1.24</td> <td nowrap="nowrap" style="text-align: left"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: right">May 31, 2019</td></tr> <tr style="background-color: white; vertical-align: bottom"> <td nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: left"> </td> <td nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: right">45,000</td> <td nowrap="nowrap" style="text-align: left; padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="text-align: left; padding-bottom: 1pt">$</td> <td nowrap="nowrap" style="text-align: right; padding-bottom: 1pt">1.00</td> <td nowrap="nowrap" style="text-align: left; padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="text-align: right; padding-bottom: 1pt">July 31, 2019</td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td nowrap="nowrap" style="border-bottom: black 2.5pt double; text-align: left"> </td> <td nowrap="nowrap" style="border-bottom: black 2.5pt double; text-align: right">1,828,059</td> <td nowrap="nowrap" style="text-align: left; padding-bottom: 2.5pt"> </td> <td nowrap="nowrap" style="padding-bottom: 2.5pt"> </td> <td nowrap="nowrap" style="text-align: left; padding-bottom: 2.5pt"> </td> <td nowrap="nowrap" style="text-align: right; padding-bottom: 2.5pt"> </td> <td nowrap="nowrap" style="text-align: left; padding-bottom: 2.5pt"> </td> <td nowrap="nowrap" style="padding-bottom: 2.5pt"> </td> <td nowrap="nowrap" style="text-align: right; padding-bottom: 2.5pt"> </td></tr> </table>   All of the warrants expiring on July 5, 2018 contain a contingent call provision whereby the Company may have the option to call for cancellation of all or any portion of the warrants for consideration equal to $0.001 per share, provided the quoted market price of the Companys common stock exceeds $6.00 for a period of twenty consecutive trading days, subject to certain minimum volume restrictions and other restrictions as provided in the warrant agreements.   During the years ended September 30, 2015 and 2014, the Company issued an aggregate of 57,500 warrants exercisable at a weighted average exercise price of $1.24 per share for a period of 4.58 years from the date of issuance in exchange for consulting services to be rendered. The weighted average grant date fair value of these warrants at issuance was $0.899 per warrant, based on the Black-Scholes option pricing model using the following weighted average assumptions: expected term 4.44 years, expected volatility 108.43%, expected dividend yield 0.00%, risk free interest rate 1.21%. Stock based compensation is being recorded in the financial statements over the vesting term of three years from the date of grant. During the three and six months ended March 31, 2016, the Company recorded $23,570 and $47,230, respectively (March 31, 2015: $2,378 and $3,634, respectively), in connection with the warrants granted.   <table cellspacing="0" cellpadding="0" style="margin-top: 0pt; width: 100%; font-size: 10pt; margin-bottom: 0pt; color: gray"> <tr style="vertical-align: top"> <td style="width: 45pt"> </td> <td style="width: 18pt">b)</td> <td style="text-align: justify">Stockbased Compensation Plan</td></tr> </table>   2015 Stock Option Plan   On September 18, 2015, the Companys board of directors approved a 2015 Omnibus Incentive Plan (the 2015 Plan), which provides for the grant of stock options and restricted stock awards to directors, officers, employees and consultants of the Company.   The maximum number of our common shares reserved for issue under the plan is 6,050,553 shares subject to adjustment in the event of a change of the Companys capitalization. As a result of the adoption of the 2015 Plan, no further option awards will be granted under any previously existing stock option plan. Stock option awards previously granted under previously existing stock option plans remain outstanding in accordance with their terms.   The 2015 Plan is administered by the board of directors, except that it may, in its discretion, delegate such responsibility to a committee of such board. The exercise price will be determined by the board of directors at the time of grant but in no event will be less than 110% of fair market value of the Companys shares of common stock on the grant date. Stock options may be granted under the 2015 Plan for an exercise period of up to ten years from the date of grant of the option or such lesser periods as may be determined by the board, subject to earlier termination in accordance with the terms of the 2015 Plan.   A summary of the status of Companys outstanding stock purchase options for the six months ended March 31, 2016 and for the year ended September 30, 2015 is presented below:   <table cellspacing="0" cellpadding="0" style="width: 85%; border-collapse: collapse; font-size: 10pt; margin-left: 65pt"> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center">Weighted</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center">Weighted Average</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center">Number of</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center">Average</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center">Grant Date fair</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Shares</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Exercise Price</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">value</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="width: 61%">Outstanding at October 1, 2014</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 10%">792,500</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 10%">2.82</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 10%"> </td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td>Forfeited</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(67,500</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">12.00</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="padding-bottom: 1pt">Granted</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,097,500</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">2.02</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; padding-bottom: 1pt">$</td> <td style="text-align: right; padding-bottom: 1pt">1.66</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="padding-bottom: 2.5pt">Outstanding at September 30, 2015</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">1,822,500</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">2.00</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt"> </td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td>Forfeited</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">-</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td>Granted</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">60,750</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">7.02</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">5.75</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="padding-bottom: 1pt">Expired</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(25,000</td> <td style="text-align: left; padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">14.68</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="text-align: right; padding-bottom: 1pt"> </td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="padding-bottom: 2.5pt">Outstanding at March 31, 2016</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">1,858,250</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">1.99</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt"> </td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="padding-bottom: 2.5pt">Exercisable at March 31, 2016</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">890,399</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">1.73</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt"> </td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="padding-bottom: 2.5pt">Exercisable at September 30, 2015</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">825,002</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">1.78</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt"> </td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="margin-top: 0pt; font-size: 10pt; margin-bottom: 0pt; width: 100%"> <tr style="vertical-align: top"> <td style="width: 45pt"> </td> <td style="width: 18pt">b)</td> <td>Stockbased Compensation Plan (contd)</td></tr> </table>   At March 31, 2016, the following stock options were outstanding:    <table cellspacing="0" cellpadding="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; margin-left: 1.3in"> <tr style="vertical-align: bottom"> <td colspan="6" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Number of Shares</td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center"> </td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="text-align: right"> </td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center; padding-bottom: 1pt">Aggregate</td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center; padding-bottom: 1pt">Remaining</td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" nowrap="nowrap" style="text-align: center"> </td> <td nowrap="nowrap" style="text-align: center"> </td> <td nowrap="nowrap" style="text-align: center"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center">Number</td> <td nowrap="nowrap" style="text-align: center"> </td> <td nowrap="nowrap" style="text-align: center"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center">Exercise</td> <td nowrap="nowrap" style="text-align: center"> </td> <td nowrap="nowrap" style="text-align: center"> </td> <td nowrap="nowrap" style="text-align: right"> </td> <td nowrap="nowrap" style="text-align: center"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center">Intrinsic</td> <td nowrap="nowrap" style="text-align: center"> </td> <td nowrap="nowrap" style="text-align: center"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center">Contractual</td> <td nowrap="nowrap" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Total</td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Vested</td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Price</td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Expiry Date</td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Value</td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Life (yrs)</td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 10%">500,000</td> <td style="text-align: left; width: 1%">(1)</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 10%">500,000</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 10%">1.60</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: right; width: 35%">July 5, 2023</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 10%">1,650,000</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 10%">7.26</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">75,000</td> <td style="text-align: left">(2)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">25,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">1.20</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: right">May 7, 2024</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">277,500</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">8.10</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">125,000</td> <td style="text-align: left">(3)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">31,250</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">1.32</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: right">May 8, 2024</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">447,500</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">8.10</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">718,750</td> <td style="text-align: left">(4)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">239,585</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">0.92</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: right">April 2, 2025</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">2,860,625</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">9.00</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">50,000</td> <td style="text-align: left">(5)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">12,500</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">1.44</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: right">June 8, 2025</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">173,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">9.19</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">50,000</td> <td style="text-align: left">(6)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">1.68</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: right">June 15, 2025</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">161,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">9.21</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">278,750</td> <td style="text-align: left">(7)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">69,688</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">5.04</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: right">September 18, 2025</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">9.47</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">1,500</td> <td style="text-align: left">(8)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,500</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">5.64</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: right">September 30, 2025</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">9.50</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">31,250</td> <td style="text-align: left">(9)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">5,209</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">5.68</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: right">October 2, 2025</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">9.51</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">25,000</td> <td style="text-align: left">(10)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">4,167</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">8.98</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: right">October 16, 2025</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">9.54</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">1,500</td> <td style="text-align: left">(11)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,500</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">5.57</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: right">December 31, 2025</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">9.75</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,500</td> <td style="text-align: left; padding-bottom: 1pt">(12)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; padding-bottom: 1pt">$</td> <td style="text-align: right; padding-bottom: 1pt">4.90</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: right; padding-bottom: 1pt">March 31, 2026</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="text-align: right; padding-bottom: 1pt">10.00</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">1,858,250</td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">890,399</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt"> </td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">5,569,625</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt"> </td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>   The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted market price of the Companys stock for the options that were in-the-money at March 31, 2016.   <table cellspacing="0" cellpadding="0" style="margin-top: 0pt; width: 100%; font-size: 10pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 0.9in"> </td> <td style="width: 0.2in">(1)</td> <td>As of March 31, 2016 and September 30, 2015 these options had fully vested. These options were granted during the year ended September 30, 2013 and vested immediately upon granting. The Company did not recognize any stock-based compensation during the six months ended March 31, 2016 (March 31, 2015: $0) in connection with these options.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="margin-top: 0pt; width: 100%; font-size: 10pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 0.9in"> </td> <td style="width: 0.2in">(2)</td> <td style="text-align: justify">As of March 31, 2016 and September 30, 2015, 25,000 of these options had vested. These options were issued during the year ended September 30, 2014 and vest annually over a three-year period commencing on the first anniversary of the date of the grant. The Company recognized stock based compensation expense of $5,764 and $11,590 during the three and six months ended March 31, 2016, respectively (March 31, 2015: $5,830 and $11,660, respectively) in connection with these options. These amounts have been included in general and administrative expenses on the Companys statement of operations.</td></tr> </table>    <table cellspacing="0" cellpadding="0" style="margin-top: 0pt; font-size: 10pt; margin-bottom: 0pt; width: 100%"> <tr style="vertical-align: top"> <td style="width: 45.1pt"> </td> <td style="width: 17.85pt">b)</td> <td>Stockbased Compensation Plan (contd)</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="margin-top: 0pt; width: 100%; font-size: 10pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 0.9in"> </td> <td style="width: 0.2in">(3)</td> <td style="text-align: justify">As of March 31, 2016 and September 30, 2015, 31,250 of these options had vested. These options were issued during the year ended September 30, 2014 and vest annually over a four-year period commencing on the first anniversary of the date of the grant. The Company recognized stock based compensation expense of $7,960 and $16,008 during the three and six months ended March 31, 2016, respectively (March 31, 2015: $8,053 and $16,106, respectively) in connection with these options. These amounts have been included in general and administrative expenses on the Companys statement of operations.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="margin-top: 0pt; width: 100%; font-size: 10pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 0.9in"> </td> <td style="width: 0.2in">(4)</td> <td style="text-align: justify">As of March 31, 2016, 239,585 of these options had vested (September 30, 2015: 239,585 of these options had vested). These options were issued during the year ended September 30, 2015 and vest in three equal installments on April 2, 2015, April 2, 2016 and April 2, 2017. The Company recognized stock based compensation expense of $42,811 and $86,093 during the three and six months ended March 31, 2016, respectively (March 31, 2015: $0 and $0, respectively) in connection with these options. These amounts have been included in general and administrative expenses on the Companys statement of operations.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="margin-top: 0pt; width: 100%; font-size: 10pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 0.9in"> </td> <td style="width: 0.2in">(5)</td> <td style="text-align: justify">As of March 31, 2016, 12,500 of these options had vested. These options were issued during the year ended September 30, 2015 and vest quarterly over a three-year period commencing on September 8, 2015. The Company recognized stock based compensation expense of $4,775 and $9,603 during the three and six months ended March 31, 2016, respectively (March 31, 2015: $0 and $0, respectively) in connection with these options. These amounts have been included in general and administrative expenses on the Companys statement of operations.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="margin-top: 0pt; width: 100%; font-size: 10pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 0.9in"> </td> <td style="width: 0.2in">(6)</td> <td style="text-align: justify">As of March 31, 2016 and September 30, 2015, none of these options had vested. These options were issued during the year ended September 30, 2015 and vest over a three-year period from the date of grant. The Company recognized stock based compensation expense of $5,573 and $11,207 during the three and six months ended March 31, 2016, respectively (March 31, 2015: $0 and $0, respectively) in connection with these options. These amounts have been included in general and administrative expenses on the Companys statement of operations.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="margin-top: 0pt; width: 100%; font-size: 10pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 0.9in"> </td> <td style="width: 0.2in">(7)</td> <td style="text-align: justify">As of March 31, 2016 and September 30, 2015, 69,688 of these options had vested. These options were issued during the year ended September 30, 2015 and vest over a three-year period from the date of grant. The Company recognized stock based compensation expense of $92,875 and $192,024 during the three and six months ended March 31, 2016, respectively (March 31, 2015: $0 and $0, respectively) in connection with these options. These amounts have been included in general and administrative expenses on the Companys statement of operations.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="margin-top: 0pt; width: 100%; font-size: 10pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 0.9in"> </td> <td style="width: 0.2in">(8)</td> <td style="text-align: justify">As of March 31, 2016, all of these options had vested. These options vested on December 31, 2015. The Company recognized stock based compensation expense of $0 and $6,800 during the three and six months ended March 31, 2016, respectively (March 31, 2015: $0 and $0) in connection with these options. These amounts have been included in general and administrative expenses on the Companys statement of operations.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="margin-top: 0pt; width: 100%; font-size: 10pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 0.9in"> </td> <td style="width: 0.2in">(9)</td> <td style="text-align: justify">As of March 31, 2016, 5,209 of these options had vested. These options were issued during the six months ended March 31, 2016 and vest in equal quarterly instalments over a three-year period from the date of grant. The Company recognized stock based compensation expense of $11,456 and $23,449 during the three and six months ended March 31, 2016, respectively (March 31, 2015: $0 and $0, respectively) in connection with these options. These amounts have been included in general and administrative expenses on the Companys statement of operations.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="margin-top: 0pt; font-size: 10pt; margin-bottom: 0pt; width: 100%"> <tr style="vertical-align: top"> <td style="width: 45pt"> </td> <td style="width: 18pt">b)</td> <td>Stockbased Compensation Plan (contd)</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="margin-top: 0pt; width: 100%; font-size: 10pt; margin-bottom: 0pt"> <tr style="text-align: justify; vertical-align: top"> <td style="width: 0.9in"> </td> <td style="text-align: left; width: 0.2in">(10)</td> <td style="text-align: justify">As of March 31, 2016, 4,167 of these options had vested. These options were issued during the six months ended March 31, 2016 and vest in equal quarterly instalments over a three-year period from the date of grant. The Company recognized stock based compensation expense of $27,906 and $27,906 during the three and six months ended March 31, 2016, respectively (March 31, 2015: $0 and $0, respectively) in connection with these options. These amounts have been included in general and administrative expenses on the Companys statement of operations.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="margin-top: 0pt; width: 100%; font-size: 10pt; margin-bottom: 0pt"> <tr style="text-align: justify; vertical-align: top"> <td style="width: 0.9in"> </td> <td style="text-align: left; width: 0.2in">(11)</td> <td style="text-align: justify">As of March 31, 2016, all of these options had vested. These options were issued during the six months ended March 31, 2016 and vested on December 31, 2015. The Company recognized stock based compensation expense of $0 and $6,800 during the three and six months ended March 31, 2016, respectively (March 31, 2015: $0 and $0) in connection with these options. These amounts have been included in general and administrative expenses on the Companys statement of operations.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="margin-top: 0pt; width: 100%; font-size: 10pt; margin-bottom: 0pt"> <tr style="text-align: justify; vertical-align: top"> <td style="width: 0.9in"> </td> <td style="text-align: left; width: 0.2in">(12)</td> <td style="text-align: justify">As of March 31, 2016, none of these options had vested. These options were issued during the six months ended March 31, 2016 and vest on December 31, 2016. The Company recognized stock based compensation expense of $0 and $0 during the three and six months ended March 31, 2016, respectively (March 31, 2015: $0 and $0) in connection with these options. These amounts have been included in general and administrative expenses on the Companys statement of operations.</td></tr> </table>   The fair value of each option award is estimated on the date of grant using the Black Scholes option pricing model based on the following weighted average assumptions:    <table cellspacing="0" cellpadding="0" style="width: 50%; border-collapse: collapse; font-size: 10pt; margin-left: 1.2in"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="6" style="text-align: center">March 31,</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2016</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2015</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; width: 72%">Risk-free interest rate</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 11%">1.68</td> <td style="text-align: left; width: 1%">%</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 11%">-</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Expected life of options (years)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">6.76</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left">Annualized volatility</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">101.92</td> <td style="text-align: left">%</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Dividend rate</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">0.00</td> <td style="text-align: left">%</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; margin-left: 45pt"> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="10" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">March 31, 2016</td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="text-align: center"> </td> <td nowrap="nowrap" style="text-align: center"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center"> </td> <td nowrap="nowrap" style="text-align: center"> </td> <td nowrap="nowrap" style="text-align: center"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center">Accumulated</td> <td nowrap="nowrap" style="text-align: center"> </td> <td nowrap="nowrap" style="text-align: center"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center"> </td> <td nowrap="nowrap" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="text-align: center"> </td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Cost</td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Depreciation</td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Net</td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="width: 61%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 10%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 10%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 10%"> </td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt">Computer equipment</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">3,015</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">2,260</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">755</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; margin-left: 45pt"> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="text-align: center"> </td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="10" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">September 30, 2015</td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="text-align: center"> </td> <td nowrap="nowrap" style="text-align: center"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center"> </td> <td nowrap="nowrap" style="text-align: center"> </td> <td nowrap="nowrap" style="text-align: center"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center">Accumulated</td> <td nowrap="nowrap" style="text-align: center"> </td> <td nowrap="nowrap" style="text-align: center"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center"> </td> <td nowrap="nowrap" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="text-align: center"> </td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Cost</td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Depreciation</td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Net</td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="width: 61%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 10%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 10%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 10%"> </td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">Computer equipment</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">3,015</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">1,763</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">1,252</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; margin-left: 1in"> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="text-align: center"> </td> <td nowrap="nowrap" style="text-align: center"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center">March 31,</td> <td nowrap="nowrap" style="text-align: center"> </td> <td nowrap="nowrap" style="text-align: center"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center">September 30,</td> <td nowrap="nowrap" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="text-align: center"> </td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">2016</td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">2015</td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; width: 74%">Promissory note dated January 9, 2013 with a principal balance of CDN$86,677, bearing interest at 12% per annum, secured by all the present and future assets of the Company; due on demand</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 10%">66,834</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 10%">64,630</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">Promissory note dated January 9, 2013 with a principal balance of CDN$27,639, bearing interest at 12% per annum, secured by all the present and future assets of the Company; due on demand</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">21,311</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">20,608</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">88,145</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">85,238</td></tr> </table>

<table cellspacing="0" cellpadding="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; margin-left: 45pt"> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="text-align: center"> </td> <td nowrap="nowrap" style="text-align: center"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center">March 31,</td> <td nowrap="nowrap" style="text-align: center"> </td> <td nowrap="nowrap" style="text-align: center"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center">September 30,</td> <td nowrap="nowrap" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="padding-bottom: 1pt">Senior Convertible Debentures</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">2016</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">2015</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="width: 74%">Senior Convertible Debentures, non-interest bearing, unsecured, due March 18, 2044</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 10%">4,982</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 10%">6,144</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">Less: Debt Discount</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(4,645</td> <td style="text-align: left; padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(5,812</td> <td style="text-align: left; padding-bottom: 1pt">)</td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td>Total carrying value</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">337</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">332</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">Less: current portion</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt">Long term liability</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">337</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">332</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>

A summary of the Companys share purchase warrants outstanding is presented below:    <table cellspacing="0" cellpadding="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; margin-left: 1.25in"> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center">Weighted</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center">Average</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Number of Shares</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Exercise Price</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="width: 73%">Balance, October 1, 2014</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 11%">18,728,910</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 10%">1.59</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td>Expired</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(62,500</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">1.40</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td>Exercised</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(15,468,520</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">1.43</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="padding-bottom: 1pt">Issued</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,075,000</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">0.76</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td>Balance, September 30, 2015</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">4,272,890</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">2.11</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="padding-bottom: 1pt">Exercised</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(2,444,831</td> <td style="text-align: left; padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">1.68</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="padding-bottom: 2.5pt">Balance, March 31, 2016</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">1,828,059</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">2.68</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>

At March 31, 2016, the Company has 1,828,059 currently exercisable share purchase warrants outstanding as follows:    <table cellspacing="0" cellpadding="0" style="width: 45%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Number</td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Exercise Price</td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Expiry Date</td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td nowrap="nowrap" style="text-align: left; width: 1%"> </td> <td nowrap="nowrap" style="text-align: right; width: 30%">1,462,180</td> <td nowrap="nowrap" style="text-align: left; width: 1%"> </td> <td nowrap="nowrap" style="width: 1%"> </td> <td nowrap="nowrap" style="text-align: left; width: 1%">$</td> <td nowrap="nowrap" style="text-align: right; width: 30%">3.00</td> <td nowrap="nowrap" style="text-align: left; width: 1%"> </td> <td nowrap="nowrap" style="width: 1%"> </td> <td nowrap="nowrap" style="text-align: right; width: 34%">July 5, 2018</td></tr> <tr style="background-color: white; vertical-align: bottom"> <td nowrap="nowrap" style="text-align: left"> </td> <td nowrap="nowrap" style="text-align: right">30,000</td> <td nowrap="nowrap" style="text-align: left"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: left">$</td> <td nowrap="nowrap" style="text-align: right">4.00</td> <td nowrap="nowrap" style="text-align: left"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: right">February 24, 2019</td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td nowrap="nowrap" style="text-align: left"> </td> <td nowrap="nowrap" style="text-align: right">277,127</td> <td nowrap="nowrap" style="text-align: left"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: left">$</td> <td nowrap="nowrap" style="text-align: right">1.20</td> <td nowrap="nowrap" style="text-align: left"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: right">March 13, 2019</td></tr> <tr style="background-color: white; vertical-align: bottom"> <td nowrap="nowrap" style="text-align: left"> </td> <td nowrap="nowrap" style="text-align: right">1,252</td> <td nowrap="nowrap" style="text-align: left"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: left">$</td> <td nowrap="nowrap" style="text-align: right">1.68</td> <td nowrap="nowrap" style="text-align: left"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: right">March 13, 2019</td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td nowrap="nowrap" style="text-align: left"> </td> <td nowrap="nowrap" style="text-align: right">12,500</td> <td nowrap="nowrap" style="text-align: left"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: left">$</td> <td nowrap="nowrap" style="text-align: right">1.24</td> <td nowrap="nowrap" style="text-align: left"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: right">May 31, 2019</td></tr> <tr style="background-color: white; vertical-align: bottom"> <td nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: left"> </td> <td nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: right">45,000</td> <td nowrap="nowrap" style="text-align: left; padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="text-align: left; padding-bottom: 1pt">$</td> <td nowrap="nowrap" style="text-align: right; padding-bottom: 1pt">1.00</td> <td nowrap="nowrap" style="text-align: left; padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="text-align: right; padding-bottom: 1pt">July 31, 2019</td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td nowrap="nowrap" style="border-bottom: black 2.5pt double; text-align: left"> </td> <td nowrap="nowrap" style="border-bottom: black 2.5pt double; text-align: right">1,828,059</td> <td nowrap="nowrap" style="text-align: left; padding-bottom: 2.5pt"> </td> <td nowrap="nowrap" style="padding-bottom: 2.5pt"> </td> <td nowrap="nowrap" style="text-align: left; padding-bottom: 2.5pt"> </td> <td nowrap="nowrap" style="text-align: right; padding-bottom: 2.5pt"> </td> <td nowrap="nowrap" style="text-align: left; padding-bottom: 2.5pt"> </td> <td nowrap="nowrap" style="padding-bottom: 2.5pt"> </td></tr> </table>

A summary of the status of Companys outstanding stock purchase options for the six months ended March 31, 2016 and for the year ended September 30, 2015 is presented below:    <table cellspacing="0" cellpadding="0" style="width: 85%; border-collapse: collapse; font-size: 10pt; margin-left: 65pt"> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center">Weighted</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center">Weighted Average</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center">Number of</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center">Average</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center">Grant Date fair</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Shares</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Exercise Price</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">value</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="width: 61%">Outstanding at October 1, 2014</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 10%">792,500</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 10%">2.82</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 10%"> </td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td>Forfeited</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(67,500</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">12.00</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="padding-bottom: 1pt">Granted</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,097,500</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">2.02</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; padding-bottom: 1pt">$</td> <td style="text-align: right; padding-bottom: 1pt">1.66</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="padding-bottom: 2.5pt">Outstanding at September 30, 2015</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">1,822,500</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">2.00</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt"> </td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td>Forfeited</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">-</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td>Granted</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">60,750</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">7.02</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">5.75</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="padding-bottom: 1pt">Expired</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(25,000</td> <td style="text-align: left; padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">14.68</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="text-align: right; padding-bottom: 1pt"> </td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="padding-bottom: 2.5pt">Outstanding at March 31, 2016</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">1,858,250</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">1.99</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt"> </td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="padding-bottom: 2.5pt">Exercisable at March 31, 2016</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">890,399</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">1.73</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt"> </td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="padding-bottom: 2.5pt">Exercisable at September 30, 2015</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">825,002</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">1.78</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt"> </td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>

The fair value of each option award is estimated on the date of grant using the Black Scholes option pricing model based on the following weighted average assumptions:    <table cellspacing="0" cellpadding="0" style="width: 50%; border-collapse: collapse; font-size: 10pt; margin-left: 1.2in"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="6" style="text-align: center">March 31,</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2016</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2015</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; width: 72%">Risk-free interest rate</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 11%">1.68</td> <td style="text-align: left; width: 1%">%</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 11%">-</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Expected life of options (years)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">6.76</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left">Annualized volatility</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">101.92</td> <td style="text-align: left">%</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Dividend rate</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">0.00</td> <td style="text-align: left">%</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td></tr> </table>

1963956

2403144

1.24

1828059 1462180 30000 277127 1252 12500 45000

296104

179598

57500

0.0168

0.0121

1.0192

1.0843

0.0000

P3Y

P4Y

P4Y6M29D

P3Y

9603

11207

192024

6800

23449

27906

16008

23570

47230

2378

3634

11590

5764

11660

5830

7960

16106

8053

86093

42811

4775

5573

92875

11456

27906

6800

3.00 4.00 1.20 1.68 1.24 1.00

2024-05-07

2018-07-05

2019-02-24

2019-03-13

2019-05-31

2019-07-31

2023-07-05

2024-05-08

2025-04-02

2025-06-08

2025-06-15

2025-09-18

2025-09-30

2025-10-02

2025-10-16

2025-12-31

2026-03-31

2013-01-09

86677

27639

86677

27639

10000000

4982

6144

Secured by all the present and future assets of the Company; due on demand.

2013-06-30

100

500 500 286455 571093

4645

5812

337

332

337

332

1.00 1.00

1167

493451

486334

1161

3918478

1161

167415 167415 1000000

18728910

4272890

1828059

62500

-15468520 -2444831

1075000

1.59 2.11 2.68 1.40 1.43 1.68 0.76

75000

1858250

500000

125000

718750

50000

278750

1500

31250

25000

1500

792500

1822500

1500

67500

1097500

60750

890399

825002

25000

1.66

5.75

0.899

1.2

1.99

1.6

1.32

0.92

1.44

1.68

5.04

5.64

5.68

8.98

5.57

2.82

2.00

4.9

12.00

2.02

7.02

1.73

1.78

14.68

2018-07-05 The Company may have the option to call for cancellation of all or any portion of the warrants for consideration equal to $0.001 per share, provided the quoted market price of the Companys common stock exceeds $6.00 for a period of twenty consecutive trading days, subject to certain minimum volume restrictions and other restrictions as provided in the warrant agreements.

P6Y9M3D

P4Y5M8D

6050553

P10Y

31250

239585

12500

69688

4167

31250

25000

5209

25000

239585

69688

Vest in three equal installments on April 2, 2015, April 2, 2016 and April 2, 2017.

Vest quarterly over a three year period commencing on September 8, 2015.

Vest over a three-year period from the date of grant.

Vest in equal quarterly instalments over a three-year period from the date of grant.

Vest annually over a four-year period commencing on the first anniversary of the date of the grant.

Vest annually over a three-year period commencing on the first anniversary of the date of the grant.

Vest in equal quarterly instalments over a three-year period from the date of grant.

25000

890399

500000

31250

239585

12500

69688

1500

5209

4167

1500

277500

5569625

1650000

447500

2860625

173000

161000

P8Y1M6D

P7Y3M4D

P8Y1M6D

P9Y

P9Y2M8D

P9Y2M16D

P9Y5M19D

P9Y6M

P9Y6M4D

P9Y6M14D

P9Y9M

P10Y

At March 31, 2016, the following stock options were outstanding:     <table cellspacing="0" cellpadding="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; margin-left: 1.3in"> <tr style="vertical-align: bottom"> <td colspan="6" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Number of Shares</td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center"> </td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="text-align: right"> </td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center; padding-bottom: 1pt">Aggregate</td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center; padding-bottom: 1pt">Remaining</td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" nowrap="nowrap" style="text-align: center"> </td> <td nowrap="nowrap" style="text-align: center"> </td> <td nowrap="nowrap" style="text-align: center"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center">Number</td> <td nowrap="nowrap" style="text-align: center"> </td> <td nowrap="nowrap" style="text-align: center"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center">Exercise</td> <td nowrap="nowrap" style="text-align: center"> </td> <td nowrap="nowrap" style="text-align: center"> </td> <td nowrap="nowrap" style="text-align: right"> </td> <td nowrap="nowrap" style="text-align: center"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center">Intrinsic</td> <td nowrap="nowrap" style="text-align: center"> </td> <td nowrap="nowrap" style="text-align: center"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center">Contractual</td> <td nowrap="nowrap" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Total</td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Vested</td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Price</td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Expiry Date</td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Value</td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Life (yrs)</td> <td nowrap="nowrap" style="text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 10%">500,000</td> <td style="text-align: left; width: 1%">(1)</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 10%">500,000</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 10%">1.60</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: right; width: 35%">July 5, 2023</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 10%">1,650,000</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 10%">7.26</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">75,000</td> <td style="text-align: left">(2)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">25,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">1.20</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: right">May 7, 2024</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">277,500</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">8.10</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">125,000</td> <td style="text-align: left">(3)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">31,250</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">1.32</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: right">May 8, 2024</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">447,500</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">8.10</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">718,750</td> <td style="text-align: left">(4)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">239,585</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">0.92</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: right">April 2, 2025</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">2,860,625</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">9.00</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">50,000</td> <td style="text-align: left">(5)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">12,500</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">1.44</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: right">June 8, 2025</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">173,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">9.19</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">50,000</td> <td style="text-align: left">(6)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">1.68</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: right">June 15, 2025</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">161,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">9.21</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">278,750</td> <td style="text-align: left">(7)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">69,688</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">5.04</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: right">September 18, 2025</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">9.47</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">1,500</td> <td style="text-align: left">(8)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,500</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">5.64</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: right">September 30, 2025</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">9.50</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">31,250</td> <td style="text-align: left">(9)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">5,209</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">5.68</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: right">October 2, 2025</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">9.51</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">25,000</td> <td style="text-align: left">(10)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">4,167</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">8.98</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: right">October 16, 2025</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">9.54</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">1,500</td> <td style="text-align: left">(11)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,500</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">5.57</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: right">December 31, 2025</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">9.75</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,500</td> <td style="text-align: left; padding-bottom: 1pt">(12)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; padding-bottom: 1pt">$</td> <td style="text-align: right; padding-bottom: 1pt">4.90</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: right; padding-bottom: 1pt">March 31, 2026</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="text-align: right; padding-bottom: 1pt">10.00</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">1,858,250</td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">890,399</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt"> </td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">5,569,625</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt"> </td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>   The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted market price of the Companys stock for the options that were in-the-money at March 31, 2016.   <table cellspacing="0" cellpadding="0" style="margin-top: 0pt; width: 100%; font-size: 10pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 0.9in"> </td> <td style="width: 0.2in">(1)</td> <td>As of March 31, 2016 and September 30, 2015 these options had fully vested. These options were granted during the year ended September 30, 2013 and vested immediately upon granting. The Company did not recognize any stock-based compensation during the six months ended March 31, 2016 (March 31, 2015: $0) in connection with these options.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="margin-top: 0pt; width: 100%; font-size: 10pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 0.9in"> </td> <td style="width: 0.2in">(2)</td> <td style="text-align: justify">As of March 31, 2016 and September 30, 2015, 25,000 of these options had vested. These options were issued during the year ended September 30, 2014 and vest annually over a three-year period commencing on the first anniversary of the date of the grant. The Company recognized stock based compensation expense of $5,764 and $11,590 during the three and six months ended March 31, 2016, respectively (March 31, 2015: $5,830 and $11,660, respectively) in connection with these options. These amounts have been included in general and administrative expenses on the Companys statement of operations.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="margin-top: 0pt; width: 100%; font-size: 10pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 0.9in"> </td> <td style="width: 0.2in">(3)</td> <td style="text-align: justify">As of March 31, 2016 and September 30, 2015, 31,250 of these options had vested. These options were issued during the year ended September 30, 2014 and vest annually over a four-year period commencing on the first anniversary of the date of the grant. The Company recognized stock based compensation expense of $7,960 and $16,008 during the three and six months ended March 31, 2016, respectively (March 31, 2015: $8,053 and $16,106, respectively) in connection with these options. These amounts have been included in general and administrative expenses on the Companys statement of operations.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="margin-top: 0pt; width: 100%; font-size: 10pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 0.9in"> </td> <td style="width: 0.2in">(4)</td> <td style="text-align: justify">As of March 31, 2016, 239,585 of these options had vested (September 30, 2015: 239,585 of these options had vested). These options were issued during the year ended September 30, 2015 and vest in three equal installments on April 2, 2015, April 2, 2016 and April 2, 2017. The Company recognized stock based compensation expense of $42,811 and $86,093 during the three and six months ended March 31, 2016, respectively (March 31, 2015: $0 and $0, respectively) in connection with these options. These amounts have been included in general and administrative expenses on the Companys statement of operations.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="margin-top: 0pt; width: 100%; font-size: 10pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 0.9in"> </td> <td style="width: 0.2in">(5)</td> <td style="text-align: justify">As of March 31, 2016, 12,500 of these options had vested. These options were issued during the year ended September 30, 2015 and vest quarterly over a three-year period commencing on September 8, 2015. The Company recognized stock based compensation expense of $4,775 and $9,603 during the three and six months ended March 31, 2016, respectively (March 31, 2015: $0 and $0, respectively) in connection with these options. These amounts have been included in general and administrative expenses on the Companys statement of operations.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="margin-top: 0pt; width: 100%; font-size: 10pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 0.9in"> </td> <td style="width: 0.2in">(6)</td> <td style="text-align: justify">As of March 31, 2016 and September 30, 2015, none of these options had vested. These options were issued during the year ended September 30, 2015 and vest over a three-year period from the date of grant. The Company recognized stock based compensation expense of $5,573 and $11,207 during the three and six months ended March 31, 2016, respectively (March 31, 2015: $0 and $0, respectively) in connection with these options. These amounts have been included in general and administrative expenses on the Companys statement of operations.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="margin-top: 0pt; width: 100%; font-size: 10pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 0.9in"> </td> <td style="width: 0.2in">(7)</td> <td style="text-align: justify">As of March 31, 2016 and September 30, 2015, 69,688 of these options had vested. These options were issued during the year ended September 30, 2015 and vest over a three-year period from the date of grant. The Company recognized stock based compensation expense of $92,875 and $192,024 during the three and six months ended March 31, 2016, respectively (March 31, 2015: $0 and $0, respectively) in connection with these options. These amounts have been included in general and administrative expenses on the Companys statement of operations.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="margin-top: 0pt; width: 100%; font-size: 10pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 0.9in"> </td> <td style="width: 0.2in">(8)</td> <td style="text-align: justify">As of March 31, 2016, all of these options had vested. These options vested on December 31, 2015. The Company recognized stock based compensation expense of $0 and $6,800 during the three and six months ended March 31, 2016, respectively (March 31, 2015: $0 and $0) in connection with these options. These amounts have been included in general and administrative expenses on the Companys statement of operations.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="margin-top: 0pt; width: 100%; font-size: 10pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 0.9in"> </td> <td style="width: 0.2in">(9)</td> <td style="text-align: justify">As of March 31, 2016, 5,209 of these options had vested. These options were issued during the six months ended March 31, 2016 and vest in equal quarterly instalments over a three-year period from the date of grant. The Company recognized stock based compensation expense of $11,456 and $23,449 during the three and six months ended March 31, 2016, respectively (March 31, 2015: $0 and $0, respectively) in connection with these options. These amounts have been included in general and administrative expenses on the Companys statement of operations.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="margin-top: 0pt; width: 100%; font-size: 10pt; margin-bottom: 0pt"> <tr style="text-align: justify; vertical-align: top"> <td style="width: 0.9in"> </td> <td style="text-align: left; width: 0.2in">(10)</td> <td style="text-align: justify">As of March 31, 2016, 4,167 of these options had vested. These options were issued during the six months ended March 31, 2016 and vest in equal quarterly instalments over a three-year period from the date of grant. The Company recognized stock based compensation expense of $27,906 and $27,906 during the three and six months ended March 31, 2016, respectively (March 31, 2015: $0 and $0, respectively) in connection with these options. These amounts have been included in general and administrative expenses on the Companys statement of operations.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="margin-top: 0pt; width: 100%; font-size: 10pt; margin-bottom: 0pt"> <tr style="text-align: justify; vertical-align: top"> <td style="width: 0.9in"> </td> <td style="text-align: left; width: 0.2in">(11)</td> <td style="text-align: justify">As of March 31, 2016, all of these options had vested. These options were issued during the six months ended March 31, 2016 and vested on December 31, 2015. The Company recognized stock based compensation expense of $0 and $6,800 during the three and six months ended March 31, 2016, respectively (March 31, 2015: $0 and $0) in connection with these options. These amounts have been included in general and administrative expenses on the Companys statement of operations.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="margin-top: 0pt; width: 100%; font-size: 10pt; margin-bottom: 0pt"> <tr style="text-align: justify; vertical-align: top"> <td style="width: 0.9in"> </td> <td style="text-align: left; width: 0.2in">(12)</td> <td style="text-align: justify">As of March 31, 2016, none of these options had vested. These options were issued during the six months ended March 31, 2016 and vest on December 31, 2016. The Company recognized stock based compensation expense of $0 and $0 during the three and six months ended March 31, 2016, respectively (March 31, 2015: $0 and $0) in connection with these options. These amounts have been included in general and administrative expenses on the Companys statement of operations.</td></tr> </table>

1:4

3691291

6101534

3015

1763

2260

10000000 50000000 P25M P36M

The Company may direct Lincoln Park, at its sole discretion, and subject to certain conditions, to purchase up to 50,000 shares of common stock on any business day, provided that at least one business day has passed since the most recent purchase. The amount of a purchase may be increased under certain circumstances provided, however that Lincoln Parks committed obligation under any single purchase shall not exceed $2,000,000. The purchase price of shares of common stock related to the future funding will be based on the then prevailing market prices of such shares at the time of sales as described in the 2015 Purchase Agreement.

89799 290523 1684561 5581

125078

3169933

16082

32465

121578 258092 13582 27465 0 610000 0 0

2290341

30500

33000

2.44 3931000

Recent Accounting Pronouncements Not Yet Adopted   In June 2014, the FASB issued ASU No. 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period ("ASU 2014-12"). ASU 2014-12 requires that a performance target that affects vesting, and that could be achieved after the requisite service period, be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant date fair value of the award. This update further clarifies that compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. The amendments in this ASU are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. The Company is currently evaluating the impact this guidance will have on its financial condition, results of operations and cash flows.   In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entitys Ability to Continue as a Going Concern (ASU 2014-15). ASU 2014-15 will explicitly require management to assess an entitys ability to continue as a going concern, and to provide related footnote disclosure in certain circumstances. The new standard will be effective for all entities in the first annual period ending after December 15, 2016. The Company is currently evaluating the impact this guidance will have on its financial condition, results of operations and cash flows.   In May, 2014, the FASB and the International Accounting Standards Board (IASB) issued a converged standard on revenue recognition from contracts with customers, ASU 2014-09 (Topic 606 and IFRS 15). This standard will supersede nearly all existing revenue recognition guidance. ASU 2014-09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. The adoption of this standard is not expected to have a material impact for any period presented.   In April 2015, the Financial Accounting Standards Board (FASB), issued the Accounting Standards Update 2015-03, Interest - Imputation of Interest (Subtopic 835-30) - Simplifying the Presentation of Debt Issuance Costs, that requires debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction from the debt liability rather than as an asset. For public business entities, the final guidance will be effective for fiscal years beginning after December 15, 2015, however, early adoption (including in interim periods) is permitted. Upon adoption, an entity must apply the new guidance retrospectively to all prior periods presented in the financial statements. An entity is also required in the year of adoption to provide certain disclosures about the change in accounting principle, including the nature of and reason for the change, the transition method, a description of the prior-period information that has been retrospectively adjusted and the effect of the change on the financial statement line items (that is, debt issuance cost asset and the debt liability). The adoption of this standard is not expected to have a material impact for any period presented.   In November 2015, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2015-17 Income Taxes: Balance Sheet Classification of Deferred Taxes (ASU 2015-17). ASU 2015-17 eliminates the requirement to bifurcate deferred taxes between current and non-current on the balance sheet and requires that deferred tax liabilities and assets be classified as noncurrent on the balance sheet. ASU 2015-17 is effective for public entities in fiscal years beginning after December 15, 2016, and for interim periods within those fiscal years. The amendments for ASU-2015-17 can be applied retrospectively or prospectively and early adoption is permitted. The adoption of this standard is not expected to have a material impact for any period presented.   In February 2016, FASB issued ASU 2016-02, Leases. The guidance would require lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right of-use assets. The guidance is effective for annual and interim reporting periods beginning on or after December 15, 2018. The Company is currently evaluating the impact this guidance will have on its financial condition, results of operations and cash flows.   In March 2016, the FASB issued ASC 2016-09, Compensation Stock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting. These amendments are intended to simplify several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. These amendments are effective for annual and interim reporting periods beginning on or after December 15, 2016. Early adoption is permitted. Entities have the option to apply the amendments on either a prospective basis or a modified retrospective basis. The Company is currently evaluating the impact this guidance will have on its financial condition, results of operations and cash flows.   Other than noted above, the Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on its results of operations, financial position or cash flow.

637027

26879

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; line-height: normal; margin-top: 0px; margin-bottom: 0px; font-size-adjust: none; font-stretch: normal"> <tr style="text-align: justify; vertical-align: top"> <td style="width: 45pt; text-align: left">Note 5</td> <td style="text-align: justify; text-decoration: underline">Deferred Grant Income</td></tr> </table>   During the year ended September 30, 2015, the Company was awarded grant funding in the amount of $286,455, of which the Company received $71,614 during the year ended September 30, 2015 and the remainder will be received in equal semi-annual instalments over the 24-month commitment. The grant was received in exchange for a commitment to provide research and development for preclinical validation of Sigma-1 receptor agonism as potential treatment for Parkinsons disease.   The grant income was deferred and is being amortized as an increase to other income over a two-year period as the related research and development expenditures are incurred. During the three and six months ended March 31, 2016, the Company recognized $26,879 and $65,934, respectively (2015: $0 and $0, respectively) of this grant on its statement of operations.    During the six months ended March 31, 2016, the Company recognized other grant income of $571,093 in respect of a research and development incentive program offered by the Australian government.

As of March 31, 2016 and September 30, 2015 these options had fully vested. These options were granted during the year ended September 30, 2013 and vested immediately upon granting. The Company did not recognize any stock-based compensation during the six months ended March 31, 2016 (March 31, 2015: $0) in connection with these options. As of March 31, 2016 and September 30, 2015, 25,000 of these options had vested. These options were issued during the year ended September 30, 2014 and vest annually over a three-year period commencing on the first anniversary of the date of the grant. The Company recognized stock based compensation expense of $5,764 and $11,590 during the three and six months ended March 31, 2016, respectively (March 31, 2015: $5,830 and $11,660, respectively) in connection with these options. These amounts have been included in general and administrative expenses on the Company's statement of operations. As of March 31, 2016 and September 30, 2015, 31,250 of these options had vested. These options were issued during the year ended September 30, 2014 and vest annually over a four-year period commencing on the first anniversary of the date of the grant. The Company recognized stock based compensation expense of $7,960 and $16,008 during the three and six months ended March 31, 2016, respectively (March 31, 2015: $8,053 and $16,106, respectively) in connection with these options. These amounts have been included in general and administrative expenses on the Company's statement of operations. As of March 31, 2016, 239,585 of these options had vested (September 30, 2015: 239,585 of these options had vested). These options were issued during the year ended September 30, 2015 and vest in three equal installments on April 2, 2015, April 2, 2016 and April 2, 2017. The Company recognized stock based compensation expense of $42,811 and $86,093 during the three and six months ended March 31, 2016, respectively (March 31, 2015: $0 and $0, respectively) in connection with these options. These amounts have been included in general and administrative expenses on the Company's statement of operations. As of March 31, 2016, 12,500 of these options had vested. These options were issued during the year ended September 30, 2015 and vest quarterly over a three-year period commencing on September 8, 2015. The Company recognized stock based compensation expense of $4,775 and $9,603 during the three and six months ended March 31, 2016, respectively (March 31, 2015: $0 and $0, respectively) in connection with these options. These amounts have been included in general and administrative expenses on the Company's statement of operations. As of March 31, 2016 and September 30, 2015, none of these options had vested. These options were issued during the year ended September 30, 2015 and vest over a three-year period from the date of grant. The Company recognized stock based compensation expense of $5,573 and $11,207 during the three and six months ended March 31, 2016, respectively (March 31, 2015: $0 and $0, respectively) in connection with these options. These amounts have been included in general and administrative expenses on the Company's statement of operations. As of March 31, 2016 and September 30, 2015, 69,688 of these options had vested. These options were issued during the year ended September 30, 2015 and vest over a three-year period from the date of grant. The Company recognized stock based compensation expense of $92,875 and $192,024 during the three and six months ended March 31, 2016, respectively (March 31, 2015: $0 and $0, respectively) in connection with these options. These amounts have been included in general and administrative expenses on the Company's statement of operations. As of March 31, 2016, all of these options had vested. These options vested on December 31, 2015. The Company recognized stock based compensation expense of $0 and $6,800 during the three and six months ended March 31, 2016, respectively (March 31, 2015: $0 and $0) in connection with these options. These amounts have been included in general and administrative expenses on the Company's statement of operations. As of March 31, 2016, 5,209 of these options had vested. These options were issued during the six months ended March 31, 2016 and vest in equal quarterly instalments over a three-year period from the date of grant. The Company recognized stock based compensation expense of $11,456 and $23,449 during the three and six months ended March 31, 2016, respectively (March 31, 2015: $0 and $0, respectively) in connection with these options. These amounts have been included in general and administrative expenses on the Company's statement of operations. As of March 31, 2016, 4,167 of these options had vested. These options were issued during the six months ended March 31, 2016 and vest in equal quarterly instalments over a three-year period from the date of grant. The Company recognized stock based compensation expense of $27,906 and $27,906 during the three and six months ended March 31, 2016, respectively (March 31, 2015: $0 and $0, respectively) in connection with these options. These amounts have been included in general and administrative expenses on the Company's statement of operations. As of March 31, 2016, all of these options had vested. These options were issued during the six months ended March 31, 2016 and vested on December 31, 2015. The Company recognized stock based compensation expense of $0 and $6,800 during the three and six months ended March 31, 2016, respectively (March 31, 2015: $0 and $0) in connection with these options. These amounts have been included in general and administrative expenses on the Company's statement of operations. As of March 31, 2016, none of these options had vested. These options were issued during the six months ended March 31, 2016 and vest on December 31, 2016. The Company recognized stock based compensation expense of $0 and $0 during the three and six months ended March 31, 2016, respectively (March 31, 2015: $0 and $0) in connection with these options. These amounts have been included in general and administrative expenses on the Company's statement of operations.

EX-101.SCH 7 avxl-20160331.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Business Description and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Recent Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Equipment link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Promissory Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Deferred Grant Income link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Senior Convertible Debentures link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Capital Stock link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Lincoln Park Purchase Agreement link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Commitments link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Supplemental Cash Flow Information link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Recent Accounting Pronouncements (Policies) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Promissory Notes Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Senior Convertible Debentures (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Commitments (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Business Description and Basis of Presentation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Promissory Notes Payable (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Promissory Notes Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Deferred Grant Income (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Senior Convertible Debentures (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Senior Convertible Debentures (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Capital Stock (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Lincoln Park Purchase Agreement (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Commitments (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Commitments (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Commitments (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Commitments (Details 3) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Commitments (Details 4) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Commitments (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Commitments (Details Narrative 1) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Supplemental Cash Flow Information (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 avxl-20160331_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 avxl-20160331_def.xml XBRL DEFINITION FILE EX-101.LAB 10 avxl-20160331_lab.xml XBRL LABEL FILE Common Stock [Member] Equity Components [Axis] Additional Paid-in Capital [Member] Common Shares to be Issued [Member] Accumulated Deficit [Member] Computer Equipment [Member] Property, Plant and Equipment, Type [Axis] 12% Promissory Note [Member] Debt Instrument [Axis] 12% Promissory Note [Member] Canada, Dollars [Member] Currency [Axis] Securities Purchase Agreement [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Senior Convertible Debentures Due March 18, 2044 [Member] Long-term Debt, Type [Axis] Purchasers [Member] Legal Entity [Axis] Series A Warrant [Member] Class of Warrant or Right [Axis] Series B Warrant [Member] Warrant [Member] Non - Purchasers [Member] Amended Registration Rights Agreement ( the Debenture Amendment) [Member] Amended Senior Convertible Debentures Due March 18, 2044 [Member] Directors and Officers [Member] Related Party [Axis] 2013 Purchase Agreement [Member] Lincoln Park Capital Fund, LLC [Member] 2015 Purchase Agreement [Member] Second Stock Option [Member] Award Type [Axis] Restricted Common Stock [Member] Share-based Compensation Award, Tranche One [Member] Vesting [Axis] Share-based Compensation Award, Tranche Two [Member] Share-based Compensation Award, Tranche Three [Member] Share-based Compensation Award, Tranche Four [Member] Purchase Warrants [Member] First Purchase Warrants [Member] Second Purchase Warrants [Member] Third Purchase Warrants [Member] Four Purchase Warrants [Member] Five Purchase Warrants [Member] Six Purchase Warrants [Member] 2015 Omnibus Incentive Plan [Member] Plan Name [Axis] First Stock Option [Member] Third Stock Option [Member] Four Stock Option [Member] Five Stock Option [Member] Six Stock Option [Member] Seven Stock Option [Member] Eight Stock Option [Member] Nine Stock Option [Member] Ten Stock Option [Member] Eleven Stock Option [Member] General and Administrative Expense [Member] Income Statement Location [Axis] 2013 Employment Agreement [Member] Consultant [Member] Twelve Stock Option [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Trading Symbol Document Period End Date Amendment Flag Current Fiscal Year End Date Entity a Well-known Seasoned Issuer Entity a Voluntary Filer Entity's Reporting Status Current Entity Filer Category Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS Current Cash Sales Tax Recoverable Prepaid expenses and deposits Current Assets Equipment Total Assets LIABILITIES Current Accounts payable and accrued liabilities Deferred grant income Promissory notes payable Current Liabilities Senior Convertible Debentures Total Liabilities STOCKHOLDERS' EQUITY Capital stock Authorized: 100,000,000 common shares, par value $0.001 per share Issued and outstanding: 35,695,572 common shares (September 30, 2015 - 32,044,213) Additional paid-in capital Common stock to be issued Accumulated deficit Stockholders' Equity Total Liabilities and Stockholder's Equity Common stock, par value (in dollars per share) Common stock, authorized Common stock, issued Common stock, outstanding Income Statement [Abstract] Operating expenses General and administrative Research and development Total operating expenses Other income (expenses) Grant income Interest income (expense), net Gain on settlement of accounts payable Financing related charges and adjustments Foreign exchange (loss) gain Total other income (expenses), net Net loss before provision for income taxes Income tax expense Net loss and comprehensive loss for the period Loss per share Basic (in dollars per share) Diluted (in dollars per share) Weighted average number of shares outstanding Basic (in shares) Diluted (in shares) Statement of Cash Flows [Abstract] Cash Flows used in Operating Activities Net loss for the period Adjustments to reconcile net loss to net cash used in operations: Amortization and depreciation Accretion of debt discount Stock-based compensation Non-cash financing related charges Change in fair value of derivative financial instruments Gain on extinguishment of debt Gain on settlement of accounts payable Unrealized foreign exchange Changes in non-cash working capital balances related to operations: Sales tax recoverable Prepaid expenses and deposits Accounts payable and accrued liabilities Deferred grant income Net cash used in operating activities Cash Flows provided by Financing Activities Issuance of common shares, net of share issue costs Repayment of promissory note Net cash provided by financing activities Decrease in cash during the period Cash, beginning of period Cash, end of period Statement [Table] Statement [Line Items] Increase (Decrease) in Stockholders' Equity [Roll Forward] Balance Beginning Balance Beginning (in shares) Equity units issued under Purchase Agreement Equity units issued under Purchase Agreement (in shares) Commitment shares issued under terms of Purchase Agreement Commitment shares issued under terms of Purchase Agreement (in shares) Capital stock issued pursuant to debt conversions - at $1.00 Capital stock issued pursuant to debt conversions - at $1.00 (in shares) Shares issued pursuant to the exercise of warrants - at $3.00 Shares issued pursuant to the exercise of warrants - at $3.00 (in shares) Shares issued pursuant to the exercise of warrants - cashless Shares issued pursuant to the exercise of warrants - cashless (in shares) Shares issued pursuant to employment agreement Shares issued pursuant to employment agreement (in shares) Shares issued for rounding in connection with 4:1 reverse stock split Shares issued for rounding in connection with 4:1 reverse stock split (in shares) Stock option compensation Balance Ending Balance Ending (in shares) Statement of Stockholders' Equity [Abstract] Debt conversions, share price (in dollars per share) Warrants exercised, share price (in dollars per share) Shares issued for rounding, reverse stock split Organization, Consolidation and Presentation of Financial Statements [Abstract] Business Description and Basis of Presentation Accounting Policies [Abstract] Recent Accounting Pronouncements Property, Plant and Equipment [Abstract] Equipment Debt Disclosure [Abstract] Promissory Notes Payable Deferred Revenue Disclosure [Abstract] Deferred Grant Income Senior Convertible Debentures Stockholders' Equity Note [Abstract] Capital Stock Business Combinations [Abstract] Lincoln Park Purchase Agreement Related Party Transactions [Abstract] Related Party Transactions Commitments and Contingencies Disclosure [Abstract] EX-101.PRE 11 avxl-20160331_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Mar. 31, 2016	May. 11, 2016
Document And Entity Information
Entity Registrant Name	ANAVEX LIFE SCIENCES CORP.
Entity Central Index Key	0001314052
Document Type	10-Q
Trading Symbol	AVXL
Document Period End Date	Mar. 31, 2016
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Entity a Well-known Seasoned Issuer	No
Entity a Voluntary Filer	No
Entity's Reporting Status Current	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		35,710,862
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2016

XML 13 R2.htm IDEA: XBRL DOCUMENT

INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)	Mar. 31, 2016	Sep. 30, 2015
Current
Cash	$ 11,950,847	$ 15,290,976
Sales Tax Recoverable	78,670	76,840
Prepaid expenses and deposits	84,977	100,845
Current Assets	12,114,494	15,468,661
Equipment	755	1,252
Total Assets	12,115,249	15,469,913
Current
Accounts payable and accrued liabilities	2,338,137	2,503,726
Deferred grant income	5,445	71,614
Promissory notes payable	88,145	85,238
Current Liabilities	2,431,727	2,660,578
Senior Convertible Debentures	337	332
Total Liabilities	2,432,064	2,660,910
STOCKHOLDERS' EQUITY
Capital stock Authorized: 100,000,000 common shares, par value $0.001 per share Issued and outstanding: 35,695,572 common shares (September 30, 2015 - 32,044,213)	35,697	32,044
Additional paid-in capital	$ 78,914,253	74,060,999
Common stock to be issued		1,997,415
Accumulated deficit	$ (69,266,765)	(63,281,455)
Stockholders' Equity	9,683,185	12,809,003
Total Liabilities and Stockholder's Equity	$ 12,115,249	$ 15,469,913

XML 14 R3.htm IDEA: XBRL DOCUMENT

INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2016	Sep. 30, 2015
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized	100,000,000	100,000,000
Common stock, issued	35,695,572	32,044,213
Common stock, outstanding	35,695,572	32,044,213

XML 15 R4.htm IDEA: XBRL DOCUMENT

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Operating expenses
General and administrative	$ 852,775	$ 451,193	$ 4,714,473	$ 903,246
Research and development	1,327,393	407,146	1,998,129	725,771
Total operating expenses	(2,180,168)	$ (858,339)	(6,712,602)	$ (1,629,017)
Other income (expenses)
Grant income	26,879		637,027
Interest income (expense), net	2,064	$ 2,228	4,206	$ (74,781)
Gain on settlement of accounts payable	151,402		151,402
Financing related charges and adjustments	(72)	$ (912,357)	(1,167)	$ (874,706)
Foreign exchange (loss) gain	(30,906)	43,609	(46,561)	66,927
Total other income (expenses), net	149,367	(866,520)	744,907	(882,560)
Net loss before provision for income taxes	$ (2,030,801)	$ (1,724,859)	(5,967,695)	$ (2,511,577)
Income tax expense			17,615
Net loss and comprehensive loss for the period	$ (2,030,801)	$ (1,724,859)	$ (5,985,310)	$ (2,511,577)
Loss per share
Basic (in dollars per share)	$ (0.06)	$ (0.12)	$ (0.17)	$ (0.18)
Diluted (in dollars per share)	$ (0.06)	$ (0.12)	$ (0.17)	$ (0.18)
Weighted average number of shares outstanding
Basic (in shares)	35,214,793	14,326,945	34,589,957	13,609,473
Diluted (in shares)	35,214,793	14,326,945	34,589,957	13,609,473

XML 16 R5.htm IDEA: XBRL DOCUMENT

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	6 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash Flows used in Operating Activities
Net loss for the period	$ (5,985,310)	$ (2,511,577)
Adjustments to reconcile net loss to net cash used in operations:
Amortization and depreciation	497	498
Accretion of debt discount	1,167	493,451
Stock-based compensation	$ 1,048,710	31,544
Non-cash financing related charges		29,000
Change in fair value of derivative financial instruments		487,000
Gain on extinguishment of debt		$ (105,745)
Gain on settlement of accounts payable	$ (151,402)
Unrealized foreign exchange	2,907	$ (13,509)
Changes in non-cash working capital balances related to operations:
Sales tax recoverable	(1,830)
Prepaid expenses and deposits	15,868
Accounts payable and accrued liabilities	(14,187)	$ 225,987
Deferred grant income	(66,169)
Net cash used in operating activities	(5,149,749)	$ (1,363,351)
Cash Flows provided by Financing Activities
Issuance of common shares, net of share issue costs	$ 1,809,620	500,000
Repayment of promissory note		(88,144)
Net cash provided by financing activities	$ 1,809,620	411,856
Decrease in cash during the period	(3,340,129)	(951,495)
Cash, beginning of period	15,290,976	7,262,138
Cash, end of period	$ 11,950,847	$ 6,310,643

XML 17 R6.htm IDEA: XBRL DOCUMENT

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) - 6 months ended Mar. 31, 2016 - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Common Shares to be Issued [Member]	Accumulated Deficit [Member]	Total
Balance Beginning at Sep. 30, 2015	$ 32,044	$ 74,060,999	$ 1,997,415	$ (63,281,455)	$ 12,809,003
Balance Beginning (in shares) at Sep. 30, 2015	32,044,213				32,044,213
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Equity units issued under Purchase Agreement	$ 291	1,684,270			$ 1,684,561
Equity units issued under Purchase Agreement (in shares)	290,523
Commitment shares issued under terms of Purchase Agreement	$ 185	(185)
Commitment shares issued under terms of Purchase Agreement (in shares)	185,179
Capital stock issued pursuant to debt conversions - at $1.00	$ 169	168,407	$ (167,415)		$ 1,161
Capital stock issued pursuant to debt conversions - at $1.00 (in shares)	168,577
Shares issued pursuant to the exercise of warrants - at $3.00	$ 42	125,018			$ 125,060
Shares issued pursuant to the exercise of warrants - at $3.00 (in shares)	41,687
Shares issued pursuant to the exercise of warrants - cashless	$ 1,964	(1,964)
Shares issued pursuant to the exercise of warrants - cashless (in shares)	1,963,956
Shares issued pursuant to employment agreement	$ 1,000	2,439,000	$ (1,830,000)		$ 610,000
Shares issued pursuant to employment agreement (in shares)	1,000,000
Shares issued for rounding in connection with 4:1 reverse stock split	$ 2	(2)
Shares issued for rounding in connection with 4:1 reverse stock split (in shares)	1,437
Stock option compensation		$ 438,710			$ 438,710
Net loss for the period				$ (5,985,310)	(5,985,310)
Balance Ending at Mar. 31, 2016	$ 35,697	$ 78,914,253		$ (69,266,765)	$ 9,683,185
Balance Ending (in shares) at Mar. 31, 2016	35,695,572				35,695,572

XML 18 R7.htm IDEA: XBRL DOCUMENT

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) (Parenthetical)	6 Months Ended
	Mar. 31, 2016 $ / shares shares
Statement of Stockholders' Equity [Abstract]
Debt conversions, share price (in dollars per share)	$ 1.00
Warrants exercised, share price (in dollars per share)	$ 3.00
Shares issued for rounding, reverse stock split \| shares	4

XML 19 R8.htm IDEA: XBRL DOCUMENT

Business Description and Basis of Presentation

6 Months Ended

Mar. 31, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Business Description and Basis of Presentation

Note 1

Business Description and Basis of Presentation

Business

Basis of Presentation

Operating results for the six months ended March 31, 2016 are not necessarily indicative of the results that may be expected for the year ending September 30, 2016.

Basic and Diluted Loss per Share

XML 20 R9.htm IDEA: XBRL DOCUMENT

Recent Accounting Pronouncements

6 Months Ended

Mar. 31, 2016

Accounting Policies [Abstract]

Recent Accounting Pronouncements

Note 2

Recent Accounting Pronouncements

Recent Accounting Pronouncements Not Yet Adopted

- Definition

The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6507316

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Direct Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=66092750

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22583-107794

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Indirect Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6515603

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22580-107794

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.10-01.(b)(6))
-URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Accounting Change
-URI http://asc.fasb.org/extlink&oid=6503790

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22499-107794

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Retrospective Application
-URI http://asc.fasb.org/extlink&oid=6523989

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=68064558&loc=d3e765-108305

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68064558&loc=d3e725-108305

+ Details

XML 21 R10.htm IDEA: XBRL DOCUMENT

Equipment

6 Months Ended

Mar. 31, 2016

Property, Plant and Equipment [Abstract]

Equipment

Note 3

Equipment

	March 31, 2016
			Accumulated
	Cost		Depreciation		Net

Computer equipment	$	3,015	$	2,260	$	755

	September 30, 2015
			Accumulated
	Cost		Depreciation		Net

Computer equipment	$	3,015	$	1,763	$	1,252

XML 22 R11.htm IDEA: XBRL DOCUMENT

Promissory Notes Payable

6 Months Ended

Mar. 31, 2016

Debt Disclosure [Abstract]

Promissory Notes Payable

Note 4

Promissory Notes Payable

	March 31,		September 30,
	2016		2015

Promissory note dated January 9, 2013 with a principal balance of CDN$86,677, bearing interest at 12% per annum, secured by all the present and future assets of the Company; due on demand	$	66,834	$	64,630

Promissory note dated January 9, 2013 with a principal balance of CDN$27,639, bearing interest at 12% per annum, secured by all the present and future assets of the Company; due on demand		21,311		20,608
	$	88,145	$	85,238

On January 9, 2013, the Company issued two (2) promissory notes (the “Secured Notes”);

XML 23 R12.htm IDEA: XBRL DOCUMENT

Deferred Grant Income

6 Months Ended

Mar. 31, 2016

Deferred Revenue Disclosure [Abstract]

Deferred Grant Income

Note 5

Deferred Grant Income

During the six months ended March 31, 2016, the Company recognized other grant income of $571,093 in respect of a research and development incentive program offered by the Australian government.

- Definition

The entire disclosure for deferred revenues at the end of the reporting period, and description and amounts of significant changes that occurred during the reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References + Details

XML 24 R13.htm IDEA: XBRL DOCUMENT

Senior Convertible Debentures

6 Months Ended

Mar. 31, 2016

Debt Disclosure [Abstract]

Senior Convertible Debentures

Note 6

Senior Convertible Debentures

	March 31,			September 30,
Senior Convertible Debentures	2016			2015

Senior Convertible Debentures, non-interest bearing, unsecured, due March 18, 2044	$	4,982		$	6,144
Less: Debt Discount		(4,645	)		(5,812	)
Total carrying value		337			332
Less: current portion		-			-
Long term liability	$	337		$	332

XML 25 R14.htm IDEA: XBRL DOCUMENT

Capital Stock

6 Months Ended

Mar. 31, 2016

Stockholders' Equity Note [Abstract]

Capital Stock

Note 7

Capital Stock

Authorized

100,000,000 shares of common stock.

Equity Transactions

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

XML 26 R15.htm IDEA: XBRL DOCUMENT

Lincoln Park Purchase Agreement

6 Months Ended

Mar. 31, 2016

Business Combinations [Abstract]

Lincoln Park Purchase Agreement

Note 8

Lincoln Park Purchase Agreement

2013 Purchase Agreement

2015 Purchase Agreement

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1524-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4922-128472

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4934-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4926-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=73530397&loc=SL65897772-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

XML 27 R16.htm IDEA: XBRL DOCUMENT

Related Party Transactions

6 Months Ended

Mar. 31, 2016

Related Party Transactions

Note 9

Related Party Transactions

The fair value of $2.44 per share for non-cash restricted stock compensation charges was determined with reference to the quoted market price of the Company’s shares on the commitment date.

XML 28 R17.htm IDEA: XBRL DOCUMENT

Commitments

6 Months Ended

Mar. 31, 2016

Commitments and Contingencies Disclosure [Abstract]

Commitments

Note 10

Commitments

Share Purchase Warrants

A summary of the Company’s share purchase warrants outstanding is presented below:

				Weighted
				Average
	Number of Shares			Exercise Price
Balance, October 1, 2014		18,728,910		$	1.59
Expired		(62,500	)	$	1.40
Exercised		(15,468,520	)	$	1.43
Issued		1,075,000		$	0.76
Balance, September 30, 2015		4,272,890		$	2.11
Exercised		(2,444,831	)	$	1.68
Balance, March 31, 2016		1,828,059		$	2.68

During the six months ended March 31, 2016, the Company issued 1,963,956 shares of common stock pursuant to the exercise of 2,403,144 share purchase warrants on a cashless basis.

At March 31, 2016, the Company has 1,828,059 currently exercisable share purchase warrants outstanding as follows:

Number		Exercise Price		Expiry Date
	1,462,180	$	3.00	July 5, 2018
	30,000	$	4.00	February 24, 2019
	277,127	$	1.20	March 13, 2019
	1,252	$	1.68	March 13, 2019
	12,500	$	1.24	May 31, 2019
	45,000	$	1.00	July 31, 2019
	1,828,059

Stock–based Compensation Plan

2015 Stock Option Plan

A summary of the status of Company’s outstanding stock purchase options for the six months ended March 31, 2016 and for the year ended September 30, 2015 is presented below:

				Weighted		Weighted Average
	Number of			Average		Grant Date fair
	Shares			Exercise Price		value
Outstanding at October 1, 2014		792,500		$	2.82
Forfeited		(67,500	)	$	12.00
Granted		1,097,500		$	2.02	$	1.66
Outstanding at September 30, 2015		1,822,500		$	2.00
Forfeited		-		$	-
Granted		60,750		$	7.02	$	5.75
Expired		(25,000	)	$	14.68
Outstanding at March 31, 2016		1,858,250		$	1.99
Exercisable at March 31, 2016		890,399		$	1.73
Exercisable at September 30, 2015		825,002		$	1.78

Stock–based Compensation Plan – (cont’d)

At March 31, 2016, the following stock options were outstanding:

Number of Shares								Aggregate		Remaining
			Number		Exercise			Intrinsic		Contractual
Total			Vested		Price		Expiry Date	Value		Life (yrs)
	500,000	⁽¹⁾		500,000	$	1.60	July 5, 2023		1,650,000		7.26
	75,000	⁽²⁾		25,000	$	1.20	May 7, 2024		277,500		8.10
	125,000	⁽³⁾		31,250	$	1.32	May 8, 2024		447,500		8.10
	718,750	⁽⁴⁾		239,585	$	0.92	April 2, 2025		2,860,625		9.00
	50,000	⁽⁵⁾		12,500	$	1.44	June 8, 2025		173,000		9.19
	50,000	⁽⁶⁾		-	$	1.68	June 15, 2025		161,000		9.21
	278,750	⁽⁷⁾		69,688	$	5.04	September 18, 2025		-		9.47
	1,500	⁽⁸⁾		1,500	$	5.64	September 30, 2025		-		9.50
	31,250	⁽⁹⁾		5,209	$	5.68	October 2, 2025		-		9.51
	25,000	⁽¹⁰⁾		4,167	$	8.98	October 16, 2025		-		9.54
	1,500	⁽¹¹⁾		1,500	$	5.57	December 31, 2025		-		9.75
	1,500	⁽¹²⁾		-	$	4.90	March 31, 2026		-		10.00
	1,858,250			890,399				$	5,569,625

⁽¹⁾

⁽²⁾

Stock–based Compensation Plan – (cont’d)

⁽³⁾

⁽⁴⁾

⁽⁵⁾

⁽⁶⁾

⁽⁷⁾

⁽⁸⁾

⁽⁹⁾

Stock–based Compensation Plan – (cont’d)

⁽¹⁰⁾

⁽¹¹⁾

⁽¹²⁾

The fair value of each option award is estimated on the date of grant using the Black Scholes option pricing model based on the following weighted average assumptions:

	March 31,
	2016			2015
Risk-free interest rate		1.68	%		-
Expected life of options (years)		6.76			-
Annualized volatility		101.92	%		-
Dividend rate		0.00	%		-

XML 29 R18.htm IDEA: XBRL DOCUMENT

Supplemental Cash Flow Information

6 Months Ended

Mar. 31, 2016

Supplemental Cash Flow Elements [Abstract]

Supplemental Cash Flow Information

Note 11

Supplemental Cash Flow Information

Investing and financing activities that do not have a direct impact on current cash flows are excluded from the statement of cash flows.

During the six months ended March 31, 2016;

During the six months ended March 31, 2015;

the Company issued 3,918,478 shares of common stock of the Company pursuant to the conversion of convertible debentures at a conversion price of $1.00 per share

ii)

the Company reclassified an amount of $3,931,000 into equity upon modification of the terms of certain derivative instruments.

These transactions have been excluded from the statement of cash flows.

XML 30 R19.htm IDEA: XBRL DOCUMENT

Recent Accounting Pronouncements (Policies)

6 Months Ended

Mar. 31, 2016

Accounting Policies [Abstract]

Recent Accounting Pronouncements Not Yet Adopted

Recent Accounting Pronouncements Not Yet Adopted

XML 31 R20.htm IDEA: XBRL DOCUMENT

Equipment (Tables)

6 Months Ended

Mar. 31, 2016

Property, Plant and Equipment [Abstract]

Schedule of equipment

	March 31, 2016
			Accumulated
	Cost		Depreciation		Net

Computer equipment	$	3,015	$	2,260	$	755

	September 30, 2015
			Accumulated
	Cost		Depreciation		Net

Computer equipment	$	3,015	$	1,763	$	1,252

XML 32 R21.htm IDEA: XBRL DOCUMENT

Promissory Notes Payable (Tables)

6 Months Ended

Mar. 31, 2016

Debt Disclosure [Abstract]

Schedule of promissory notes payable

	March 31,		September 30,
	2016		2015

Promissory note dated January 9, 2013 with a principal balance of CDN$86,677, bearing interest at 12% per annum, secured by all the present and future assets of the Company; due on demand	$	66,834	$	64,630

Promissory note dated January 9, 2013 with a principal balance of CDN$27,639, bearing interest at 12% per annum, secured by all the present and future assets of the Company; due on demand		21,311		20,608
	$	88,145	$	85,238

XML 33 R22.htm IDEA: XBRL DOCUMENT

Senior Convertible Debentures (Tables)

6 Months Ended

Mar. 31, 2016

Debt Disclosure [Abstract]

Schedule of senior convertible debentures

	March 31,			September 30,
Senior Convertible Debentures	2016			2015

Senior Convertible Debentures, non-interest bearing, unsecured, due March 18, 2044	$	4,982		$	6,144
Less: Debt Discount		(4,645	)		(5,812	)
Total carrying value		337			332
Less: current portion		-			-
Long term liability	$	337		$	332

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

+ Details

XML 34 R23.htm IDEA: XBRL DOCUMENT

Commitments (Tables)

6 Months Ended

Mar. 31, 2016

Commitments and Contingencies Disclosure [Abstract]

Schedule of purchase warrants outstanding

A summary of the Company’s share purchase warrants outstanding is presented below:

				Weighted
				Average
	Number of Shares			Exercise Price
Balance, October 1, 2014		18,728,910		$	1.59
Expired		(62,500	)	$	1.40
Exercised		(15,468,520	)	$	1.43
Issued		1,075,000		$	0.76
Balance, September 30, 2015		4,272,890		$	2.11
Exercised		(2,444,831	)	$	1.68
Balance, March 31, 2016		1,828,059		$	2.68

Schedule of exercisable share purchase warrants outstanding

At March 31, 2016, the Company has 1,828,059 currently exercisable share purchase warrants outstanding as follows:

Number		Exercise Price		Expiry Date
	1,462,180	$	3.00	July 5, 2018
	30,000	$	4.00	February 24, 2019
	277,127	$	1.20	March 13, 2019
	1,252	$	1.68	March 13, 2019
	12,500	$	1.24	May 31, 2019
	45,000	$	1.00	July 31, 2019
	1,828,059

Schedule of outstanding stock purchase options

A summary of the status of Company’s outstanding stock purchase options for the six months ended March 31, 2016 and for the year ended September 30, 2015 is presented below:

				Weighted		Weighted Average
	Number of			Average		Grant Date fair
	Shares			Exercise Price		value
Outstanding at October 1, 2014		792,500		$	2.82
Forfeited		(67,500	)	$	12.00
Granted		1,097,500		$	2.02	$	1.66
Outstanding at September 30, 2015		1,822,500		$	2.00
Forfeited		-		$	-
Granted		60,750		$	7.02	$	5.75
Expired		(25,000	)	$	14.68
Outstanding at March 31, 2016		1,858,250		$	1.99
Exercisable at March 31, 2016		890,399		$	1.73
Exercisable at September 30, 2015		825,002		$	1.78

Schedule stock options outstanding

At March 31, 2016, the following stock options were outstanding:

Number of Shares								Aggregate		Remaining
			Number		Exercise			Intrinsic		Contractual
Total			Vested		Price		Expiry Date	Value		Life (yrs)
	500,000	⁽¹⁾		500,000	$	1.60	July 5, 2023		1,650,000		7.26
	75,000	⁽²⁾		25,000	$	1.20	May 7, 2024		277,500		8.10
	125,000	⁽³⁾		31,250	$	1.32	May 8, 2024		447,500		8.10
	718,750	⁽⁴⁾		239,585	$	0.92	April 2, 2025		2,860,625		9.00
	50,000	⁽⁵⁾		12,500	$	1.44	June 8, 2025		173,000		9.19
	50,000	⁽⁶⁾		-	$	1.68	June 15, 2025		161,000		9.21
	278,750	⁽⁷⁾		69,688	$	5.04	September 18, 2025		-		9.47
	1,500	⁽⁸⁾		1,500	$	5.64	September 30, 2025		-		9.50
	31,250	⁽⁹⁾		5,209	$	5.68	October 2, 2025		-		9.51
	25,000	⁽¹⁰⁾		4,167	$	8.98	October 16, 2025		-		9.54
	1,500	⁽¹¹⁾		1,500	$	5.57	December 31, 2025		-		9.75
	1,500	⁽¹²⁾		-	$	4.90	March 31, 2026		-		10.00
	1,858,250			890,399				$	5,569,625

⁽¹⁾

⁽²⁾

⁽³⁾

⁽⁴⁾

⁽⁵⁾

⁽⁶⁾

⁽⁷⁾

⁽⁸⁾

⁽⁹⁾

⁽¹⁰⁾

⁽¹¹⁾

⁽¹²⁾

Schedule of weighted average assumptions for fair value of each option award

The fair value of each option award is estimated on the date of grant using the Black Scholes option pricing model based on the following weighted average assumptions:

	March 31,
	2016			2015
Risk-free interest rate		1.68	%		-
Expected life of options (years)		6.76			-
Annualized volatility		101.92	%		-
Dividend rate		0.00	%		-

XML 35 R24.htm IDEA: XBRL DOCUMENT

Business Description and Basis of Presentation (Details Narrative) - $ / shares		6 Months Ended	12 Months Ended
	Oct. 07, 2015	Mar. 31, 2016	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Reverse stock split	1:4
Common stock, shares authorized	400,000,000	100,000,000	100,000,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001
Potentially dilutive common shares related to outstanding options, warrants, and convertible debentures and shares to be issued		3,691,291	6,101,534

XML 36 R25.htm IDEA: XBRL DOCUMENT

Equipment (Details) - USD ($)	Mar. 31, 2016	Sep. 30, 2015
Property, Plant and Equipment [Line Items]
Net	$ 755	$ 1,252
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Cost	3,015	3,015
Accumulated Depreciation	2,260	1,763
Net	$ 755	$ 1,252

XML 37 R26.htm IDEA: XBRL DOCUMENT

Promissory Notes Payable (Details)	6 Months Ended
Promissory Notes Payable (Details)	Mar. 31, 2016 USD ($)	Mar. 31, 2016 CAD	Sep. 30, 2015 USD ($)	Jan. 09, 2013 CAD
Short-term Debt [Line Items]
Total promissory notes payable	$ 88,145		$ 85,238
12% Promissory Note [Member]
Short-term Debt [Line Items]
Total promissory notes payable	$ 66,834		64,630
Debt instrument, issuance date	Jan. 09, 2013
Description of collateral	Secured by all the present and future assets of the Company; due on demand.
12% Promissory Note [Member] \| Canada, Dollars [Member]
Short-term Debt [Line Items]
Principal balance \| CAD		CAD 86,677		CAD 86,677
12% Promissory Note [Member]
Short-term Debt [Line Items]
Total promissory notes payable	$ 21,311		$ 20,608
Debt instrument, issuance date	Jan. 09, 2013
Description of collateral	Secured by all the present and future assets of the Company; due on demand.
12% Promissory Note [Member] \| Canada, Dollars [Member]
Short-term Debt [Line Items]
Principal balance \| CAD		CAD 27,639		CAD 27,639

XML 38 R27.htm IDEA: XBRL DOCUMENT

Promissory Notes Payable (Details Narrative) - 12% Promissory Note [Member]	Jan. 09, 2013 USD ($)	Mar. 31, 2016 CAD	Jan. 09, 2013 CAD
Short-term Debt [Line Items]
Maturity date	Jun. 30, 2013
Late fees, per day per note	$ 100
Additional late fees, per day per note	$ 500
Canada, Dollars [Member]
Short-term Debt [Line Items]
Principal balance \| CAD		CAD 86,677	CAD 86,677
Maturity date	Jun. 30, 2013
Late fees, per day per note	$ 100
Additional late fees, per day per note	$ 500
Canada, Dollars [Member]
Short-term Debt [Line Items]
Principal balance \| CAD		CAD 27,639	CAD 27,639

XML 39 R28.htm IDEA: XBRL DOCUMENT

Deferred Grant Income (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
Deferred Grant Income (Details Narrative) - USD ($)	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015	Sep. 30, 2015
Deferred Revenue Disclosure [Abstract]
Awarded grant funding amount					$ 286,455
Deferred grant income	$ 5,445		$ 5,445		$ 71,614
Other grant income			571,093
Grant income	$ 26,879		$ 637,027

XML 40 R29.htm IDEA: XBRL DOCUMENT

Senior Convertible Debentures (Details) - Securities Purchase Agreement [Member] - Senior Convertible Debentures Due March 18, 2044 [Member] - Purchasers [Member] - USD ($)	Mar. 31, 2016	Sep. 30, 2015	Mar. 13, 2014
Senior Convertible Debentures, non-interest bearing, unsecured, due March 18, 2044	$ 4,982	$ 6,144	$ 10,000,000
Less: Debt Discount	(4,645)	(5,812)
Total carrying value	$ 337	$ 332
Less: current portion
Long term liability	$ 337	$ 332

XML 41 R30.htm IDEA: XBRL DOCUMENT

Senior Convertible Debentures (Details Narrative)	3 Months Ended		6 Months Ended
Senior Convertible Debentures (Details Narrative)	Mar. 31, 2016 USD ($) $ / shares	Mar. 31, 2015 USD ($) $ / shares	Mar. 31, 2016 USD ($) N $ / shares	Mar. 31, 2015 USD ($) N $ / shares	Sep. 30, 2015 USD ($)	Mar. 13, 2014 USD ($) $ / shares
Conversion price (in dollars per share) \| $ / shares	$ 1.00	$ 1.00	$ 1.00	$ 1.00
Number of equity instrument issued upon conversion \| N			1,161	3,918,478
Debt beneficial conversion feature			$ 1,161
Securities Purchase Agreement [Member] \| Senior Convertible Debentures Due March 18, 2044 [Member] \| Purchasers [Member]
Aggregate principal amount	$ 4,982		$ 4,982		$ 6,144	$ 10,000,000
Conversion price (in dollars per share) \| $ / shares						$ 1.20
Amended conversion price (in dollars per share) \| $ / shares	$ 1.00		$ 1.00			$ 1.00
Amortization debt discount issuance	$ 72	$ 486,334	$ 1,167	$ 493,451
Number of equity instrument issued upon conversion \| N			1,161
Debt beneficial conversion feature			$ 1,161

XML 42 R31.htm IDEA: XBRL DOCUMENT

Capital Stock (Details Narrative) - shares	6 Months Ended	12 Months Ended
Capital Stock (Details Narrative) - shares	Mar. 31, 2016	Sep. 30, 2015	Oct. 07, 2015
Common stock, authorized	100,000,000	100,000,000	400,000,000
Number of shares for incorrect conversion price	167,415	167,415
2013 Employment Agreement [Member] \| Directors and Officers [Member] \| Common Shares to be Issued [Member]
Number of shares for common stock to be issued	1,000,000

XML 43 R32.htm IDEA: XBRL DOCUMENT

Lincoln Park Purchase Agreement (Details Narrative) - Lincoln Park Capital Fund, LLC [Member] - USD ($)			6 Months Ended
	Oct. 21, 2015	Jul. 05, 2013	Mar. 31, 2016
2013 Purchase Agreement [Member]
Total number of shares obligated to purchase		$ 10,000,000
Agreement term		25 months
Number of shares issued			296,104
Number of shares issued for aggregate purchase price			290,523
Value of shares issued for aggregate purchase price			$ 1,684,561
Number of shares issued for commitment			5,581
2015 Purchase Agreement [Member]
Total number of shares obligated to purchase	$ 50,000,000
Agreement term	36 months
Description of purchases price	The Company may direct Lincoln Park, at its sole discretion, and subject to certain conditions, to purchase up to 50,000 shares of common stock on any business day, provided that at least one business day has passed since the most recent purchase. The amount of a purchase may be increased under certain circumstances provided, however that Lincoln Park’s committed obligation under any single purchase shall not exceed $2,000,000. The purchase price of shares of common stock related to the future funding will be based on the then prevailing market prices of such shares at the time of sales as described in the 2015 Purchase Agreement.
Number of shares issued			179,598
Pro rata basic number of shares obligated to purchase			89,799

XML 44 R33.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015	Sep. 30, 2015
Restricted Common Stock [Member]
Related Party Transaction [Line Items]
Fair value of non-cash stock compensation charges (in dollars per share)			$ 2.44
Directors and Officers [Member]
Related Party Transaction [Line Items]
Accounts payable and accrued liabilities	$ 30,500		$ 30,500		$ 33,000
Directors and Officers [Member] \| 2013 Employment Agreement [Member]
Related Party Transaction [Line Items]
General and administrative expenses	125,078	$ 16,082	3,169,933	$ 32,465
Non-cash stock option compensation charges	121,578	13,582	258,092	27,465
Non-cash restricted stock compensation charges	0	0	610,000	0
Tax payment	$ 0	$ 0	$ 2,290,341	$ 0

XML 45 R34.htm IDEA: XBRL DOCUMENT

Commitments (Details) - Purchase Warrants [Member] - $ / shares	6 Months Ended	12 Months Ended
	Mar. 31, 2016	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Balance, at beginning	4,272,890	18,728,910
Expired		(62,500)
Exercised	(2,444,831)	(15,468,520)
Issued		1,075,000
Balance, at end	1,828,059	4,272,890
Share based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Exercise Price [Rollforward]
Balance, at beginning	$ 2.11	$ 1.59
Expired		1.40
Exercised	1.68	1.43
Issued		0.76
Balance, at end	$ 2.68	$ 2.11

XML 46 R35.htm IDEA: XBRL DOCUMENT

Commitments (Details 1)	6 Months Ended
Commitments (Details 1)	Mar. 31, 2016 $ / shares shares
First Purchase Warrants [Member]
Number	1,462,180
Exercise Price \| $ / shares	$ 3.00
Expiry Date	Jul. 05, 2018
Second Purchase Warrants [Member]
Number	30,000
Exercise Price \| $ / shares	$ 4.00
Expiry Date	Feb. 24, 2019
Third Purchase Warrants [Member]
Number	277,127
Exercise Price \| $ / shares	$ 1.20
Expiry Date	Mar. 13, 2019
Four Purchase Warrants [Member]
Number	1,252
Exercise Price \| $ / shares	$ 1.68
Expiry Date	Mar. 13, 2019
Five Purchase Warrants [Member]
Number	12,500
Exercise Price \| $ / shares	$ 1.24
Expiry Date	May 31, 2019
Six Purchase Warrants [Member]
Number	45,000
Exercise Price \| $ / shares	$ 1.00
Expiry Date	Jul. 31, 2019
Purchase Warrants [Member]
Number	1,828,059

XML 47 R36.htm IDEA: XBRL DOCUMENT

Commitments (Details 2) - 2015 Omnibus Incentive Plan [Member] - $ / shares	6 Months Ended	12 Months Ended
	Mar. 31, 2016	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding at beginning	1,822,500	792,500
Forfeited		(67,500)
Granted	60,750	1,097,500
Expired	(25,000)
Outstanding at ending	1,858,250	1,822,500
Exercisable at ending	890,399	825,002
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Outstanding at beginning	$ 2.00	$ 2.82
Forfeited		12.00
Granted	$ 7.02	2.02
Expired	14.68
Outstanding at ending	1.99	2.00
Exercisable at ending	1.73	1.78
Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Grant Date fair value [Abstract]
Granted	$ 5.75	$ 1.66

XML 48 R37.htm IDEA: XBRL DOCUMENT

Commitments (Details 3) - USD ($)

6 Months Ended

Mar. 31, 2016

Sep. 30, 2015

Sep. 30, 2014

2015 Omnibus Incentive Plan [Member]

Total Number of Shares

1,858,250

1,822,500

792,500

Number of Vested Shares

890,399

Exercise Price

$ 1.99

$ 2.00

$ 2.82

Aggregate Intrinsic Value

$ 5,569,625

First Stock Option [Member]

Total Number of Shares

^[1]

500,000

Number of Vested Shares

500,000

Exercise Price

$ 1.6

Expiry Date

Jul. 05, 2023

Aggregate Intrinsic Value

$ 1,650,000

Remaining Contractual Life (in years)

7 years 3 months 4 days

Second Stock Option [Member]

Total Number of Shares

^[2]

75,000

Number of Vested Shares

25,000

Exercise Price

$ 1.2

Expiry Date

May 07, 2024

Aggregate Intrinsic Value

$ 277,500

Remaining Contractual Life (in years)

8 years 1 month 6 days

Third Stock Option [Member]

Total Number of Shares

^[3]

125,000

Number of Vested Shares

31,250

Exercise Price

$ 1.32

Expiry Date

May 08, 2024

Aggregate Intrinsic Value

$ 447,500

Remaining Contractual Life (in years)

8 years 1 month 6 days

Four Stock Option [Member]

Total Number of Shares

^[4]

718,750

Number of Vested Shares

239,585

Exercise Price

$ 0.92

Expiry Date

Apr. 02, 2025

Aggregate Intrinsic Value

$ 2,860,625

Remaining Contractual Life (in years)

9 years

Five Stock Option [Member]

Total Number of Shares

^[5]

50,000

Number of Vested Shares

12,500

Exercise Price

$ 1.44

Expiry Date

Jun. 08, 2025

Aggregate Intrinsic Value

$ 173,000

Remaining Contractual Life (in years)

9 years 2 months 8 days

Six Stock Option [Member]

Total Number of Shares

^[6]

50,000

Number of Vested Shares

Exercise Price

$ 1.68

Expiry Date

Jun. 15, 2025

Aggregate Intrinsic Value

$ 161,000

Remaining Contractual Life (in years)

9 years 2 months 16 days

Seven Stock Option [Member]

Total Number of Shares

^[7]

278,750

Number of Vested Shares

69,688

Exercise Price

$ 5.04

Expiry Date

Sep. 18, 2025

Aggregate Intrinsic Value

Remaining Contractual Life (in years)

9 years 5 months 19 days

Eight Stock Option [Member]

Total Number of Shares

^[8]

1,500

Number of Vested Shares

1,500

Exercise Price

$ 5.64

Expiry Date

Sep. 30, 2025

Aggregate Intrinsic Value

Remaining Contractual Life (in years)

9 years 6 months

Nine Stock Option [Member]

Total Number of Shares

^[9]

31,250

Number of Vested Shares

5,209

Exercise Price

$ 5.68

Expiry Date

Oct. 02, 2025

Aggregate Intrinsic Value

Remaining Contractual Life (in years)

9 years 6 months 4 days

Ten Stock Option [Member]

Total Number of Shares

^[10]

25,000

Number of Vested Shares

4,167

Exercise Price

$ 8.98

Expiry Date

Oct. 16, 2025

Aggregate Intrinsic Value

Remaining Contractual Life (in years)

9 years 6 months 14 days

Eleven Stock Option [Member]

Total Number of Shares

^[11]

1,500

Number of Vested Shares

1,500

Exercise Price

$ 5.57

Expiry Date

Dec. 31, 2025

Aggregate Intrinsic Value

Remaining Contractual Life (in years)

9 years 9 months

Twelve Stock Option [Member]

Total Number of Shares

^[12]

1,500

Number of Vested Shares

Exercise Price

$ 4.9

Expiry Date

Mar. 31, 2026

Aggregate Intrinsic Value

Remaining Contractual Life (in years)

10 years

[1]	As of March 31, 2016 and September 30, 2015 these options had fully vested. These options were granted during the year ended September 30, 2013 and vested immediately upon granting. The Company did not recognize any stock-based compensation during the six months ended March 31, 2016 (March 31, 2015: $0) in connection with these options.
[2]	As of March 31, 2016 and September 30, 2015, 25,000 of these options had vested. These options were issued during the year ended September 30, 2014 and vest annually over a three-year period commencing on the first anniversary of the date of the grant. The Company recognized stock based compensation expense of $5,764 and $11,590 during the three and six months ended March 31, 2016, respectively (March 31, 2015: $5,830 and $11,660, respectively) in connection with these options. These amounts have been included in general and administrative expenses on the Company's statement of operations.
[3]	As of March 31, 2016 and September 30, 2015, 31,250 of these options had vested. These options were issued during the year ended September 30, 2014 and vest annually over a four-year period commencing on the first anniversary of the date of the grant. The Company recognized stock based compensation expense of $7,960 and $16,008 during the three and six months ended March 31, 2016, respectively (March 31, 2015: $8,053 and $16,106, respectively) in connection with these options. These amounts have been included in general and administrative expenses on the Company's statement of operations.
[4]	As of March 31, 2016, 239,585 of these options had vested (September 30, 2015: 239,585 of these options had vested). These options were issued during the year ended September 30, 2015 and vest in three equal installments on April 2, 2015, April 2, 2016 and April 2, 2017. The Company recognized stock based compensation expense of $42,811 and $86,093 during the three and six months ended March 31, 2016, respectively (March 31, 2015: $0 and $0, respectively) in connection with these options. These amounts have been included in general and administrative expenses on the Company's statement of operations.
[5]	As of March 31, 2016, 12,500 of these options had vested. These options were issued during the year ended September 30, 2015 and vest quarterly over a three-year period commencing on September 8, 2015. The Company recognized stock based compensation expense of $4,775 and $9,603 during the three and six months ended March 31, 2016, respectively (March 31, 2015: $0 and $0, respectively) in connection with these options. These amounts have been included in general and administrative expenses on the Company's statement of operations.
[6]	As of March 31, 2016 and September 30, 2015, none of these options had vested. These options were issued during the year ended September 30, 2015 and vest over a three-year period from the date of grant. The Company recognized stock based compensation expense of $5,573 and $11,207 during the three and six months ended March 31, 2016, respectively (March 31, 2015: $0 and $0, respectively) in connection with these options. These amounts have been included in general and administrative expenses on the Company's statement of operations.
[7]	As of March 31, 2016 and September 30, 2015, 69,688 of these options had vested. These options were issued during the year ended September 30, 2015 and vest over a three-year period from the date of grant. The Company recognized stock based compensation expense of $92,875 and $192,024 during the three and six months ended March 31, 2016, respectively (March 31, 2015: $0 and $0, respectively) in connection with these options. These amounts have been included in general and administrative expenses on the Company's statement of operations.
[8]	As of March 31, 2016, all of these options had vested. These options vested on December 31, 2015. The Company recognized stock based compensation expense of $0 and $6,800 during the three and six months ended March 31, 2016, respectively (March 31, 2015: $0 and $0) in connection with these options. These amounts have been included in general and administrative expenses on the Company's statement of operations.
[9]	As of March 31, 2016, 5,209 of these options had vested. These options were issued during the six months ended March 31, 2016 and vest in equal quarterly instalments over a three-year period from the date of grant. The Company recognized stock based compensation expense of $11,456 and $23,449 during the three and six months ended March 31, 2016, respectively (March 31, 2015: $0 and $0, respectively) in connection with these options. These amounts have been included in general and administrative expenses on the Company's statement of operations.
[10]	As of March 31, 2016, 4,167 of these options had vested. These options were issued during the six months ended March 31, 2016 and vest in equal quarterly instalments over a three-year period from the date of grant. The Company recognized stock based compensation expense of $27,906 and $27,906 during the three and six months ended March 31, 2016, respectively (March 31, 2015: $0 and $0, respectively) in connection with these options. These amounts have been included in general and administrative expenses on the Company's statement of operations.
[11]	As of March 31, 2016, all of these options had vested. These options were issued during the six months ended March 31, 2016 and vested on December 31, 2015. The Company recognized stock based compensation expense of $0 and $6,800 during the three and six months ended March 31, 2016, respectively (March 31, 2015: $0 and $0) in connection with these options. These amounts have been included in general and administrative expenses on the Company's statement of operations.
[12]	As of March 31, 2016, none of these options had vested. These options were issued during the six months ended March 31, 2016 and vest on December 31, 2016. The Company recognized stock based compensation expense of $0 and $0 during the three and six months ended March 31, 2016, respectively (March 31, 2015: $0 and $0) in connection with these options. These amounts have been included in general and administrative expenses on the Company's statement of operations.

XML 49 R38.htm IDEA: XBRL DOCUMENT

Commitments (Details 4)	6 Months Ended
Commitments (Details 4)	Mar. 31, 2016	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Risk-free interest rate	1.68%
Expected life of options (years)	6 years 9 months 3 days
Annualized volatility	101.92%
Dividend rate	0.00%

XML 50 R39.htm IDEA: XBRL DOCUMENT

Commitments (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
Commitments (Details Narrative) - USD ($)	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015	Sep. 30, 2015	Sep. 30, 2014
Risk-free interest rate			1.68%
Expected life (in years)			6 years 9 months 3 days
Expected volatility			101.92%
Dividend yields			0.00%
Purchase Warrants [Member]
Number of common shares called	1,963,956		1,963,956
Number of warrant exercised	2,403,144		2,403,144
Number of warrant exercisable	1,828,059		1,828,059
Expiration date			Jul. 05, 2018
Description of cancellation policy			The Company may have the option to call for cancellation of all or any portion of the warrants for consideration equal to $0.001 per share, provided the quoted market price of the Company’s common stock exceeds $6.00 for a period of twenty consecutive trading days, subject to certain minimum volume restrictions and other restrictions as provided in the warrant agreements.
Purchase Warrants [Member] \| Consultant [Member]
Number of warrant exercised					1.24	1.24
Number of warrant issued					57,500	57,500
Risk-free interest rate					1.21%	1.21%
Expected life (in years)					4 years 5 months 8 days	4 years 5 months 8 days
Weighted average grant date fair value per warrant					$ 0.899	$ 0.899
Expected volatility					108.43%	108.43%
Dividend yields					0.00%	0.00%
Vesting period			3 years		4 years 6 months 29 days	4 years 6 months 29 days
Stock based compensation expense	$ 23,570	$ 2,378	$ 47,230	$ 3,634

XML 51 R40.htm IDEA: XBRL DOCUMENT

Commitments (Details Narrative 1) - 2015 Omnibus Incentive Plan [Member] - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015	Sep. 30, 2015
Maximum number of common shares reserved for future issuance	6,050,553		6,050,553
Expiration period			10 years
First Stock Option [Member]
Stock based compensation expense				$ 0
Second Stock Option [Member]
Vesting period			3 years
Fair value of options			$ 25,000		$ 25,000
Description of vesting period rights			Vest annually over a three-year period commencing on the first anniversary of the date of the grant.
Second Stock Option [Member] \| General and Administrative Expense [Member]
Stock based compensation expense	$ 5,764	$ 5,830	$ 11,590	11,660
Third Stock Option [Member]
Vesting period			4 years
Fair value of options			$ 31,250		31,250
Stock based compensation expense	7,960	8,053	$ 16,008	16,106
Description of vesting period rights			Vest annually over a four-year period commencing on the first anniversary of the date of the grant.
Four Stock Option [Member]
Vesting period			3 years
Fair value of options			$ 239,585		239,585
Description of vesting period rights			Vest in three equal installments on April 2, 2015, April 2, 2016 and April 2, 2017.
Four Stock Option [Member] \| General and Administrative Expense [Member]
Stock based compensation expense	42,811	0	$ 86,093	0
Five Stock Option [Member]
Vesting period			3 years
Fair value of options			$ 12,500
Description of vesting period rights			Vest quarterly over a three year period commencing on September 8, 2015.
Five Stock Option [Member] \| General and Administrative Expense [Member]
Stock based compensation expense	4,775	0	$ 9,603	0
Six Stock Option [Member]
Vesting period			3 years
Description of vesting period rights			Vest over a three-year period from the date of grant.
Six Stock Option [Member] \| General and Administrative Expense [Member]
Stock based compensation expense	5,573	0	$ 11,207	0
Seven Stock Option [Member]
Vesting period			3 years
Fair value of options			$ 69,688		$ 69,688
Description of vesting period rights			Vest over a three-year period from the date of grant.
Seven Stock Option [Member] \| General and Administrative Expense [Member]
Stock based compensation expense	92,875	0	$ 192,024	0
Eight Stock Option [Member] \| General and Administrative Expense [Member]
Stock based compensation expense	0	0	$ 6,800	0
Nine Stock Option [Member]
Vesting period			3 years
Fair value of options			$ 5,209
Description of vesting period rights			Vest in equal quarterly instalments over a three-year period from the date of grant.
Nine Stock Option [Member] \| General and Administrative Expense [Member]
Stock based compensation expense	11,456	0	$ 23,449	0
Ten Stock Option [Member]
Vesting period			3 years
Fair value of options			$ 4,167
Description of vesting period rights			Vest in equal quarterly instalments over a three-year period from the date of grant.
Ten Stock Option [Member] \| General and Administrative Expense [Member]
Stock based compensation expense	27,906	0	$ 27,906	0
Eleven Stock Option [Member] \| General and Administrative Expense [Member]
Stock based compensation expense	0	0	6,800	0
Twelve Stock Option [Member] \| General and Administrative Expense [Member]
Stock based compensation expense	$ 0	$ 0	$ 0	$ 0

XML 52 R41.htm IDEA: XBRL DOCUMENT

Supplemental Cash Flow Information (Details Narrative)	6 Months Ended		12 Months Ended
Supplemental Cash Flow Information (Details Narrative)	Mar. 31, 2016 USD ($) N $ / shares shares	Mar. 31, 2015 USD ($) N $ / shares	Sep. 30, 2015 shares
Supplemental Cash Flow Elements [Abstract]
Capital stock issued pursuant to debt conversions (in shares) \| N	1,161	3,918,478
Debt beneficial conversion feature	$ 1,161
Conversion price (in dollars per share) \| $ / shares	$ 1.00	$ 1.00
Number of shares for incorrect conversion price \| shares	167,415		167,415
Reclassification of derivative liability		$ 3,931,000

EXCEL 53 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 54 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * / var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 55 report.css IDEA: XBRL DOCUMENT / Updated 2009-11-04 / / v2.2.0.24 / / DefRef Styles / ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } / Report Styles / ..pl a, .pl a:visited { color: black; text-decoration: none; } / table / ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } / Top labels / ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; / word-wrap: break-word; / } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } / Header rows... / ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } / Calendars... / ..report .rc { background-color: #f0f0f0; } / Even rows... / ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } / Odd rows... / ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } / styles for footnote marker / ..report .fn { white-space: nowrap; } / styles for numeric types / ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } / styles for text types / ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 57 FilingSummary.xml IDEA: XBRL DOCUMENT 3.4.0.3 html 169 182 1 true 39 0 false 6 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://anavex.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Sheet http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Sheet http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Sheet http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) Sheet http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) Statements 6 false false R7.htm 00000007 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) (Parenthetical) Sheet http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquityParenthetical INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) (Parenthetical) Statements 7 false false R8.htm 00000008 - Disclosure - Business Description and Basis of Presentation Sheet http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation Business Description and Basis of Presentation Notes 8 false false R9.htm 00000009 - Disclosure - Recent Accounting Pronouncements Sheet http://anavex.com/role/RecentAccountingPronouncements Recent Accounting Pronouncements Notes 9 false false R10.htm 00000010 - Disclosure - Equipment Sheet http://anavex.com/role/Equipment Equipment Notes 10 false false R11.htm 00000011 - Disclosure - Promissory Notes Payable Notes http://anavex.com/role/PromissoryNotesPayable Promissory Notes Payable Notes 11 false false R12.htm 00000012 - Disclosure - Deferred Grant Income Sheet http://anavex.com/role/DeferredGrantIncome Deferred Grant Income Notes 12 false false R13.htm 00000013 - Disclosure - Senior Convertible Debentures Sheet http://anavex.com/role/SeniorConvertibleDebentures Senior Convertible Debentures Notes 13 false false R14.htm 00000014 - Disclosure - Capital Stock Sheet http://anavex.com/role/CapitalStock Capital Stock Notes 14 false false R15.htm 00000015 - Disclosure - Lincoln Park Purchase Agreement Sheet http://anavex.com/role/LincolnParkPurchaseAgreement Lincoln Park Purchase Agreement Notes 15 false false R16.htm 00000016 - Disclosure - Related Party Transactions Sheet http://anavex.com/role/RelatedPartyTransactions Related Party Transactions Notes 16 false false R17.htm 00000017 - Disclosure - Commitments Sheet http://anavex.com/role/Commitments Commitments Notes 17 false false R18.htm 00000018 - Disclosure - Supplemental Cash Flow Information Sheet http://anavex.com/role/SupplementalCashFlowInformation Supplemental Cash Flow Information Notes 18 false false R19.htm 00000019 - Disclosure - Recent Accounting Pronouncements (Policies) Sheet http://anavex.com/role/RecentAccountingPronouncementsPolicies Recent Accounting Pronouncements (Policies) Policies http://anavex.com/role/RecentAccountingPronouncements 19 false false R20.htm 00000020 - Disclosure - Equipment (Tables) Sheet http://anavex.com/role/EquipmentTables Equipment (Tables) Tables http://anavex.com/role/Equipment 20 false false R21.htm 00000021 - Disclosure - Promissory Notes Payable (Tables) Notes http://anavex.com/role/PromissoryNotesPayableTables Promissory Notes Payable (Tables) Tables http://anavex.com/role/PromissoryNotesPayable 21 false false R22.htm 00000022 - Disclosure - Senior Convertible Debentures (Tables) Sheet http://anavex.com/role/SeniorConvertibleDebenturesTables Senior Convertible Debentures (Tables) Tables http://anavex.com/role/SeniorConvertibleDebentures 22 false false R23.htm 00000023 - Disclosure - Commitments (Tables) Sheet http://anavex.com/role/CommitmentsTables Commitments (Tables) Tables http://anavex.com/role/Commitments 23 false false R24.htm 00000024 - Disclosure - Business Description and Basis of Presentation (Details Narrative) Sheet http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative Business Description and Basis of Presentation (Details Narrative) Details http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation 24 false false R25.htm 00000025 - Disclosure - Equipment (Details) Sheet http://anavex.com/role/EquipmentDetails Equipment (Details) Details http://anavex.com/role/EquipmentTables 25 false false R26.htm 00000026 - Disclosure - Promissory Notes Payable (Details) Notes http://anavex.com/role/PromissoryNotesPayableDetails Promissory Notes Payable (Details) Details http://anavex.com/role/PromissoryNotesPayableTables 26 false false R27.htm 00000027 - Disclosure - Promissory Notes Payable (Details Narrative) Notes http://anavex.com/role/PromissoryNotesPayableDetailsNarrative Promissory Notes Payable (Details Narrative) Details http://anavex.com/role/PromissoryNotesPayableTables 27 false false R28.htm 00000028 - Disclosure - Deferred Grant Income (Details Narrative) Sheet http://anavex.com/role/DeferredGrantIncomeDetailsNarrative Deferred Grant Income (Details Narrative) Details http://anavex.com/role/DeferredGrantIncome 28 false false R29.htm 00000029 - Disclosure - Senior Convertible Debentures (Details) Sheet http://anavex.com/role/SeniorConvertibleDebenturesDetails Senior Convertible Debentures (Details) Details http://anavex.com/role/SeniorConvertibleDebenturesTables 29 false false R30.htm 00000030 - Disclosure - Senior Convertible Debentures (Details Narrative) Sheet http://anavex.com/role/SeniorConvertibleDebenturesDetailsNarrative Senior Convertible Debentures (Details Narrative) Details http://anavex.com/role/SeniorConvertibleDebenturesTables 30 false false R31.htm 00000031 - Disclosure - Capital Stock (Details Narrative) Sheet http://anavex.com/role/CapitalStockDetailsNarrative Capital Stock (Details Narrative) Details http://anavex.com/role/CapitalStock 31 false false R32.htm 00000032 - Disclosure - Lincoln Park Purchase Agreement (Details Narrative) Sheet http://anavex.com/role/LincolnParkPurchaseAgreementDetailsNarrative Lincoln Park Purchase Agreement (Details Narrative) Details http://anavex.com/role/LincolnParkPurchaseAgreement 32 false false R33.htm 00000033 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://anavex.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://anavex.com/role/RelatedPartyTransactions 33 false false R34.htm 00000034 - Disclosure - Commitments (Details) Sheet http://anavex.com/role/CommitmentsDetails Commitments (Details) Details http://anavex.com/role/CommitmentsTables 34 false false R35.htm 00000035 - Disclosure - Commitments (Details 1) Sheet http://anavex.com/role/CommitmentsDetails1 Commitments (Details 1) Details http://anavex.com/role/CommitmentsTables 35 false false R36.htm 00000036 - Disclosure - Commitments (Details 2) Sheet http://anavex.com/role/CommitmentsDetails2 Commitments (Details 2) Details http://anavex.com/role/CommitmentsTables 36 false false R37.htm 00000037 - Disclosure - Commitments (Details 3) Sheet http://anavex.com/role/CommitmentsDetails3 Commitments (Details 3) Details http://anavex.com/role/CommitmentsTables 37 false false R38.htm 00000038 - Disclosure - Commitments (Details 4) Sheet http://anavex.com/role/CommitmentsDetails4 Commitments (Details 4) Details http://anavex.com/role/CommitmentsTables 38 false false R39.htm 00000039 - Disclosure - Commitments (Details Narrative) Sheet http://anavex.com/role/CommitmentsDetailsNarrative Commitments (Details Narrative) Details http://anavex.com/role/CommitmentsTables 39 false false R40.htm 00000040 - Disclosure - Commitments (Details Narrative 1) Sheet http://anavex.com/role/CommitmentsDetailsNarrative1 Commitments (Details Narrative 1) Details http://anavex.com/role/CommitmentsTables 40 false false R41.htm 00000041 - Disclosure - Supplemental Cash Flow Information (Details Narrative) Sheet http://anavex.com/role/SupplementalCashFlowInformationDetailsNarrative Supplemental Cash Flow Information (Details Narrative) Details http://anavex.com/role/SupplementalCashFlowInformation 41 false false All Reports Book All Reports avxl-20160331.xml avxl-20160331.xsd avxl-20160331_cal.xml avxl-20160331_def.xml avxl-20160331_lab.xml avxl-20160331_pre.xml true true ZIP 59 0001615774-16-005331-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001615774-16-005331-xbrl.zip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end